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Abstract 
 
Neuropeptide S (NPS) is the last neuropeptide identified via reverse pharmacology 
techniques. NPS selectively binds and activates a previously orphan GPCR, now named NPSR, 
producing intracellular Ca2+ mobilization and stimulation of cAMP levels. Biological functions 
modulated by the NPS/NPSR system include anxiety, arousal, locomotion, food intake, learning 
and memory, pain and drug addiction. In our laboratories we provided further evidence that NPS 
injected supraspinally in mice acts as a stimulatory anxiolytic. In fact, in the mouse righting reflex 
(RR) test, NPS (0.01- 1 nmol, i.c.v.) was able to reduce in a dose dependent manner the percent of 
animals losing the RR in response to diazepam (15mg/kg, i.p.) and their sleep time. Furthermore, 
NPS in the same range of doses caused a significant increase in locomotor activity (LA) in mice. 
These effects were associated with a clear anxiolytic-like action elicited by NPS in the mouse 
elevated plus maze (EPM) test, open field (OF) test and stress-induced hyperthermia (SIH) assay. 
Thus NPS evokes an unique pattern of behavioural effects: stimulation associated with anxiolysis. 
To deeply investigate the biological roles played by the NPS/NPSR system the development of 
pharmacological (i.e. selective NPSR ligands, particularly antagonists) and genetic (i.e. receptor 
knockout animals) tools are needed. In collaboration with the medicinal chemistry group of the 
University of Ferrara, we performed a series of classical structure-activity (SAR) studies on NPS 
sequence. Specifically, NPS positions 2, 3, 4 and 5 were investigated in details, since they were 
demonstrated to be crucial for NPS bioactivity. Studies focussed on NPS position 5 led to the 
identification of the first generation of NPSR peptide antagonists. In vitro, in HEK293 cells stably 
expressing the mouse NPSR, [D-Cys(tBu)5]NPS up to 100 μM did not stimulate Ca2+ mobilization 
but was able to counteract in a competitive manner the stimulatory action of NPS (pA2: 6.44). In 
vivo, in the RR test, [D-Cys(tBu)5]NPS at 10 nmol was inactive per se but dose dependently 
antagonized the arousal-promoting action of NPS 0.1 nmol. [D-Val5]NPS acted in vitro as a pure 
NPSR antagonist, with a pKB of 6.54 in inhibition experiments. In vivo, in LA test, [D-Val5]NPS at 
10 nmol completely blocked the stimulatory effect evoked by NPS. In a further medicinal chemistry 
study, the potent NPSR antagonist [tBu-D-Gly5]NPS was identified. In vitro, [tBu-D-Gly5]NPS did 
not stimulate calcium mobilization but blocked the stimulant action of NPS with a pKB of 7.06. In 
vivo, in RR assay, [tBu-D-Gly5]NPS (0.1-10 nmol, i.c.v.) was inactive per se but dose dependently 
antagonized the arousal-promoting action of NPS 0.1 nmol. Similarly in the LA assay [tBu-D-
Gly5]NPS (0.1-10 nmol, i.c.v.) was inactive per se but was able to counteract the stimulatory effect 
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evoked by 0.1 nmol NPS in a dose dependent manner. SHA 68 has been previously identified as the 
first non peptide NPSR antagonist. In our laboratories we further assessed the pharmacological 
profile of SHA 68 in vitro and in vivo. In vitro SHA 68 was inactive per se up to 10 μM while it 
antagonized NPS-stimulated Ca2+ mobilization in a competitive manner showing a pA2 value of 
8.06. In vivo, in the mouse RR assay, SHA68 50 mg/kg i.p. fully prevented the arousal promoting 
action of  NPS 0.1 nmol. In LA experiments, SHA 68 50 mg/kg i.p. was able to partially counteract 
the stimulant effects elicited by NPS 0.1 nmol. Instead, the anxiolytic-like effects of NPS 0.1 nmol 
in mouse OF test were slightly reduced by SHA 68. Collectively these data demonstrated the 
exclusive involvement of NPSR in the arousal promoting and locomotor stimulant effects of NPS. 
Finally, we backcrossed on the CD-1 strain the NPSR knockout mice originally generated on the 
129Sv/Ev genetic background. A first phenotype analysis revealed no locomotor differences 
between NPSR(+/+) and NPSR(-/-) mice, with the exception of rearing behaviour that was reduced 
in knockout animals. Furthermore, the behaviour of NPSR(+/+) and NPSR(-/-) mice in the EPM, 
OF and SIH tests is superimposable. Similarly no differences were detected in the novel object 
recognition, forced swimming, RR and formalin assays. However, the stimulant actions of 1 nmol 
NPS in RR and in LA test could be detected in NPSR(+/+) but not in NPSR(-/-) mice. Collectively 
these data demonstrated that endogenous NPS/NPSR system does not play a role in the control of 
locomotion, anxiety, depression and memory, at least under the present experimental conditions. 
These results demonstrated that the NPS stimulant effects are selectively due to NPSR activation, 
corroborating the findings obtained with NPSR antagonists. In conclusion, the research activity 
performed during the PhD program led to the identification of the first generation of NPSR peptide 
antagonists. The use of these research tools in parallel with knockout studies generated converging 
evidence demonstrating that the biological effects of NPS are selectively due to the selective 
activation of NPSR. 
introduction 
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1. INTRODUCTION
 
 
1.1 Orphan G-protein coupled receptors and the reverse pharmacology approach 
G-protein coupled receptors (GPCRs) are one of the largest family of proteins acting as 
modulators of intercellular interactions and regulating biological functions in the human body, in 
particularly in the central nervous system (CNS). There are numerous GPCRs in living organisms, 
but the function of many of them is still unknown. The human genome encompasses ~ 800 GPCRs, 
of which more than half are olfactory and/or taste GPCRs. GPCRs are targets of most of the 
primary messengers including neurotransmitters, all neuropeptides, glycoprotein hormones, lipid 
mediators and other small molecules; thus they have considerable pharmaceutical interest. Drugs 
acting at GPCRs are used to treat numerous disorders. More than 30% of the approximately 500 
clinically used drugs, are modulators of GPCRs function, representing around 9% of global 
pharmaceutical sales; this makes GPCRs the most successful of any target class in terms of drug 
discovery 1. 
367 transmitter GPCRs have been identified within the human genome, the majority of these 
GPCRs have been identified on the basis of their sequence similarities, either by homology cloning 
or by bioinformatics analyses. Some of these receptors luck their endogenous ligand and they are 
defined ‘orphans’. Currently the orphan GPCRs are ~ 140.  
The first step in the characterization of an orphan GPCRs is the search of the activating 
ligand. As the genomes of most studied model organisms have now been sequenced, the process of 
discovery of GPCRs-ligand pairs has been reversed. Until recently, neuropeptides have been 
traditionally identified either on the basis of their chemical characteristics 2 or of their effects in 
particular assay systems 3. Although highly successful, these approaches had reached a stand still by 
the mid 80’s. 
Through DNA recombination techniques, it is now possible to transfect the sequence of an 
orphan receptor of which the function is not yet known, into an appropriate cellular expression 
system. This leads to the use of orphan receptors as baits to isolate their natural ligands from 
fractions of tissue extracts in high-throughput screening (HTS). This approach has been named 
“reverse pharmacology”. The expression system provides the necessary trafficking and G-protein-
signalling machinery to enable the successful identification of the activating ligand. By exposing 
the transfected cell to a tissue extract containing the natural ligand of the orphan receptor, a change  
introduction 
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in intracellular second messengers will be induced and will serve as a parameter to monitor orphan 
receptor ligand purification. Despite the logic of the theory, the process is not simple, since the 
chemical nature of the ligand and the type of the second messenger response that it will generate, 
are unknown. However, structural features in an orphan GPCR will determine its relationship to 
known receptors and will help in evaluating the nature of the receptor’s ligand and its cellular 
action. Indeed, an orphan receptor which is related, even to a low degree, to a particular receptor 
family has a higher probability of sharing a ligand of the same physical nature and a coupling to 
similar G proteins. Notably this strategy has already led to several significant discoveries. The 
orphan receptor strategy was first proven to be successful with the discovery of the neuropeptide 
nociceptin/orphanin FQ as the endogenous ligand of the orphan GPCR opioid receptor-like 1 4-5. 
 
 
 
Figure 1 The orphan receptor strategy (Civelli et al.,TRENDS in Neurosciences Vol.24 No.4 April 2001). The orphan 
receptor strategy was developed to identify the natural ligands of orphan G-protein-coupled receptors (GPCRs) with the 
aim of discovering novel transmitters (defined in the main text). This strategy involves: (1) expression of the cloned 
orphan GPCR in an heterologous cell line; (2) exposure of this transfected cell line to a tissue extract that is expected to 
contain the natural ligand; (3) recording of the change in second messenger response elicited by activation of the orphan 
GPCR; (4) fractionation of the tissue extract and isolation of a surrogate, the active component; (5) determination of the 
chemical structure of the active component and (6) chemical synthesis of the active component and demonstration that 
it exhibits identical activity to that of the purified ligand.  
 
 
 
 
introduction 
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This first successful example of orphan receptor strategy was followed by the identification 
of other novel bioactive peptides such as: hypocretins and orexins, prolactin-releasing peptide, 
apelin, ghrelin, melanin-concentrating hormone, urotensin II, neuromedin U, metastin, neuropeptide 
B, neuropeptide W. The last success of reverse pharmacology was in 2004 the identification of 
neuropeptide s, the subject of this thesis, as the endogenous ligand of the previously orphan GPCR 
GPR154, now named NPSR. Each of these discoveries was a landmark in its field 6. The success in 
GPCRs deorphanization led to the approach being used by pharmaceutical industry 7, which had 
mastered the HTS of thousands of ligands. This led to thousands of potential transmitters and 
unexpected ligands (also of non-peptide nature) being tested on dozens of orphan GPCRs and a 
revival of the reverse pharmacology approach. The novel information emerging from reverse 
pharmacology discoveries substantially increased our knowledge on the diverse physiological 
functions modulated by peptidergic systems and most likely will open novel avenues for treating 
several diseases including food intake and sleep disorders, pain, anxiety and depression in the near 
future. Table 1 summarizes the transmitters of peptidic and non-peptidic nature identified as ligands 
of orphan GPCRs 6.  
introduction 
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Table 1 Transmitters identified as ligands of  orphan GPCRs after nociceptin/orphanin FQ 6. 
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1.2 Neuropeptide S  
 
The identification of NPS as the endogenous ligand of the previous orphan GPCR GPR154 
was first reported in the patent literature in 2002 8. The patent reported the sequence of GPR154 
(GenBank accession numbers BD183774, BD183814, BD183773) and the isolation of NPS as its 
endogenous ligand, but nothing is provided about the biological functions and the pharmacological 
characteristics of this new system. Then, in 2004, an elegant study by Xu et al. 9 described for the 
first time some functional features of the NPS/GPR154 system. Following the description by Xu et 
al. 9, in the present work the GPR154 receptor will be indicated as NPSR. However this latter 
abbreviation has to be considered provisional since it is not in line with IUPHAR recommendations 
for nomenclature of receptors (the receptor name should not include the letter R as an abbreviation 
for receptor 10).  
 
The primary sequence of NPS in humans is SFRNGVGTGMKKTSFQRAKS. The amino 
acid at the N-terminus of the peptide is serine (S) in all animal species and this was the reason of 
naming the peptide NPS 9. The NPS sequence is highly conserved among vertebrates with few 
variations located in the centre and C-terminus of the peptide 11 (figure 2). The N-terminal sequence 
Ser1-Phe2-Arg3-Asn4-Gly5-Val6-Gly7 is identical in all species, thus suggesting that this may 
represent the bioactive core of this peptide 11. Curiously, the peptide is absent in fish genomes (e.g., 
zebrafish and fugu) and is also not found in amphibian or reptile DNA sequences, indicating that 
this transmitter arose relatively late during vertebrate evolution 11. As other neuropeptides, NPS is 
cleaved from a larger precursor protein. NPS peptide precursor (ppNPS) is a typical neuropeptide 
precursor containing a hydrophobic signal peptide at the beginning of its sequence and a pair of 
basic residues (Lys-Arg) before the mature NPS sequence 12. 
 
introduction 
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Figure 2 Alignment of NPS peptide structures from various species. Sequences were deduced from GenBank finished 
and unfinished genome sequences. Amino acids different from human NPS are highlighted in red 13. 
 
 
The regional distribution of  NPS in rat has been described in two publications by Xu et al. 
9,14, using quantitative real time  polymerase chain reaction (RT-PCR) and in situ hybridization 
techniques. Quantitative RT-PCR showed that NPS mRNA are expressed in various tissues and the 
highest levels were found in brain, thyroid, salivary, and mammary glands 9. Xu and colleague 
focused their attention to the distribution of NPS and its receptor in the CNS. In situ hybridization 
experiments demonstrated that in rat brain ppNPS  mRNA is expressed discretely in a few areas, 
with strongest expression in the locus (LC) coeruleus area, principle sensory trigeminal nucleus, 
and lateral parabrachial nucleus. Moderate expression was also found in a few scattered cells of the 
dorsomedial hypothalamic nucleus and the amygdala 9. In particular, in the LC area NPS-expressing 
neurons defines a previously unrecognized population of cells located between the noradrenergic 
LC and the Barrington’s nucleus 9. Double label in situ hybridization studies demonstrated that 
most of the NPS expressing cells in the LC area are glutamatergic neurons, few are cholinergic, 
while none produce GABA 14. In the principle sensory trigeminal nucleus many of the NPS 
expressing neurons use glutamate as a neurotransmitter 14. Finally, in the lateral parabrachial 
nucleus NPS positive cells co-express CRF 14. NPS seems to be co-expressed with excitatory 
neurotransmitters and on this basis it has been proposed that NPS may provide additional excitatory 
input to the postsynaptic target of these excitatory neurons. 
introduction 
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1.3 NPS receptor 
 
NPSR is also know as vasopressin receptor-related receptor (VRR1) 15 or G protein coupled 
receptor for asthma susceptibility (GPRA) 16. NPSR is a typical GPCR, but it shows moderate 
homology to other members of the GPCR family, the closest relatives being the vasopressin (i.e., 
V1a and V2) receptors. Human and mouse NPSR were studied in heterologous expression systems, 
showing that NPS both stimulates intracellular calcium levels and cAMP accumulation with EC50 
values in the low nanomolar range 9,17. This indicates that the NPSR can signal via both Gq and Gs 
protein to increase cellular excitability.  
Multiple single-nucleotide polymorphisms (SNP) and several splice variants have been 
identified in the human NPSR (hNPSR) gene that is located on chromosome 7p14-15 (figure 3). On 
note Laitinen et al. 16 described different polymorphisms in the hNPSR gene linked to an increased 
susceptibility for asthma and potentially other forms of allergy that are characterized by high IgE 
serum levels in Finnish and Canadian asthma patients 16. In particular the study described two 
different C-terminal splicing variant of hNPSR, named “GPRA isoform A” (GenBank accession 
number NP_997055) and “GPRA isoform B” (Gen-Bank accession number NP_997056) 16. The 
“GPRA isoform A” corresponds to the NPSR receptor extensively studied by Xu 17. The most 
interesting of SNPs described for hNPSR gene is an Asn-Ile exchange at position 107 of the mature 
hNPSR protein (SNP591694 A>T; refSNP ID: rs324981) 17. This receptor polymorphism seems to 
have functional implications since the hNPSRIle107 receptor displayed similar binding affinity but 
higher NPS potency (by approx. 10-fold) than hNPSRAsn107 17. This result has been replicated in 
different laboratories, using different assays (intracellular calcium and cAMP accumulation) as well 
as different cell types (HEK293 and CHO) 17-18. Instead, the C-terminal splice variant of NPSR did 
not appear to cause measurable differences in the pharmacological profile of the receptor 17-18. It is 
worthy of mention that the rat and mouse NPSR contain Ile at position 107. Different 
epidemiological studies reported a gender-specific association of the hNPSRAsn107Ile 
polymorphism with panic disorder, sleep behaviour, bowel disease and asthma susceptibility 16,19-21, 
however, the pathophysiological implications of NPSR polymorphisms are far from being fully 
understood.  
 
introduction 
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Figure 3 Schematic diagram of the hNPSR protein showing the presumed location of the N107I polymorphism and the 
sequence of the alternatively spliced carboxyl-terminal tail in NPSR C-alt 17. 
 
Quantitative RT-PCR and in situ hybridization experiments reported that the NPSR mRNA 
is widely distributed in the brain 9,14. High levels of expression are found in areas involved in 
olfactory processing, including the anterior olfactory nucleus, the endopiriform nucleus, and the 
piriform cortex. NPSR mRNA is also highly expressed in the amygdaloid complex, in the thalamus 
and in the preoptic region. Furthermore, multiple hypothalamic nuclei, including the dorsomedial 
and the ventromedial hypothalamic nucleus and the posterior arcuate nucleus, express high levels of 
NPSR mRNA. In addition, NPSR mRNA is strongly expressed in major output and input regions of 
hippocampus, including the parahippocampal regions, the lateral entorhinal cortex, and the 
retrosplenial agranular cortex. These data suggested that the NPS system may play a key role in 
modulating a variety of physiological functions, especially arousal, anxiety, learning and memory, 
and energy balance. NPSR transcripts were also found in peripheral tissues, including thyroid, 
salivary, and mammary glands, which might indicate additional endocrine functions 9. Recently, 
Leonard and colleagues generated and validated a NPSR-specific antibody to determine the 
distribution of the NPSR protein in the rat brain 22. The localization of the NPSR receptor identified 
by the use of the antibody was consistent with the mRNA distribution identified by Xu et al. using  
in situ hybridization techniques 14. NPSR protein was in fact detected in the medial amygdala, 
substantia nigra pars compacta, subiculum, dorsal raphe, and several  hypothalamic and  thalamic  
introduction 
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regions. Additionally, NPSR protein was localized in the pyramidal cell layer of the ventral 
hippocampus, the medial habenula, and was widely distributed in the cortex 22.  
introduction 
 16
 
1.4 Biological actions of NPS 
 
1.4.1 In vitro studies 
 
Most of the in vitro studies were performed with cells expressing the recombinant NPSR 
receptor. In these studies NPS was able to increase both intracellular calcium and cAMP levels, 
displaying similar high potency (EC50 in the low nanomolar range) at the rat, mouse and human 
NPSR. As mentioned above, NPS displayed 10 fold higher potency at the hNPSRIle107 isoform than 
hNPSRAsn107. 
Only limited information is available on the in vitro effects of NPS in cells/tissues 
expressing the native NPSR. In our laboratories we assessed the effects of NPS in a series of cell 
lines measuring intracellular calcium mobilization and in several animal tissues taken from the 
gastrointestinal, genitourinary, and respiratory system measuring myotropic effects; however, we 
were not able to find any NPS sensitive preparation. The only peripheral cell types reported to be 
sensitive to NPS are macrophages and lymphocytes 23-24. Specifically, macrophages responds to 
NPS with reduced adhesion and increased phagocytosis,  chemotaxis and production of the pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α 23-24; moreover NPS stimulates lymphocytes 
proliferation 24. These findings together with those coming from genetic studies, which provide 
evidence for association of NPSR gene polymorphism with chronic inflammatory diseases of the 
respiratory 16 and gastrointestinal 19 systems, indicate that the NPS/NPSR system may have a role in 
modulating innate immunity and chronic inflammatory diseases of epithelial barrier organs.  
As far as CNS preparations are concerned, NPS has been reported to modulate synaptic 
activity in mouse brain slices 25-26 and neurotransmitter release in mouse synaptosomes 27. In 
particular, two complimentary studies performed in mouse coronal brain slices reported distinct 
actions of NPS in the amygdala. Meis et al. 26 reported in response to NPS an increase in 
glutamatergic synaptic transmission onto basolateral amygdala GABAergic interneurons; this effect 
was sensitive to tetrodotoxin suggesting dependence from action potential propagation. The 
endopiriform nucleus was identified as the site of action of NPS. This NPS sensitive circuit might 
be responsible for the inhibitory effect of the peptide on the expression of contextual fear 26. Using 
the same preparation, Jungling et al. 25 demonstrated that NPS increases glutamatergic transmission 
to intercalated GABAergic neurons in the amygdala via presynaptic NPS receptors onto connected 
principal neurons. This electrophysiological effect of NPS may likely be important for both the 
anxiolytic-like action of the peptide and for its ability to facilitate extinction of aversive 
introduction 
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memories25. The electrophysiological actions of NPS modulating the activity of the circuit 
endopiriform cortex, lateral, basolateral, and central amygdala has been nicely summarized by Pape 
et al. 28. Recently, electrophysiological studies demonstrated that NPS depolarizes and thereby 
excites ventromedial hypothalamic neurons 29. This depolarization is postsynaptic and involves R- 
and T-type calcium channels and non selective cation channels 29. The excitatory effect on 
ventromedial hypothalamic neurons can represent the cellular process by which NPS participates in 
the regulation of food intake and energy homeostasis 29. Furthermore, NPS has been reported to 
behave as an extremely potent (pM range of concentrations) inhibitor of the release of 5-HT and 
NA from mouse frontal cortex synaptosomes. In parallel experiments NPS did not modify the 
release of GABA and glutamate and weakly reduced, only at high concentrations, dopamine and 
acetylcholine release 27. However, no evidence was provided for the involvement of the NPSR in 
these neurochemical actions of NPS. Based on the reported cellular actions of NPS (i.e. increase in 
intracellular calcium concentrations and cAMP), the ability of NPS to inhibit neurotransmitter 
release should be considered unexpected. However, the existence of excitatory G protein coupled 
receptor mediating inhibitory effects on neurotransmitter release has been repeatedly reported (for 
detailed discussion see Raiteri et al. 27). There is convincing evidence in the literature that elevation 
of 5-HT and NA levels is associated with anxiety like behaviours; therefore, the inhibition of 5-HT 
and NA release elicited by NPS may represent at least one of the mechanisms by which NPS 
promotes its anxiolytic-like effects. The results obtained by Raiteri et al. with mouse frontal cortex 
synaptosomes 27 are in contrast with the recent study performed by Si and colleagues 30 using in 
vivo microdialysis in freely moving rats. Si et al. 30 shown in fact that NPS administration increases 
release of dopamine in the medial prefrontal cortex but does not change 5-HT levels in this brain 
area. This stimulatory effect of NPS on dopamine release in the medial prefrontal cortex might be 
functionally connected to the effects of NPS on fear extinction and anxiety 30. Furthermore, NPS 
given in the ventral tegmental area was reported to increase dopamine levels in the nucleus 
accumbens shell in rats, activating the mesolimbic dopaminergic pathway 31. NPS induced 
stimulation might likely be mediated by the activation of  the dopaminergic release in this circuit 31.  
introduction 
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1.4.2 In vivo studies 
 
 
Locomotor activity 
 
In the pivotal study by Xu et al. 9 it has been reported that the supraspinal administration of 
NPS in mice stimulates locomotor activity (LA). This effect is evoked by low doses (0.1 nmol) of 
peptide, lasts for about 1 hr, and is similar in naïve mice and animals habituated to the test chamber. 
These findings were later confirmed in several studies both in mice 32-34 and rats 35, suggesting that 
the hyperlocomotor action of NPS is a robust phenomenon among experimental conditions and 
animal species. The involvement of NPSR in the locomotor stimulatory effect of NPS has been 
demonstrated with the use of the NPSR antagonist SHA 68 33 that was able to counteract the 
stimulatory effect of NPS being per se inactive. These results were corroborate by the use of the 
NPSR knockout (NPSR(-/-)) mice. NPS was in fact able to increase animals LA in NPSR wild type 
(NPSR(+/+)) but not in NPSR(-/-) mice and no differences were recorded between NPSR(+/+) and 
NPSR(-/-) mice 36-38. All these findings demonstrate that this peptide action is due to NPSR 
activation and suggest that the endogenous NPS system does not exert a tonic control on animal 
locomotor behaviour. It was demonstrated that a brain area important for NPS hyperlocomotor 
action is the ventral tegmental area 31. Specifically, NPS seems activate the mesolimbic 
dopaminergic system, that origins from this area and projects in the nucleus accumbens. In fact the 
NPS stimulant effects were completely block by the administration in the shell of the nucleus 
accumbens of sulpiride, a dopamine D2 –like receptor antagonist 31. This finding indicates a role of 
the dopaminergic pathway in the neurochemical mechanisms responsible for NPS induced 
hyperlocomotion. Furthermore, a study by Boeck et al. 39 demonstrated that the pharmacological 
blockade of adenosine A2A receptors by caffeine and the selective A2A antagonist ZM241385 
significantly attenuate NPS stimulant effects. Thus the endogenous adenosine system seems play a 
role in mediating this NPS function. Also corticotrophin releasing factor signalling via CRF1 
receptors seems to be involved in the hyperlocomotor action of NPS. In fact this effect of NPS is 
blocked by the selective CRF1 antagonist antalarmin and is not evident in CRF1(-/-) mice 34. The 
microinjection of NPS into the paraventricular nucleus 35 or amygdale 25 mimicked the effects of the 
peptide given i.c.v. on food intake and anxiety states, respectively, but did not stimulate locomotion. 
Thus it is likely that these brain areas are not important for the locomotor stimulant effect of NPS.  
 
introduction 
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Arousal and sleep 
 
Electroencephalografic studies in rats demonstrated that the i.c.v. injection of NPS reduced 
all stages of sleep promoting wakefulness 9. Similar to the locomotor stimulant action in mice, this 
effect of NPS lasted for about 1 h and can be evoked using low doses of peptide (0.1-1 nmol). The 
arousal promoting action of NPS has been also demonstrated using the righting reflex assay. In fact 
NPS dose dependently (0.1 – 10 nmol) reduced the sleep time of rat treated with ketamine (100 
mg/kg) and thiopental (45 mg/kg) 40. The NPSR antagonist [D-Cys(tBu)5]NPS at the dose of 20 
nmol was able to completely prevent the arousal promoting action of NPS 1 nmol giving evidence 
that the arousal promoting action of NPS is due to selective NPSR activation 40. Moreover, [D-
Cys(tBu)5]NPS per se prolonged both ketamine and thiopental anesthesia duration, suggesting that 
the NPS/NPSR system tonically controls the anesthesia state 40. These findings parallel the 
peptidergic arousal promoting system of the orexins. In fact, orexin receptor antagonists prolonged 
barbiturate sleeping time in rats 41 and emergence from general anesthesia 42. Recent studies 
performed with NPSR(-/-) mice suggested a role played by NPSergic pathways in the modulation 
of circadian rhythm. In fact NPSR(-/-) mice displayed reduced late peak wheel running (an index 
of activity of the internal clock) 36 and reduced LA during the dark phase 37 compared to 
NPSR(+/+) mice. Clearly further studies performed both with NPSR ligands and NPSR(-/-) mice 
are needed to investigate the role of the NPS/NPSR system in the regulation of wakefulness and 
sleep physiology and pathology. As far as the brain areas possibly relevant for the arousal 
promoting effect of NPS are concerned, NPSR mRNA has been reported to be expressed in several 
structures known to play a major role in the regulation of arousal including the thalamus, 
hypothalamus, ventral tuberomammilary nucleus, substantia nigra and ventral tegmental area, and 
the pontine reticular nucleus 14. In particular the thalamic midline nuclei which integrate the 
arousal circuit reticular formation-thalamus-cortex express high levels of NPSR mRNA. 
Microinjection and electrophysiological studies are now needed to establish the role of the above 
mentioned brain structures in the arousal promoting action of NPS. Interestingly enough, a recent 
genetic epidemiology study performed on 749 subjects found a clear association between the 
NPSRAsn107Ile polymorphism and mean bedtime delay 20. While these findings require replication 
in other samples, they provide evidence for a role of the NPS/NPSR system in regulating sleep 
physiology in humans.  
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Anxiety and mood 
 
The studies by Xu et al. 9,14 demonstrated a strong expression of NPSR mRNA in different 
brain areas related to stress, including the amygdala, bed nucleus of the stria terminalis, 
hypothalamus, raphe nucleus and ventral tegmental area. This NPSR distribution suggests that the 
NPS system might influence emotional behaviours such as stress and anxiety responses. The pivotal 
study by Xu et al. 9 reported that the supraspinal administration of NPS in the 0.01 – 1 nmol range 
of doses evokes a clear anxiolytic-like effects in mice subjected to a battery of validated assays 
including the elevated plus maze (EPM), the light-dark box, and the open field (OF) 9. These initial 
observations were later confirmed and extended to other assays such as the four-plate test and 
elevated zero maze 34,43. These tests are based on the natural aversion of rodents for open or 
unfamiliar spaces and anxiolytic drugs increase exploration of these exposed areas. It should be 
considered that these assays are sensitive to the confounding effects of drugs, like NPS, that 
stimulate locomotor activity since in these tests anxiety levels are measured as inhibited behaviours. 
However NPS was reported to be able to reduce in a dose dependent manner the number of marbles 
buried in the marble burying test 9,34, a model which is not biased by locomotion since anxiety 
levels are measured as an active behaviour. Furthermore Leonard and colleagues 43 demonstrated 
that anxiolytic-like effects can be measured in response to NPS in mice in the stress induced 
hyperthermia (SIH) test. These results provide evidence that the anxiolytic-like action of NPS is a 
genuine effect. Subsequently the anxiolytic-like effects of NPS were confirmed and extended to a 
different species, the rat, and a different assay, the defensive burying test 44. It was demonstrated 
that NPS (0.1 – 10 nmol) reduces cumulative burying behaviour in a dose dependent manner 
without modifying other parameters including latency to contact the probe, burying behaviour 
latency, number of shocks received or immobility/freezing duration 44. Again, since the main 
parameter predictive of anxiolysis in this assay is the inhibition of an active defensive behaviour, 
motor activity can be considered a minor bias in the outcome of the defensive burying test 45.  
The NPS effects were also investigated in the Pavlovian fear conditioning test 25, an 
established model for fear and emotional memory. In this paradigm, an aversive stimulus 
(unconditioned stimulus, i.e. short electric foot shock) is associated with a neutral stimulus 
(conditioned stimulus). After the training (pairing of unconditioned stimulus and conditioned 
stimulus), associative fear memory is tested by presentation of conditioned stimulus alone and 
fearful responses can be recorded reliably by measuring ‘‘freezing’’ behaviour. Repeated 
presentation of the conditioned stimulus alone without the aversive stimulus leads to a gradual 
decline in fear responses, which indicates extinction of fear memory. It was demonstrated that NPS 
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given into the amygdala produces a significant decrease of fear behaviour and facilitates the 
extinction of conditioned fear responses 25. Next, Fendt et al. 46 reported that the intra amygdala 
administration of  NPS completely block the expression of the fear-potentiated startle 46. Thus the 
NPS/NPSR system seems to have a role in controlling the mechanisms of conditioned fear, in 
particular eliciting fear reducing effects. 
The amygdala can be the brain area crucial for NPS anxiolytic action. In fact, the intra 
amygdala injection of NPS promoted clear anxiolytic effects in the mouse EPM and OF assays 25, 
mimicking the effects of the peptide given i.c.v 9. Furthermore the NPS effects on fear expression 
were detected giving it into the amygdala 25,46. Another brain region important for the NPS effects 
on anxiety and fear seems to be the medial prefrontal cortex, where NPS induces an increase in 
dopamine levels, probably through the activation of the dopaminergic neurons originated in the 
ventral tegmental area 30.  
The endogenous NPS/NPSR system might tonically control anxiety levels since the intra 
amygdala injection of the NPSR antagonist SHA 68 produces robust anxiogenic effects in mice 
subjected to the open field 25. Furthermore a study by Duangdao and colleagues 36 reported that 
NPSR(-/-) mice display an anxious phenotype  compared to their wild type littermates in the light-
dark box, EPM and OF. On the contrary Zhu et al. 38 and Fendt et al. 37 observed no differences 
between the behaviour of NPSR(+/+) and NPSR(-/-) mice in the OF, EPM and elevated zero maze 
tests, suggesting that the endogenous NPSergic pathway does not tonically control anxiety levels. 
The hypothesis that the NPS/NPSR system does not play a role in modulating anxiety is 
corroborated by the absence of anxiogenic effects per se of the NPSR antagonist SHA 68 in the 
EPM and defensive baring assays in rat 47. These indications need however to be confirmed in 
future studies investigating the effects of different chemically unrelated NPSR receptor selective 
antagonists as well as performing systematic investigations of the phenotype of  NPSR(-/-) and 
possibly ppNPS(-/-) 48 mice in different assays predictive of anxiety states. Interestingly NPS 
failed to elicit anxiolytic-like actions in OF and elevated zero maze assays in mice lacking the 
NPSR protein 38, demonstrating that the NPS anxiolytic activity is selectively due to the NPSR 
activation. This is also demonstrated by the fact that SHA 68 was able to counteract the NPS 
effects in the EPM and defensive baring assays in rats 47. 
On note different epidemiological studies reported an association between NPSR SNPs and 
susceptibility to panic disorders. In particular the NPSR isoform NPSRAsn107 was found  
underrepresented in patients with panic disorder and the NPSRIle107 isoform was found associated 
with an over interpretation of fear reaction and a tendency to catastrophizing 21,49-51. This 
association of the gain of function SNP hNPSRIle107 with panic disorder in humans is unexpected 
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and seems inconsistent with findings in rodent models, where NPS have been shown to exert a 
dose dependent anxiolytic effect. Thus the role plays by the NPS/NPSR system in the control of 
panic is still unclear and further studies are needed to address this issue. 
Interestingly enough, the effect of NPS on emotional behaviour seems to be restricted to 
anxiety and fear since the peptide was found inactive in tests such as the tail suspension 43 or the 
forced swimming test (FST) (Rizzi et al., unpublished results) that are sensitive to the 
antidepressant- like effects of drugs. However preliminary results indicate that NPS may alter both 
anxiety- and depression-like behaviours in a rat genetic model of depression. In fact, in flinders 
sensitive rats NPS decreased depression-like behaviour in the forced swimming test and anxiety-
related behaviour on the EPM in a dose-dependent manner (0.05 – 1 nmol, i.c.v.). In contrast, NPS 
did not alter the behaviour of flinders resistant animals 52. A recent study performed with NPSR(-/-) 
mice reported that male mice lacking the NPSR receptor display increased depression-like 
behaviour in the FST. However Duangdao et al. reported no differences in the behavior of NPSR 
deficient mice compared to wild type mice in the FST 36.  Thus the role of the NPS/NPSR system in 
mood regulation is not well understood. 
In conclusion, the initial findings by Xu et al. 9 were replicated and extended in different 
laboratories confirming that NPS promotes in the same range of doses stimulation of locomotor 
activity and arousal associated to a genuine anxiolytic-like action. Thus, the proposal of NPS as an 
activating anxiolytic 9, is confirmed after six years of research activities. This rather unique 
behavioral profile challenges the common idea that anxiolytics are also sedative (i.e. 
benzodiazepines) or that stimulants are also anxiogenic (i.e. caffeine, cocaine, and amphetamines). 
The only substance which shares this behavioral profile with NPS is nicotine which increases 
arousal and wakefulness and produces, at least in smokers, anxiolysis and antistress effects 53. 
Interestingly enough, chronic nicotine treatment in rats increases both NPS and NPSR expression in 
the brainstem and NPSR in the hypothalamus 54. Thus nicotine might produce some of its effects 
via regulation of the endogenous NPS/NPSR system. 
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Drug addiction 
 
The unique pattern of behavioral effects elicited by NPS (arousal promoting action 
associated with anxiolysis) together with the expression of NPSR in brain areas involved in the 
rewording effects of drugs has prompted the investigation of NPS effects on drug addiction. 
In conditioned place preference studies in mice, NPS neither induced place preference nor 
aversion. However, NPS blocked the acquisition of conditioned place preference to morphine. 
Moreover, the expression of conditioned place preference induced by morphine was also inhibited 
by NPS. These results revealed the involvement of NPS in rewarding activities of morphine 55. 
The effects of NPS were also evaluated on ethanol drinking in alcohol-preferring and non 
preferring rats 56. NPS given i.c.v. reduced ethanol intake in alcohol-preferring, but not in non 
preferring rats. The peptide neither altered anxiety-like behavior in the EPM test nor modified 
general motor activity. However, there was an increase in the amount of time spent in the center of 
the activity cage following infusions of 0.6 nmol of NPS in preferring, but not in non preferring 
rats, indicating anxiolytic actions of the peptide. Thus, this study suggests a role for NPS in the 
modulation of ethanol drinking and possibly anxiety-like behavior in rats selectively bred for high 
alcohol drinking 56. 
Recently, two complimentary studies investigated the role of NPS in drug seeking behavior 
34,57. Cocaine-seeking behavior was evaluated in mice by Paneda et al. 34. It was demonstrated that 
i.c.v. NPS reinstates extinguished cocaine-seeking behavior in a dose-dependent manner. At the 
highest dose tested i.e. 0.45 nmol, NPS increased active lever pressing in the absence of cocaine to 
levels that were equivalent to those observed during self-administration. This action of NPS 
involved corticotropin-releasing factor receptor signaling via CRF1 receptor since  CRF1(-/-) mice 
did not respond to the cocaine reinstatement effects of NPS and the CRF1 antagonist antalarmin 
blocked the increase in active lever responding in response to NPS 34. Ethanol seeking behavior 
was investigated in rats by Cannella et al. 57. In self-administration experiments, the stable 
response rates observed for ethanol reinforcement were not modified by i.c.v NPS (1.0 and 2.0 
nmol). In reinstatement experiments, ethanol-associated cues induced robust rates of ethanol 
seeking. NPS i.c.v. injection resulted in a significant increase of ethanol seeking elicited by 
ethanol-associated cues. Site-specific NPS injection (0.1 and 0.5 nmol) into the lateral 
hypothalamus also reinstated extinguished responding to ethanol. This effect was selectively 
blocked by pre-treatment with the OX1 receptor antagonist SB-334867 which did not modify 
alcohol reinstatement per se. This study provided the first demonstration that activation of NPSR 
in the lateral hypothalamus, via activation of orexin releasing neurons, intensifies relapse to 
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ethanol-seeking elicited by environmental conditioning factors 57. Furthermore NPSR mRNA 
expression was found enhanced in rat with a history of ethanol addiction in different brain areas, 
suggesting an involvement of the NPS/NPSR system in controlling mechanisms of ethanol abuse 
58. Finally, a very recent study performed by Kallupi et al. 59 confirmed that NPS increases 
conditioned reinstatement of cocaine-seeking in rats through the activation of orexin 
immunoreactive neurons in the lateral hypothalamus. Interestingly the administration of the two 
chemically distinct NPS receptor antagonists SHA 68 and [D-Cys(tBu)5]NPS potently and 
selectively prevented cue-induced cocaine seeking, suggesting that the endogenous NPS may have 
a role in the pathophysiology of drug relapse 59. Based on these findings, the NPSR receptor 
represents an important and unique target for the treatment of drug craving and the prevention of 
relapses in addicted patients. 
 
Food intake 
 
Several studies demonstrated that NPS is able to reduce food intake acting as an 
anorexigenic signal in the brain. The first evidence for this NPS action was provided by Beck et al. 
60 who demonstrated that the i.c.v. injection of NPS in the 0.4 – 4 nmol range strongly inhibited 
chow intake in overnight fasted rats with effects of longer duration with the highest dose. In the 
same study similar inhibitory effects were observed for the spontaneous intake of a palatable diet 
60. Smith and colleagues 35 later demonstrated that the injection of low NPS doses in the 
paraventricular nucleus of the hypothalamus produces robust anorexigenic effects. The 
observations in rats were confirmed in chicks where NPS inhibits food intake both injected i.c.v. 
and in the paraventricular nucleus or lateral hypothalamus 61. In a follow up study 62 the same 
authors demonstrated that chickens lines selected for low or high body weight are differently 
sensitive to NPS. These data indicate that NPS may differentially affect appetite-related processes 
in hypo- and hyperphagic individuals. Subsequently, Fedeli et al. 63 further demonstrated that NPS 
elicits a marked inhibition of palatable food consumption in rats and that the paraventricular 
nucleus of the hypothalamus represents an important site of action for this NPS effect 63. Moreover 
the NPSR antagonists [D-Cys(tBu)5]NPS was able to completely counteract the NPS action on 
palatable food intake being per se inactive 63. These results demonstrate that the NPSR protein is 
involved in the anorectic action of NPS and suggest that the NPS/NPSR system does not exert a 
tonic control on this biological function. This hypothesis were then confirmed in two parallel 
studies by Peng et al. 64 using the NPSR antagonists [D-Val5]NPS and Cifani et al. 65 using the 
NPSR antagonists [D-Cys(tBu)5]NPS and [tBu-D-Gly5]NPS and the NPSR partial agonists 
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[Aib5]NPS and [Ala3]NPS. [D-Val5]NPS was in fact able to block the NPS anorectic action being 
per se inactive in fasted mice 64, moreover [D-Cys(tBu)5]NPS and [tBu-D-Gly5]NPS counteracted 
the palatable food intake inhibition induced by NPS and they did not affect palatable food intake 
alone 65. [Aib5]NPS, like NPS, reduced food intake, instead [Ala3]NPS blocked the NPS action 
being per se inactive 65. All these results corroborate the evidence that NPS elicits inhibition of 
food consumption through selective NPSR activation and that the NPSergic pathway does not have 
a role in the tonic regulation of feeding behaviour. Obviously studies performed with NPSR(-/-) 
mice are needed to further confirm these findings. 
Interestingly, the NPS effects on food consumption were not modified by the CRF receptor 
antagonists CRF 9–41 63 and NBI-27914 64, indicating that palatable food intake inhibition by NPS 
is independent from the activation of the CRF system.  
While the above mentioned studies converge indicating that NPS reduce food intake, the 
report by Niimi et al. 66 provided opposite findings showing that the i.c.v. injection of NPS (1 
nmol) in rats slightly but significantly stimulated feeding. In the same study it has been shown that 
centrally administered NPS increased Fos-like immunoreactivity in orexin-expressing neurons of 
the lateral hypothalamic area. Thus the orexin system may take part to the actions of NPS on food 
intake. 
 
Learning and memory 
 
NPSR mRNA is expressed significantly in the major input and output regions of 
hippocampal formation, which are critical in the modulation of learning and memory. The first 
study aimed to investigate the effects of NPS on spatial learning and memory was performed by 
Han et al. 67 using the Morris water maze task. It was demonstrated that NPS (1 nmol) given i.c.v. 
before training trials facilitates spatial memory acquisition, in fact NPS treated mice spent 
significant more time in the target quandrant of the maze 67. Furthermore NPS was able to mitigate 
the spatial memory impairment caused by the N-methyl-D-aspartate receptor antagonist MK801 67 
and by rapid eye movement sleep deprivation 68. This first study by Han and colleagues 67 did not 
provide any indication regarding the role exerts by the endogenous NPS in regulating the 
mechanisms of spatial learning and memory. However a subsequent study performed with NPSR(-
/-) mice reported  no differences between the performance of  NPSR(+/+) and NPSR(-/-) mice in 
the Morris water maze test, suggesting  that endogenous NPS may not modulate spatial learning 
and memory under basal conditions 38. A very recent study by Okamura et al. 69 demonstrated that 
NPS enhances long-term memory, possibly by acting during the consolidation phase. In the 
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inhibitory avoidance test NPS (1 nmol) was able to enhance emotionally aversive long-term 
memory until 96 hours after post training session 69. Similarly, NPS increased the non-aversive 
memory in the novel object recognition (NOR) task until one week after the training trial 69. Of 
note, NPS was effective when given after the training session, instead pre-training or pre-retrieval 
NPS administrations failed to enhance memory retention, suggesting that NPS may act during the 
consolidation phase 69. Interestingly the NPSR antagonist SHA 68 completely counteracted the 
NPS effect in the inhibitory avoidance paradigm demonstrating that the mechanism by which NPS 
facilitate emotionally aversive memory is the selective activation of the NPSR protein 69. 
Furthermore NPSR deficient mice shown impaired performance in the inhibitory aversive memory, 
novel object recognition, and novel place or context recognition, suggesting that activity of the 
endogenous NPS system is required for memory formation 69. The central noradrenergic system 
seems to be involved in the NPS-induced memory enhancement, since the block of the 
noradrenergic receptors by propranolol attenuated this NPS effect 69. In summary NPS system can 
have a significant role in the facilitation of various type of memory, such us spatial, emotional 
aversive and non aversive memory. 
 
Pain transmission 
 
NPSR mRNA is highly expressed in the periaqueductal gray 14, which is an important 
component of descending analgesic system 70. Using the tail withdrawal and hot-plate test Li et al. 
71 demonstrated that NPS (0.01–1 nmol, i.c.v.) caused a dose-dependent antinociceptive effect. The 
first findings by Li et al. were then confirmed by Peng and colleagues 72, using the formalin test. 
This is a very useful model of clinical pain in which the first phase seems to be caused by direct 
activation of peripheral nociceptors, while the second phase  is considered to be dependent on an 
inflammatory reaction caused by peripheral and central sensitization. NPS injected i.c.v. 
significantly reduced both the first and the second phase of nociceptive behaviour 72. Interestingly, 
the antinociceptive effects elicited by NPS in the tail withdrawal and hot-plate test were 
completely prevented by the NPSR peptide antagonist [D-Cys(tBu)5]NPS 71, while the NPSR 
antagonist [D-Val5]NPS was able to block the NPS actions in the formalin assay 72. The NPSR 
antagonists given alone did not modify nociceptive transmission 71-72. These results reveal that 
NPS may produce antinociceptive effects through NPSR activation and suggest that the 
endogenous NPS pathway does not control pain transmission under these experimental condition. 
Naloxone did not affect NPS antinociceptive activity in all the assays, indicating that opioid 
systems are not involved in this action 71-72. The antinociception induced by NPS can be due to the 
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activation of neurons in periaqueductal gray, as suggested by the increased c-Fos expression in this 
brain area measured in response to NPS administration 72. 
 
Colonic transit 
 
It has also been reported that NPS inhibited, in a dose-dependent manner (0.001–1 nmol), 
distal colonic transit (measured as fecal pellet output and bead expulsion time) after i.c.v. but not 
i.p. administration 73. The effect evoked by NPS 0.01 nmol was sensitive to the NPSR antagonist 
[D-Val5]NPS (0.1 and 1 nmol, i.c.v.), demonstrating the involvement of NPSR in this biological 
action of NPS 73. Of note, two different studies reported that NPS, in HEK293cells trasfected with 
the NPSR receptor, increases the expression of several peptide involved in the control of 
physiological motor and sensory functions in the gastrointestinal tract, such as somatostatin, 
cholecystokinin, vasoactive intestinal peptide and peptide YY 74-75. Obviously further study are 
needed to verify this NPS action in  native intestinal enteroendocrine cells. 
 
In conclusion there is convincing evidence in the literature that the NPS/NPSR system 
regulates multiple biological functions including locomotor activity, arousal and wakefulness, fear 
expression and anxiety, food intake and gastrointestinal functions, drug addiction, memory 
processes, and pain transmission.  
introduction 
 28
 
1.5 NPSR ligands 
 
1.5.1 NPSR peptide ligands 
 
 
Soon after the identification of the NPS/NPSR system, different research groups started 
medicinal chemistry programs directed to identify the NPS bioactive sequence and its crucial 
residues involved in NPSR recognition. To this aim classical Ala- and D-scans together with N- and 
C-terminal truncation studies were performed 17-18,76. The systematic replacement of the NPS amino 
acid sequence with Ala residues can give information on the contribution of each amino acid side 
chain for NPS bioactivity. Nineteen Ala-substituted NPS analogues were synthesized and evaluated 
in a calcium mobilization assay using HEK293 cells expressing the hNPSR receptor by Roth et al. 
76. Results of these studies indicated that positions 2, 3, 4, and 7 are crucial for NPS bioactivity. In 
particular, the replacement of Phe2 with Ala generated a completely inactive NPS analogue while 
[Ala4]NPS and [Ala7]NPS displayed a drastic loss of potency. Interestingly, [Ala3]NPS bound to the 
NPSR receptor with about 10-fold reduced potency compared to NPS and was able to elicit 
maximal effects corresponding to 50% of those elicited by the natural peptide. Thus, [Ala3]NPS 
behaves as a NPSR partial agonist. Ala substitution in the other NPS positions was fully tolerated 
and did not significantly modified either the potency or the efficacy of the [Alax]NPS analogs. 
Similar studies provided converging evidence demonstrating that the sequence Phe2-Arg3-Asn4 is 
critical for NPS biological activity 18. This study also confirmed the important role played by Gly7 
for NPSR recognition. D-scan investigation was applied to collect information on the contribution 
of the single amino acid chirality for NPS biological activity. Confirming Ala-scan results, these 
studies revealed that the NPS portion Phe2-Arg3-Asn4 is of great importance for NPSR binding and 
activation 76. In fact, replacement of these residues with their enantiomers consistently produced an 
important loss of peptide potency. Inversion of chirality of Val6 generated a low potency NPS 
derivative. D-amino acid substitution of all the other chiral positions did not modify either the 
potency or the efficacy of the [D-Xaax]NPS analogues 76. N- and C-terminal truncation studies 17-
18,76 consistently identified in the N-terminal portion of NPS the crucial amino acid sequence needed 
for NPSR binding and activation. In particular, the deletion of Ser produced a moderate decrease in 
peptide potency while further deletion of Phe2 generated an inactive analog 18,76. In contrast, 
systematic deletion of up to ten residues from the C-terminal part of NPS did not produce major 
changes in peptide biological activity 17-18,76. Further, C-terminal shortening of the NPS sequence 
produced different results with Roth et al. 76 reporting loss of activity while Bernier et al. 18 
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reporting NPS(1–6) as a high potency NPSR agonist. The NPS(1–10) fragment was further 
investigated in vivo in locomotor activity experiments performed in mice. While NPS elicited a 
dose-dependent stimulatory effect in the range 0.01–1 nmol, NPS(1–10) was found inactive up to 
10 nmol 76. These results indicated that the NPS(11–20) sequence seems to be important for 
maintaining in vivo biological activity. Collectively, the data obtained with these first SAR studies 
demonstrated that: (i) the most important residues for NPSR recognition are Phe2-Arg3-Asn4; (ii) 
the sequence Val6-Gly7 is also important for NPSR bioactivity; (iii) the C-terminal 11–20 sequence 
of NPS is not required for in vitro activity while it is necessary for its in vivo biological effects. 
Important suggestions for the design of novel peptide ligands can be obtained investigating the 
conformation of a given peptide in different environments. NPS conformational investigations 
performed by NMR experiments indicated that NPS presents a completely disordered conformation 
in water 77. However, several NH-NH cross peaks were observed by Bernier et al. 18 in the NPS 
region 5–13; this lead these authors to hypothesize the presence of a nascent helix in this region, 
which, during the NPSR binding process, may favour the formation of a stable α helix structure. On 
the other hand, disordered NPS conformations were observed in different NMR solvent mixtures 
that may favour helicity 77. This NPS behaviour has been ascribed, at least in part, to the presence in 
position 5, 7, and 9 of the flexible amino acid residue Gly. In order to force NPS to adopt a stable a 
helix structure, residues 7, 9, and 13 were replaced with Ala. NMR analyses confirmed that 
[Ala7,9,13]NPS adopts a very stable helix spanning all the peptide sequence but this peptide was 
completely inactive at NPSR 77. Single amino acid substitutions indicated that only the replacement 
of Gly7 with Ala or Aib (2-amino-2-methylpropionic acid) is able to induce a significant helical 
structure, whereas [Ala9]NPS and [Ala13]NPS showed a limited degree of helicity 77. Interestingly, 
[Ala9]NPS and [Ala13]NPS were almost as active as NPS at NPSR while [Ala7]NPS and [Aib7]NPS 
were found inactive. These results indicate that a helical conformation centred around position 7 is 
not compatible with NPS biological activity. Different results were obtained with substitution of 
Gly5 with L- and D-Ala. In fact, both substitutions generated peptide derivatives that showed only 
slightly reduced potency compared to NPS 77. This suggests that an a helix conformation (favoured 
by L-Ala but not by D-Ala) is, at least in this portion of the NPS sequence, not important for NPSR 
binding. Interestingly, [D-Ala5]NPS behaves as a partial agonist at NPSR with efficacy 
corresponding to half of that of NPS. The replacement of Gly5 with the achiral α helix promoting 
residue Aib did not produce a significant increase in peptide helicity and generated an NPS 
analogue with reduced potency and, more importantly, with a statistically significant reduction in 
efficacy 77. These results may be interpreted assuming that the introduction of a methyl group (L-
and D-Ala) or two methyl groups (Aib) on the Cα carbon of position 5 limits peptide flexibility and 
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this causes a reduction in potency. In addition, this reduction of conformational freedom may favour 
partial agonist ([D-Ala5]NPS, [Aib5]NPS), or full agonist ([L-Ala5]NPS) pharmacological activities.  
Collectively, this conformation-activity study together with SAR investigations 
demonstrated that: (i) the sequence Gly5-Val6-Gly7 may represent a flexible peptide region 
important for inducing and/or stabilizing NPS bioactive conformations; (ii) an α helix conformation 
around position 7 is not compatible with NPS biological activity; (iii) modifications of Gly5 may be 
critical for the design of NPSR ligand with reduced efficacy. 
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1.5.2 NPSR non peptide ligands 
 
The first example of non peptide molecules able to interact with the NPSR was reported in 
the patent literature by Takeda researchers 78. These compounds are characterized by a 3-oxo-
tetrahydro-oxazolo[3,4-a]pyrazine scaffold mainly substituted in position 1 and 7. Among this 
series of compounds, SHA 68 (figure 3) i.e. the racemic mixture (9R/S)-3-oxo- 1,1-diphenyl-
tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (reported as example 25 
in Fukatzu et al. 78) has been selected by Okamura et al. 33 for in vitro and in vivo pharmacological 
characterization. In radioligand ([125I][Tyr10]NPS) binding experiments SHA 68 displayed high 
affinity (pKi 7.3) for human NPSR. In cells expressing the hNPSR SHA 68 was inactive per se 
while antagonizing the stimulatory effects of NPS on calcium mobilization in a competitive manner. 
Similar high pA2 values were obtained at hNPSR Ile107 (7.6) and Asn107 (7.8) receptor isoforms. 
SHA 68 appears to be selective for NPSR since it did not affect signalling at 14 NPSR unrelated G-
protein coupled receptors 33. Pharmacokinetic analysis demonstrated that SHA 68 reaches 
pharmacologically relevant levels in plasma and brain after i.p. administration. Furthermore, 
peripheral administration of SHA 68 in mice (50 mg/kg i.p.) was able to antagonize NPS-induced 
stimulation of locomotor activity 33. In a separate study SHA 68 given into the amygdala exerted 
functionally opposing responses compared to NPS 25. Thus, available data demonstrated that SHA 
68 behaves as a potent and selective NPSR pure antagonist. SAR studies performed on position 7 of 
SHA 68 indicate that a urea functionality is required for potent NPSR antagonist activity while 
alkylation of the urea nitrogen or replacement with carbon or oxygen generated less potent 
derivatives. In addition, compounds with a-methyl substitution or elongated alkyl chains had 
reduced potency, indicating a limited tolerance for position 7 substituents. The only chemical 
modification tolerated in this position was the elimination of the fluorine atom in the para position 
of the phenyl ring; this generates a molecule (SHA 66), which displays similar potency to the parent 
compound 33,79. 
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Figure 4 Chemical structure of the non peptide NPSR antagonist SHA 68 
 
 
Subsequently, Merck researchers, using HTS techniques, identified and developed two new 
structural classes of potent NPSR antagonists, characterized by a quinoline 80 and a tricyclic 
imidazole 81 scaffold. From the first series of compounds the NPSR antagonist NPSR-QA1 has been 
identified. This compound showed potent binding to the rat NPSR receptor in in vitro binding 
displacement studies with an IC50 of 1.3 nM, furthermore it provided high occupancy of NPSR in 
the brain after i.p. dosing 80. From the tricyclic imidazole series the compound NPSR-PI1 was 
identified, with an IC50 of 43 nM in FLIPR experiments. It exhibited significant plasma free 
fractions after i.p. administration, enabling in vivo central nervous system exposure 81. Thus NPSR-
QA1 and NPSR-PI1 are potent, highly selective and CNS penetrant NPSR antagonist and they 
represent a useful pharmacologic tool for further study of the effects of central NPSR antagonism in 
vivo. Up to now no data are reported on the effectiveness of these NPSR antagonists in vivo.  
Recently GlaxoSmithKline researchers published a new series of NPSR antagonists, with 5-
phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-one structure 
82. 
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1.6 NPSR knockout mice 
 
NPSR(-/-) mice were generated on 129S6/SvEv strain in Taconic laboratories as described 
in Allen et al. 83. The inactivation of the NPSR protein was obtained by replacing the majority of 
exon 4 with the neomycin cassette. This deletion is predicted to remove the third transmembrane 
spanning domain and regions of the intracellular loop 2 83. Allen and colleagues investigated the 
functional significance of NPSR in the regulation of lung physiology and pathology. Despite the 
loss of functional NPSR, no differences were detected in the development of asthma and allergic 
lung pathology in NPSR(-/-) mice. Neither qualitative nor quantitative differences in the cellular 
infiltrate, nor the development of airway hyperresponsiveness in response to methacholine, 
distinguished the mutant mice from their littermate controls 83. Thus, no evidence for abnormal 
respiratory or immunological functions were recorded in mice lacking NPSR. These first findings 
by Allen and colleagues were very  recently confirmed in a study performed by Zhu et al. 84 using 
NPSR deficient mice in which the exon 2 was deleted. No differences in the lung inflammation and 
respiration in response to ovalbumine or A. fumigatus exposure were measured between NPSR(+/+) 
and NPSR(-/-) mice, suggesting that endogenous NPS is not directly involved in the development of 
experimental asthma 84. 
In the last few years the behavioural phenotype of NPSR(-/-) mice was deeply investigated 
in different laboratories, using NPSR(-/-) mice on a 129S6/SvEv 36 or C57BL/6 genetic background 
37-38,50. The first of these studies was performed by Duangdao et al. 36. They reported that NPSR(-/-) 
mice display lower late peak wheel running activity during the subjective evening at the end of the 
dark phase, suggesting that a functional NPS system is required for expression or maintenance of 
arousal. This hypothesis was corroborate by the subsequent results obtained by Fendt and 
colleagues 37, that recorded a decreased LA during the dark phase in mice lacking the NPSR 
protein.  
Interestingly, NPSR(-/-) mice were found by Duangdao et al. 36 to display increased levels 
of anxiety-like behaviours in the OF, EPM and light dark box tests, providing evidence for a 
substantial role of the endogenous NPS system in regulating anxiety levels. On the contrary, no 
differences were observed in the OF and in the elevated zero maze assays by Zhu and colleagues 38 
and in the OF and EPM tests by Fendt et al.37. Importantly, NPS failed to have anxiolytic effects in 
the elevated zero maze and OF tests in mice lacking the NPSR receptor 38. Thus it was 
demonstrated that NPS elicits anxiolysis through the selective activation of the NPSR protein.  
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 No differences were recorded between NPSR(+/+) and NPSR(-/-) mice by Duangdao et al. 
36 in the FST, indicating that NPS/NPSR system is not involved in regulating depressive-like 
behaviour, instead Zhu et al. 38 found an increased depressive phenotype in male NPSR(-/-) mice in 
the FST but not in the tail suspension test. Furthermore NPSR(-/-) mice are reported to be less 
reactive in the acoustic startle response test by Zhu et al. and Fendt et al. 37-38, but no differences 
were recorded by Duangdao et al. 36 in this paradigm.  
No differences were reported between NPSR(+/+) and NPSR(-/-) mice in terms of 
spontaneous LA 36-38, furthermore the sensitivity of NPSR(-/-) mice to the stimulant action of 
metamphetamine 38 and cocaine 37 was superimposable to that of NPSR(+/+) mice. These results 
clearly indicate that the endogenous NPS does not control mice locomotion and is not involved in 
the mechanisms by which cocaine and metamphetamine elicit stimulation. All the research groups 
demonstrated that NPS is able to increase mice locomotion in NPSR(+/+) but not in NPSR(-/-) 
mice, thus the NPS stimulant effects are selectively due to the NPSR activation 36-38.  NPSR(-/-) 
appear to have improved motor coordination in the accelerating rotarod test when compared to 
NPSR(+/+) mice, instead body weight and body length appeared equal between both groups of mice 
36. 
A very recent study by Okamura et al. 69 shown that mice lacking the functional NPSR 
receptor display deficits in inhibitory avoidance memory,  NOR and novel place or context 
recognition, suggesting that activity of the endogenous NPS system is required for memory 
formation. Instead the performance of NPSR(-/-) mice in the Morris water maze test was similar to 
NPSR(+/+) mice, indicating that the NPS/NPSR system is not involved in spatial learning and 
memory mechanisms 38.  
Finally, the plasma corticosterone levels after a stressful event (FST or immobilization) were 
found superimposable in NPSR(+/+) and NPSR(-/-) mice 38,50, instead after 1 hour of  
immobilization the gene expression levels of some anxiety and stress-related genes was found 
altered in NPSR(-/-) mice. In particular these mice presented an upregulation of JunB and 
interleukin 1 β in the cortex and hypothalamus and a downregulation of  the neurotrophic factor 
neurotrophin 3 in cortex and striatum 50. 
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1.7 Aims 
 
The main objectives of this work have been to: 
 
• perform SAR studies aimed at the identification of novel and useful ligands selective for the 
NPSR receptor; these activities allow us to identified the first generation of NPSR peptide 
antagonists. 
• investigate the in vivo action of NPS in mice in different behavioural assays, including LA, 
RR, EPM, OF and SIH tests. 
• characterize the in vitro and in vivo pharmacological profile of peptide and non peptide 
NPSR antagonists. 
• deeply evaluate the phenotype and NPS sensitivity of mice lacking the NPSR receptor in a 
battery of behavioural assays.
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2. MATERIALS AND METHODS 
 
2.1 Drugs and reagents 
NPS and all related peptides described in this study were synthesized in the laboratory of 
Prof Guerrini (Department of Pharmaceutical Sciences and Biotechnology Centre, University of 
Ferrara) using standard solid-phase synthesis techniques and purified using High Pressure Liquid 
Chromatography, according to previously published methods 76. Amino acids, protected amino 
acids, and chemicals were purchased from Bachem, Novabiochem, Fluka (Switzerland) or Chem-
Impex International (U.S.A).  
The compound SHA 68 was synthesized using the procedures described by Okamura et al. 
33. 
Caffeine and diazepam were purchased from Sigma Chemical Co (St Louis, MO, USA). All 
cell culture media and supplements were from Invitrogen (Paisley, U.K.). GoTaq DNA Polymerase 
and all PCR reagents were from Promega (Milan, IT). All the consumables and reagents were of the 
highest purity available.  
For in vitro experiments, the peptides were solubilized in bidistilled water and stock 
solutions (1 mM) were stored at -20 °C until use; SHA 68 was solubilized in dimethyl sulfoxide at a 
final concentration of 10 mM and stock solutions were kept at -20 °C until use. The successive 
dilutions were made in HBSS/HEPES (20mM) buffer (containing 0.02% bovine serum albumin 
fraction V). 
For in vivo studies, all peptides were dissolved in saline; SHA 68 was dissolved in saline 
containing 10% cremophor EL (Sigma) just before performing the experiment. Caffeine, morphine 
and amphetamine were dissolved in bidistilled water; diazepam was dissolved in water containing 
0.5% Tween 80 (Sigma). 
 
 2.2 Buffer composition 
Calcium mobilization assay buffers: 
 
HBSS (Hanks’ Balanced Salt Solution): KCl (5.4 mM), KH2PO4 (0.44 mM), NaCl (137 
mM), NaHCO3 (4.2 mM), Na2HPO4 x 7 H2O (0.25 mM), CaCl2 (1.3 mM), MgSO4 x 7 H2O (1 
mM), glucose (5 mM). 
Loading solution: cell culture medium, HEPES (20 mM), probenecid (2.5 mM), calcium-
sensitive fluorescent dye Fluo 4AM (3 µM), pluronic acid (0.01%). 
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Dye loading solution: HBSS, HEPES (20 mM), probenecid (2.5 mM), Brilliant Black (500 
µM). 
 
2.3 In vitro studies 
2.3.1 Calcium mobilization assay 
 
Human Embryonic Kidney (HEK) 293 cells stably expressing the mouse recombinant NPSR 
receptor (HEK293mNPSR) were generated as described in Reinscheid et al. 17, maintained in DMEM 
medium supplemented with 10% fetal bovine serum, 2 mM, L-glutamine and Hygromycin (100 
mg/L) and cultured at 37 °C in 5% CO2 humidified air.  
HEK293mNPSR was seeded at a density of 50000 cells/well into poly D-lysine coated, 96-
well, black, clear-bottom plates. The following day the cells were incubated with the loading 
solution for 30 min at 37 °C (figure 5). Afterwards the loading solution was aspirated and 100 
µl/well of dye loading solution was added. After placing cell culture plate and compound plate into 
the FlexStation II (Molecular Device, Union City, CA 94587, US), fluorescence changes were 
measured at real time or at 37°C. On-line additions were carried out in a volume of 50 µl/well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Diagram depicting the experimental protocol of the calcium mobilization assay. Cells are incubated with 
Fluo-4 AM, de-esterification of the ester group (AM) traps the dye in the cells and further leakage of the dye is 
prevented by blockage of organic anion-transport inhibitors using probenecid. Background fluorescence is reduced by 
addition of Brilliant Black dye which blocks extracellular signalling from any leaked Fluo-4. 
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Cell counting 
 
Accurate cell number in a cell suspension can be efficiently calculated using a cell counting 
chamber (Burker’s chamber, figure 6). A small volume of the cell suspension (10 µl) was pipetted 
onto the chamber, the capillary action under the cover slip will draw the suspension into the 
counting chamber. The space between the cover slip and the counting chamber ensures a specific 
volume of cell suspension is present. 
 
 
 
Figure 6 Burker’s chamber. 
 
Under a microscope the number of cells in diagonally opposite counting areas were counted, 
(figure 7).  
 
Figure 7. Schematic representation of the counting grid of the Burker’s chamber. 
 
The Burker’s chamber is formed of 3x3 major squares, each of these major squares is 
subdivided into a grid of 4x4 squares. The number of cells present in three major cells are counted, 
cells in contact with two of the squares sides are included and the average taken. The volume of a 
major square is 0.1 mm3 which is equal to 0.0001 ml. To determine the number of cells per ml the 
average number of cells determined is increased by a factor of 104. 
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Instruments 
 
[Ca2+]i levels were monitored using a FlexStation II fluorimeter (figure 8). The FlexStation 
II system includes: 
1 Xenon-lamp light source 
2 Automatic eight-channel pipettor 
3 Tip rack drawer 
4 Compound plate drawer 
5 Reading chamber drawer 
 
The Xenon-lamp light source and dual monochromators permit the use of essentially all 
dual-wavelength dyes for functional cellular assays. 
 
 
Figure 8. Diagram of FlexStation II used for calcium mobilization assay. 
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 2.4 Ex vivo studies 
 2.4.1 DNA extraction and PCR 
 
DNAs were prepared from tail biopsies using Eazy Nucleic Acid Isolation Tissue DNA Kit 
(Omega Biotek). One µl of genomic DNA was added to a PCR reaction mix containing 3 mM 
MgCl2, deoxribonucleotide triphosphates (dNTPs) and primers in a final concentration of 4 µg/ml. 
Three oligonucleotide primers were used. The first one was a forward primer specific to the 
endogenous NPSR locus (5’)CCTTATCCTCAAACCACGAAGTAT(3’). The second one was a 
common reverse primer (5’)GTGGGTACATGAGAAGGTTAGGAG(3’) and the third one was a 
forward primer (5’)AAATGCCTGCTCTTTACTGAAGG(3') specific to the targeting plasmid. The 
reagents were mixed in a Green GoTaq ThermoPol Reaction Buffer. 2.5 units/reactions of GoTaq 
DNA Polymerase and an aliquot of water were added to bring the reaction mix to 50 µl total 
volume. The reaction was placed in a thermal cycler and heated to 94°C for 1 minute. The reaction 
was allowed to proceed for 39 cycles as follows: 94°C for 30 seconds, 55°C for 30 seconds, 72°C 
for 1 minute. Finally the reaction was heated to 72°C for 2 minutes and then stored at 4°C. The 
reaction products were separated in 1% agarose by horizontal gel electrophoresis in Tris-acetate-
EDTA buffer, stained with ethidium bromide, and photographed under UV light (figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 PCR protocol and products.  
418 bp 
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 2.5 In vivo studies 
 2.5.1 Animals 
 
All experimental procedures for in vivo studies complied with the standards of the European 
Communities Council directives (86/609/EEC) and National regulations (DL 116/ 92). Male CD-1 
mice (2–3 months old, 28–35 g) were used. They were housed in 425x266x155 mm cages 
(Tecniplast, MN, Italy), eight animals per cage, under standard conditions (24°C, 55% humidity, 
12-h light–dark cycle, lights on 07:00 hours) with food (MIL, standard diet Morini RE, Italy) and 
water ad libitum for at least 10 days before experiments began. All experiments were performed 
between 9:00 and 13:00 and the day before each experiment mice were moved to the testing room 
to acclimate. Each animal was used only once. All non peptide compounds were administered to the 
animals intraperitoneally (i.p., 100 µl/mouse) whereas NPS and related peptides were given to the 
lateral cerebral ventricle (intracerebroventricularly; i.c.v.). I.c.v. injections were performed either 
free hand or using a stainless-steel guide cannula (22 GA) (Plastic One, Roanoke, VA, USA) 
stereotaxically implanted. For each experiment at least four mice were randomly assigned to each 
experimental group, and the experiment was repeated at least three times: therefore each 
experimental point is the mean of the results obtained in >12 mice. All procedures were randomized 
across test groups and, in all the experiments, food was not available during testing.  
 
Free hand i.c.v. injections (2 µl/mouse) were given, under light isofluorane anaesthesia (just 
sufficient to produce a loss of the righting reflex), in the left ventricule according to the procedure 
described by Laursen and Belknap 85. Briefly, the syringe was held at an approximate 45° angle to 
the skull. Bregma was found by lightly rubbing the point of the needle over the skull until the suture 
was felt. Once found, care was taken to maintain the approximate 45° angle and the needle was 
inserted about 2 mm lateral to the midline. The skull is relatively thin at this point, so only mild 
pressure was required to insert the needle. The solutions of drugs were then injected slowly (2 µl in 
about 20 s). 
 
Implantation of cannula into lateral ventricle: Mice (25–30 g) were anesthetized with isofluorane 
and placed in a stereotaxic apparatus. A vertical incision was made in the skin to expose the skull. A 
stainless steel guide cannula was implanted into the lateral ventricle and was fixed with 3 skull 
screws and dental cement. Coordinates toward the bregma were L -1.1  mm, A - 0.5 mm, V + 3 
mm. To prevent occlusion, a dummy cannula was inserted into the guide cannula. The dummy 
cannula did not protrude the guide cannula. After surgery, the animals were allowed to recover for 
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at least 5 days, and during this period, mice were gently handled daily to minimize the stress 
associated with manipulation of the animals throughout the experiments. For i.c.v. injection, awake 
mice were gently restrained by hand and the solutions of drugs (2 µl/mouse) were then injected 
slowly. After completion of testing, mice were i.c.v. injected with trypan blue dye (2 µl) that was 
allowed to diffuse for 10 min. Then mice were decapitated, and their brains were removed and 
rapidly frozen. Gross dissection of the brain was used to verify the placement of the cannula. Only 
the data from those animals with dispersion of the dye throughout the ventricles were used. 
 
NPSR(+/+) and NPSR(-/-) mice 
 
129/SvEv NPSR(+/+) and NPSR(-/-) mice, generated as described in Allen et al. 83, were 
obtained from Taconic Farms (Germantown, NY, USA).  Knock out of the NPSR locus was 
achieved by replacing a 744-bp region containing the majority of exon 4 with a neomycin resistant 
cassette. Exon 4 includes regions of the gene encoding the third transmembrane domain and regions 
of the 2° intracellular loop. For a first series of experiments, NPSR(+/+) and NPSR(-/-) littermates 
were obtained by mating heterozygous NPSR(+/-) 129/SvEv mice. In parallel, mice with the genetic 
background of 129/SvEv were backcrossed for 8 generations to CD-1 mice, to obtain NPSR(+/+) 
and NPSR(-/-) CD-1 congenic colonies (figure 10). All mice were genotyped using PCR to 
determine the target disruption of the NPSR gene. 
Experiments were conducted using adult male NPSR(+/+) and NPSR(-/-) mice 8 - 10 weaks 
old (weighing 28–35 g). For phenotype studies mice were moved to the test chamber at least one 
weak before the experiments to acclimate. Little is known about the potential carry over effect of 
experience of one behavioral test to another 86. However, mice repeatedly exposed to the same test 
display altered responses when reassessed in that given animal model of anxiety 87. Taking into 
account these considerations, our experiments were performed by subjecting two different groups of 
NPSR(+/+) and NPSR(-/-) mice to the procedure described in table 2.  
 
Table 2 Experimental design used to develop the present study 
 
Group 1 EPM OF LA NOR FST RR 
Group 2 OF EPM LA NOR SIH FT 
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Figure 10. Generation of a CD-1 congenic strain. Congenic lines are generated by an outcross of 129Sv/Ev NPSR(+/-) 
to CD-1 strain followed by successive back-crosses of eterozigous to CD-1 strain. The strain is considered congenic 
after the 8 backcross generation. Most loci, except those tightly linked to the mutant locus, are derived from the host 
strain. At this stage it is possible to split the colony in NPSR(+/+) and NPSR(-/-) colonies and generate experimental 
animals. 
CD-1 
CD-1 
CD-1 
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 2.5.2 Locomotor activity 
 
For LA experiments the ANY-maze video tracking system was used (Ugo Basile, 
application version 4.52c Beta). Mice were positioned in square plastic cages (40 cm × 40 cm), one 
mouse per cage. Four mice were monitored in parallel. Mouse horizontal activity was monitored by 
a camera while vertical activity was measured by an infrared beam array. The parameters measured 
were cumulative distance travelled (total distance in m that the animal travelled during the test), 
total time immobile (the amount of seconds the animal stays immobile during the test; the animal is 
considered immobile when 90% of his image remains in the same place for at least 2.5 s), and the 
number of animal rearings (the number of beam breaks due to vertical movements). Naïve mice 
(that is, animals not habituated to the test cage before the experiment) were injected with NPS i.c.v. 
5 min before the beginning of the test. Habituated mice were acclimatised to the test cage for 60 
min before the i.c.v. injection of NPS and then returned to the test cage. Diazepam-treated mice 
received an i.p. injection (100 ml) of diazepam (5 mg/kg) in Tween 80 (0.5%) 15 min before the 
i.c.v. injection of NPS or the i.p. injection of caffeine. NPS (0.01, 0.1, 1 nmol) was given i.c.v. 5 
min before the beginning of the test, [D-Val5]NPS (10 nmol, i.c.v.) was co-injected with NPS, 
instead [tBu-D-Gly5]NPS (1, 3 and 10 nmol) was administered 15 min before i.c.v. injections of 
NPS. SHA 68 (10 and 50 mg/kg) was given i.p. 10 min before NPS or caffeine injection. Caffeine 
(20 mg/kg) was given i.p. 15 min before recording LA. 
 
 2.5.3 Recovery of the righting reflex 
 
The  RR assay was performed according to the procedures described by 88. Mice were given 
an i.p. injection of diazepam 15mg/kg .When the animals lost RR, they were placed in a plastic cage 
and the time was recorded by an expert observer, blind to drug treatments and/or genotype. Animals 
were judged to have regained the RR response when they could right themselves three times within 
30 s. Sleeping time is defined as the amount of time between the loss and regaining of the RR; it 
was rounded to the nearest minute. Caffeine (20 mg/kg, i.p.)  and NPS (0.01, 0.1, 1 nmol, i.c.v.) 
were administered 15 and 5 min before the injection of diazepam, respectively. [D-Cys(tBu)5]NPS 
(10 nmol, i.c.v.) was co-injected with NPS, instead [tBu-D-Gly5]NPS (0.1, 1, 3 and 10 nmol, i.c.v.) 
was administered 15 min before i.c.v. injections of NPS. SHA 68 (10 and 50 mg/kg) was given i.p. 
10 min before NPS. In a separate series of experiments SHA 68 (50mg/kg, i.p.) was injected 10 min 
before the administration of different doses (5, 10, and 15mg/kg) of diazepam. 
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 2.5.4 Elevated plus maze 
 
The EPM assay was carried out essentially as previously described by Pellow et al. 89. The 
EPM apparatus (Hamilton–Kinder, Poway, CA, USA) consists of two open arms (30x5x0.6 cm), 
which are facing two opposite wall-enclosed arms (30x5x20 cm) connected by a central platform 
(5x5 cm) elevated 50 cm from the floor. A red light was focused on the central platform (100 lux). 
Animals were placed at the centre of the maze, with the head facing an open arm. The number of 
entries and the time spent in both closed and open arms and some ethological variables (rearing, 
head dipping and stretch attend postures) were recorded during a 5min period by an experienced 
observer. An entry was scored as such only when the animal placed all four limbs into any given 
arm. The ratio of ‘time spent in the open arms divided by time spent in all (open and closed) arms’ 
and ‘number of entries into open arms divided by total entries into all arms’ was calculated and 
multiplied by 100, to yield the percentage of time spent in and the frequency of entries into open 
arms, respectively. NPS (0.001, 0.01, 0.1, 1 nmol) was given i.cv. 15 min before the beginning of 
the test, caffeine (20 mg/kg) and diazepam (1 mg/kg, i.p.) were administered i.p. 15 and 30 before 
starting the test respectively. 
 
 2.5.5 Stress induced hyperthermia 
 
The SIH test was performed according to the method previously reported by Olivier et al. 90. 
Rectal temperatures were measured to the nearest 0.1°C using an ELLAB instruments thermometer 
(Copenhagen, Denmark) using a lubricated thermistor probe designed for mice (2 mm diameter) 
inserted 20 mm into the rectum, while the mouse was handheld near the base of the tail. The probe 
was left in place until steady readings were obtained (approximately 10 s). Rectal temperatures 
were measured twice in each mouse, at t= 0min (T1) and t= 10min (T2). The first rectal body 
temperature measurement (T1) induces a mild stress that causes an increase in the second value (T2). 
The difference in temperature (T2-T1) was considered to reflect SIH. NPS (0.01, 0.1 and 1 nmol, 
i.c.v.) and diazepam (1, 3 and 5mg/kg, i.p.) were administered 60 min before the test. This relatively 
long period of pretreatment is needed because the injection procedure (handling plus injection) 
evokes a similar increase in core body temperature as the rectal temperature measurement 
procedure. This stress effect had waned after 60min and the basal body temperature returned to the 
undisturbed baseline 90. 
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 2.5.6 Open field  
 
The OF test was performed using the ANY-maze video tracking system (Ugo Basile, 
application version 4.52c Beta). Briefly the mouse was placed in a square plastic cage (40×40 cm) 
and ambulatory behaviour was monitored for 10 min. The central zone of the open field was 
defined as the central 20×20 cm square. Horizontal activity was monitored by a camera. Four mice 
were monitored in parallel in each experiment. The parameters measured were the same considered 
in the LA assay. The number of entries in the central zone and the time spent by the animal in the 
central area of the field were also measured. An entry in the central zone occurred when the entire 
area of the animal was in the central square and the time in the central zone is defined as the amount 
of time in seconds that the animal spent in the central square. Diazepam (0.3, and 1 mg/kg) was 
administer i.p. 30 min before the beginning of the experiment. NPS (0.01, 0.1 and 1 nmol) was 
given i.c.v. 15 min before the beginning of the test,  evaluated. SHA 68 (50 mg/kg, i.p.) was 
administered 10 min before NPS injections. 
 
 2.5.7 Novel object recognition 
 
The NOR was performed according to the method reported by Ennaceur et al. 91. The test 
was conducted in three phases: acclimation, acquisition and test. For acclimation, the mouse was 
placed into the NOR chamber (a square open field 40×40 cm) and allowed to explore freely for 30 
min. No objects were placed in the box during the habituation trial. Immediatly after habituation, 
the acquisition trial was conducted by placing the mouse in the field, in which two identical objects 
were positioned on the corners of  the arena approximately 5 cm from the walls. Mice were allowed 
to explore the two objects for 10 min, and exploratory activity (i.e., the time spent exploring each 
object) was recorded. After 3 h, mice were re-exposed to the same object of the acquisition phase, 
together with a novel object (not used in acquisition phase). Once again, the time that each animal 
spent exploring each object was measured. A mouse was considered to be involved in exploratory 
behaviour when its head was oriented directly towards the object and within approximately 1-2 cm 
from it. For test data, the percentage of exploration time spent at the novel object was determined. 
The choice of object for novel or familiar was counterbalanced, and the position of each object was 
also alternated between trials to avoid any misinterpretation of data. After each exposure, the 
objects and test chamber were cleaned with 10% ethanol to eliminate odour cues. These 
experiments were performed using the ANY-maze video tracking system (Ugo Basile, application 
version 4.52c Beta). 
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 2.5.8 Forced swimming test 
 
The FST was performed as described by Porsolt et al. 92. Mice were placed individually in 
polyethylene cylinders (18.5 cm high, 12.5 cm diameter), containing water (25 ± 1 °C, 13.5 cm 
deep), for two swimming sessions: an initial 15 min training session on day 1, which was followed, 
24 h later (day 2), by a 5 min test session. Results were relative to this 5 min test session. The 
immobility time (i.e. the time spent floating in the water without struggling) was recorded. Scoring 
was performed by an observer blind to the animal genotype. At the end of the swimming sessions, 
the animal was removed from the cylinder, dried with paper towels, placed in an individual cage to 
rest and recover, and then it was returned to its collective home cage. 
 
2.5.9 Formalin test 
 
The procedure used was essentially the same as reported by Hunskaar et al. 93. 
Approximately 30 min before testing, mice were individually placed in transparent observations 
chambers (32 cm high, 24 cm diameter) for adaptation. Then the animal was taken out of the 
chamber, and 20 µl of 1.5% formalin solution was injected into the dorsal surface of the right hind 
paw. Immediately after formalin injection, each mouse was returned to the observation chamber, 
and time (s) spent by the animal displaying pain-related behaviours was measured with a hand-held 
stopwatch for each 5-min block for 45 min after formalin injection. The nociceptive behaviours 
consisted of licking, biting and lifting of the injected paw. Time spent by the animal showing all 
these pain-related behaviour was cumulatively measured and expressed as seconds of nociceptive 
behaviour/min. The cumulative response times during 0-10 min and during 15-45 min were 
regarded as the first phase and second phase responses, respectively. 
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 2.6 Data analysis and terminology 
All data are expressed as means ± standard error of the mean (s.e.m.) of n experiments. For 
potency values 95 % confidence limits were indicated. Data have been statistically analyzed with 
the Student’s t test for unpaired data, one way ANOVA followed by the Dunnett’s test, or two-way 
ANOVA followed by the Bonferroni post hoc test, as specified in table and figure legends; p values 
less than 0.05 were considered to be significant. The pharmacological terminology adopted in this 
manuscript is consistent with the IUPHAR recommendations 94. 
Calcium mobilization data are expressed as fluorescence intensity units (FIU) in percent 
over the baseline.  
Agonist potencies are given as pEC50 = the negative logarithm to base 10 of the molar 
concentration of an agonist that produces 50% of the maximal possible effect of that agonist. 
Concentration response curve to agonists were fitted with the following equation: 
 
Effect = baseline + (Emax-baseline)/(1+10^((LogEC50 - X)*HillSlope)) 
 
where X is the agonist concentration. 
The Emax is the maximal effect that an agonist can elicit in a given tissue.  
Antagonist properties were first evaluated in inhibition response experiments, antagonist 
potency was expressed as pKB values. pKB values were derived from inhibition response curves 
using the following equation:  
 
KB = IC50/([2 +([A]/EC50)n]1/n – 1) 
  
where IC50 is the concentration of antagonist that produces 50% inhibition of the agonist response, 
[A] is the concentration of agonist, EC50 is the concentration of agonist producing a 50% maximal 
response and n is the Hill coefficient of the concentration response curve to the agonist 95. 
Moreover to investigate the type of antagonism exerted by NPSR ligands the classical Schild 
protocol was performed. In case of a competitive antagonist potency was expressed as pA2. pA2 is 
the negative logarithm to base 10 of the antagonist molar concentration that makes it necessary to 
double the agonist concentration to elicit the original response. The pA2 values are calculated using 
Schild’s linear regression, that correlates the log of concentrations of antagonists (x axis) to the log 
of (CR-1) (y axis), where CR is the ratio between the EC50 (nM) values of agonist, in the presence 
and in absence of antagonist. The value of x for y=0 represents the pA2 value, and the slope not 
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significantly different from the unity means that the antagonist is competitive. In case of a non 
competitive antagonist potency was expressed as pKB. pKB values were derived from Shild protocol 
experiments using the following equation:  
 
pKB = log10[(slope-1)/[B]] 
 
where slope is calculated from a double-reciprocal plot of equieffective concentrations of agonist in 
the absence and presence of antagonist [B] 95.
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3. RESULTS AND DISCUSSION 
 
3.1 In vitro pharmacological characterization of NPS analogues modified in position 2, 3 and 
4 
 
Pivotal structure and conformational–activity relationship studies consistently demonstrated 
that the N-terminal part of NPS is crucial for biological activity 17,76-77. In particular, based on 
findings obtained from Ala- and D-aminoacid-scan studies, Phe2-Arg3-Asn4 18,76 were identified as 
the most important residues in NPS sequence. Thus, we decided to deeply investigate the chemical 
features of NPS position 2, 3 and 4 for biological activity. 
 
In a first study Phe2 was replaced with 10 different coded amino acids, with aromatic, 
lipophilic, and hydrophilic side chains. Subsequently Phe2 was replaced with 21 non coded Phe 
analogues. These Phe analogues were used with the aim of examining in detail the effects on the 
NPS biological activity of (i) modifications of the aromaticity, length, size, and position of the 
amino acid side chain, (ii) conformational restrictions, and (iii) insertion of different chemical 
groups in the phenyl ring. All the compounds were tested for intracellular calcium mobilization 
using HEK293mNPSR cells in the fluorometric imaging plate reader FlexStation II. In the calcium 
mobilization assay NPS increased the initial calcium concentrations in a concentration dependent 
manner with pEC50 and Emax values of 8.96 and 270% over the basal ones, respectively (figure 11).  
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Figure 11 Concentration-response curves to NPS in HEK293mNPSR. Data are mean±s.e.m of 4 experiments made in 
duplicate.  
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Table 3 summarizes data obtained investigating the SAR requirements of NPS positions 2 with 
natural amino acids.  
 
Table 3 Effects of NPS and [X2]NPS analogues substituted with coded residues in HEK293mNPSR cells 
  pEC50 (CL95%) Emax ± sem 
 NPS 8.96 (8.81-9.11) 270 ± 12 % 
1 [His2]hNPS 6.88 (6.79-6.97) 288 ± 5 % 
2 [Tyr2]hNPS 8.63 (8.38-8.88) 312 ± 5 % 
3 [Trp2]hNPS 8.65 (8.45-8.85) 323 ± 4 % 
4 [Leu2]hNPS 8.08 (7.92-8.24) 282 ± 15 % 
5 [Lys2]hNPS Crc incomplete: at 10 µM 103 ± 15 % 
6 [Asp2]hNPS Crc incomplete: at 10 µM 39 ± 3 % 
7 [Glu2]hNPS Crc incomplete: at 10 µM 170 ± 20 % 
8 [Asn2]hNPS Crc incomplete: at 10 µM 49 ± 2 % 
9 [Gln2]hNPS Crc incomplete: at 10 µM 54 ± 6 % 
10 [Thr2]hNPS Crc incomplete: at 10 µM 114 ± 5 % 
Data are means of at least 4 separate experiments, performed in duplicate.  
 
The replacement of Phe2 with His (compound 1) produced a 100-fold reduction in potency while 
that with Tyr (compound 2) and Trp (compound 3) generated only a slight decrease in biological 
activity. The nonaromatic lipophilic residue Leu produced a peptide (compound 4) about 10-fold 
less potent than NPS. The series of hydrophilic residues with basic (compound 5), acidic 
(compounds 6 and 7), and neutral (compounds 8–10) side chains produced a drastic (3 log unit) loss 
of potency. These results suggested that the lipophilicity of the side chain of the residue in position 
2 is indeed a crucial requirement for the NPSR interaction. However, steric hindrance is also 
important since Ala/Phe2 substitution has been consistently reported to be highly detrimental for 
biological activity. Although aromaticity is not strictly required, none of the investigated NPS 
analogues displayed higher potency than the natural sequence, thus indicating that the benzyl 
moiety of Phe2 is the most effective chemical structure in promoting receptor binding. On the 
aforementioned bases, a second round of synthesis was planned to investigate in details the SAR 
requirements of the Phe2 benzyl moiety. The biological results of this study are summarized in table 
4. The elimination of aromaticity (compound 11) is well tolerated and generates an NPS analogue 
equipotent to the natural ligand. Data obtained with compound 11 confirmed those relative to 
compound 4 indicating that aromaticity in position 2 is not crucial for the NPSR interaction. 
However, cyclic lipophilicity seems to be favored, since [Cha2]NPS is equipotent to the reference 
peptide while 6-fold more potent than [Leu2]NPS. The introduction, into the para position of the 
phenyl ring, of an atom of the halogen series (compounds 12–15) as well as of chemical groups 
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with electron donor (compound 16) or withdrawing (compounds 17–19) properties seemed to be 
well tolerated, and it generated NPS analogues with similar potency to that of the natural sequence. 
Similarly, the introduction of a methyl group into the ortho position of the phenyl ring (compound 
20) did not affect the biological activity at NPSR. Collectively, these data indicate that the 
modulation of the electronic asset of the benzyl side chain of Phe2 is not important for the NPSR 
interaction. Changes of the distance between the Phe2 phenyl ring and the peptide backbone 
obtained by eliminating (compound 21) or adding (compound 22) a methylene group produced very 
different results. In fact, compound 21 was almost inactive up to 10 µM while compound 22 was 
only 3-fold less potent than NPS. The shift of the Phe2 benzyl moiety with respect to the peptide 
backbone produced a 10-fold less active derivative in the case of N-shift (compound 23) while 
substituting Phe with β-Phe (compound 24) generated an inactive derivative. These results together 
with the detrimental effect obtained by changing the chirality of Phe2 demonstrated that the spatial 
disposition of the phenyl moiety relative to the peptide backbone was indeed very important for 
biological activity.  
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Table 4 Effects of NPS and [X2]NPS analogues substituted with non coded residues in HEK293mNPSR cells 
N° Compound pEC50 (CL95%) Emax ± sem 
 NPS 8.93 (8.81-9.05) 277 ± 11 % 
11 [Cha2]NPS 8.87 (8.29-9.45) 221 ± 16 % 
12 [(pI)Phe2]NPS 8.75 (8.54-8.96) 243 ± 25 % 
13 [(pF)Phe2]NPS 8.96 (8.72-9.20) 291 ± 21 % 
14 [(pCl)Phe2]NPS 9.15 (8.81-9.49) 298 ± 27 % 
15 [(pBr)Phe2]NPS 9.19 (8.93-9.45) 309 ± 26 % 
16 [(pCH3)Phe2]NPS 9.17 (8.77-9.57) 317 ± 18 % 
17 [(pCF3)Phe2]NPS 8.59 (8.34-8.84) 286 ± 12 % 
18 [(pCN)Phe2]NPS 8.48 (8.19-8.77) 296 ± 14 % 
19 [p(NO2)Phe2]NPS 8.44 (8.24-8.64) 290 ± 10 % 
20 [(oCH3)Phe2]NPS 8.73 (7.89-9.57) 222 ± 40 % 
21 [Phg2]NPS crc incomplete: at 10 µM:141 ± 24 % 
22 [hPhe2]NPS 8.38 (7.43-9.33) 196 ± 23 % 
23 [NPhe2]NPS 7.81 (7.25-8.37) 246 ± 13 % 
24 [βPhe2]NPS crc incomplete: at 10 µM:177 ± 24 % 
25 [Tic2]NPS 8.09 (8.01-8.17) 244 ± 19 % 
26 [Atc2]NPS 7.95 (7.30-8.60) 257 ± 27 % 
27 [Aic2]NPS 7.95 (7.30-8.60) 257 ± 27 % 
28 [1Nal2]NPS 8.71 (8.24-9.18) 232 ± 6 % 
29 [2Nal2]NPS 8.66 (8.44-8.88) 203 ± 14 % 
30 [Bip2]NPS 7.70 (6.98-8.42) 170 ± 19 %* 
31 [Dip2]NPS crc incomplete: at 10 µM:130 ± 24 % 
Data are means of at least 4 separate experiments, performed in duplicate.. *p < 0.05 vs NPS Emax according to one-
way ANOVA followed by the Dunnett test. 
 
This was further corroborated by the results obtained with the introduction in position 2 of 
constrained Phe analogues. In fact, the cyclization of the benzyl side chain on the nitrogen 
(compound 25) or on the Phe chiral carbon (compounds 26 and 27) produced NPS derivatives 
approximately 10-fold less potent than NPS. The addition of a further phenyl ring on the Phe2 side 
chain was well tolerated in the case of Nal isomers (compounds 28 and 29) but not in the case of 
[Bip2]NPS (compound 30) or [Dip2]NPS (compound 31), which were 10- and 1000-fold less potent 
than the parent peptide, respectively. Collectively, these results suggest that the NPSR ligand 
binding pocket allocating the side chain of Phe2 does not show particularly stringent hindrance 
requirements. In fact, among the enlarged aromatic side chain analogues tested, only compound 31 
completely lost biological activity. Interestingly, compound 30 displays a statistically significant 
reduction of efficacy, with its maximal effect being only 62% of those elicited by the natural 
peptide (figure 12). This suggests that the correct position of the phenyl ring of Phe2 into the NPSR 
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ligand-binding pocket is important not only for binding but also for receptor activation. Other 
NPSR ligands with reduced efficacy have been described by substituting Arg3 with Ala 76 and Gly5 
with 2-aminoisobutyric acid (Aib) or D-Ala 77. Collectively, these findings corroborate the proposal 
18,76 that the N-terminal part of NPS represents the message domain of this peptide. 
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Figure 12 Concentration-response curves to NPS and [Bip2]NPS obtained in the same plates of HEK293mNPSR. Data are 
mean±s.e.m of 4 experiments made in duplicate. *p < 0.05 vs NPS Emax according to the Student t test for unpaired data 
 
 
A subsequent study was performed by replacing Arg3 and Asn4 with several coded and non 
coded amino acid residues. 38 novel NPS analogues were synthesised and pharmacologically 
evaluated in a calcium mobilization assay using HEK293mNPSR and the fluorometric imaging plate 
reader FlexStation II. All data obtained investigating the SAR requirements of NPS positions 3 and 
4 are summarized in tables 5 and 6, respectively. The substitution of Arg3 with aromatic residues 
(compounds 32–34) produced a drastic loss of biological activity; the best compound ([His3]NPS) 
being more than 100-fold less potent than the natural peptide. Similar results were obtained with 
non-aromatic lipophilic residues (compounds 35–36). The introduction in position 3 of residues 
with hydrophilic neutral (compounds 37–42), basic (compound 43) or acidic (compounds 44–45) 
character produced low potency or inactive NPS analogues. Among these, only [Lys3]NPS 
displayed a potency value similar to that of native NPS. These results, obtained by exchanging Arg3 
with coded amino acids, suggest that position 3 does not tolerate substitution with aromatic and 
aliphatic branched residues. The Arg3 replacement with hydrophilic residues with short side chain 
produced in general low potency peptides (compounds 37-41). Interestingly, while the substitution 
of Arg3 with Gln (compound 42) reduced peptide potency only by 10-fold, exchanges to Asn or Glu 
lead to inactive analogs. These results, together with the inactivity of [Val3]NPS, indicate that a 
linear 3-carbon atom moiety of the amino acid side chain, which is similar in both Arg and Gln, but 
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not in Val or Ala 18,76, is important for binding the NPSR pocket that harbors the Arg3 side chain. 
However, this same pocked does not tolerate an acidic side chain as demonstrated by the lack of 
activity of [Glu3]NPS. Moreover, the data obtained by the replacement Arg/Gln suggested that 
basicity in position 3 is not crucial for bioactivity. The shortening of the Lys side chain by one 
carbon atom (compound 46) appears to be well tolerated producing a peptide only 2-fold less 
potent. In addition, the elimination of the primary amino function (compound 47) produced a 
modest reduction of biological activity corroborating the hypothesis that basicity in position 3 is not 
a stringent requirement for NPSR interaction. Further shortening of the side chain (compound 48) 
reduced peptide potency while the addition on the ethyl moiety of an amino function, as in Dab 
(compound 49), produced an NPS analog with similar potency as compound 47. Finally, the 
elimination of a methylene group from the side chain of compound 49 (compound 50) produced 
negligible changes in biological activity. Collectively, these data indicate that the length of the side 
chain of the amino acid in position 3 and its linear shape seem to be more important for biological 
activity than its basic character. Surprisingly, the transformation of the guanidine function into urea 
(compound 51) generated a peptide 10-fold less potent than NPS. Since compound 51 is also less 
potent than compound 43 or 45, it is probable that the reduction of NPSR binding is due to the urea 
carbonyl (C=O), rather than to its non basic character. An increase in length of the side chain of 
Arg3 (compound 52) or its methylation (compounds 53 and 54) are completely tolerated. The 
elimination of the basic character of the Arg3 side chain obtained with compound 55 was tolerated 
while that obtained with compound 56 was not. Collectively these results corroborate the hypothesis 
that the guanidine moiety and its basicity are not particularly relevant for biological activity. In 
addition, the steric hindrance of the guanidine moiety does not seem to represent a particularly 
stringent chemical requirement since it can be enlarged (as in compounds 53–55) without loss of 
potency. However, this does not apply for moieties as bulky as tosyl since compound 56 was found 
inactive. The elimination of the Lys side chain basicity (compound 57) produced a 3-fold decrease 
of activity compared to 43; this could be due, at least in part, to the increase of the side chain steric 
hindrance, similar to what observed with compound 56. Finally we inserted in position 3 amino 
acids with a pyridine nucleus as side chain, which combines in the same moiety aromatic character 
and a nitrogen atom able to accept hydrogen bond (compounds 58–60). In line with previous 
findings (see compounds 32–34) this chemical substitution was not tolerated, corroborating the 
evidence that aromaticity in position 3 is detrimental for NPSR binding.  
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Table 5 Effects of NPS and [X3]NPS analogues in HEK293mNPSR cells 
N° Compound pEC50 (CL95%) Emax ± sem 
 NPS 7.92 (7.83-8.01) 267 ± 10 % 
32 [Phe3]NPS Crc incomplete: at  10 µM: 46 ± 6 % 
33 [Tyr3]NPS Crc incomplete: at  10 µM: 73 ± 34 % 
34 [His3]NPS 5.81 (5.20-6.42) 273 ± 18 % 
35 [Leu3]NPS Crc incomplete: at  10 µM: 36 ± 9 % 
36 [Val3]NPS Crc incomplete: at  10 µM: 129 ± 30 % 
37 [Thr3]NPS 6.06 (5.97-6.15) 272 ± 20 % 
38 [Ser3]NPS Crc incomplete  10 µM: 175 ± 19 % 
39 [Cys3]NPS 6.43 (5.97-6.89) 256 ± 26 % 
40 [Gly3]NPS 5.90 (5.71-6.09) 264 ± 7 % 
41 [Asn3]NPS Crc incomplete  10 µM: 161 ± 33 % 
42 [Gln3]NPS 6.89 (6.76-7.02) 295 ± 21 % 
43 [Lys3]NPS 7.74 (7.70-7.78) 290 ± 17 % 
44 [Asp3]NPS Crc incomplete  10 µM: 73 ± 24 % 
45 [Glu3]NPS Crc incomplete  10 µM: 89 ± 3 % 
46 [Orn3]NPS 7.50 (7.24-7.76) 318 ± 11 % 
47 [Nva3]NPS 6.87 (5.95-7.79) 207 ± 23 % 
48 [Abu3]NPS 6.29 (5.43-7.15) 218 ± 17 % 
49 [Dab3]NPS 6.69 (6.12-7.26) 207 ± 32 % 
50 [Dap3]NPS 6.62 (6.32-6.87) 196 ± 17 % 
51 [Cit3]NPS 6.78 (6.45-7.11) 285 ± 11 % 
52 [hArg3]NPS 7.97 (7.70-8.24) 288 ± 16 % 
53 [Arg(Me)23(Asym)]NPS 7.65 (7.52-7.78) 281 ± 15 % 
54 [Arg(Me)23(Sym)]NPS 7.50 (7.40-7.60) 272 ± 10 % 
55 [Arg(NO2)3]NPS 7.66 (7.49-7.83) 288 ± 17 % 
56 [Arg(Tos)3]NPS Crc incomplete  10 µM: 104 ± 16 % 
57 [Lys(Tfa)3]NPS 7.07 (6.60-7.54) 288 ± 17 % 
58 [2’-Pal3]NPS Crc incomplete  10 µM: 19 ± 4 % 
59 [3’-Pal3]NPS Crc incomplete  10 µM: 42 ± 11 % 
60 [4’-Pal3]NPS Crc incomplete  10 µM: 154 ± 17 % 
Data are means of at least 4 separate experiments, made in duplicate.  
 
The replacement of position 4 with amino acids with acidic (compound 61) or aromatic 
(compound 62) side chains produced inactive derivatives. Previous findings indicated that 
aromaticity in position 4 is detrimental for biological activity since [His4]NPS was found more than 
100 fold less potent than NPS. A 10-fold reduction of potency has been obtained by replacing Asn 
with Thr (compound 63) while the Asn related amino acid Gln (compound 64) produced a larger 
decrease of biological activity (55 fold). To investigate in details the contribution of the primary 
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amide function of Asn4 to biological activity, we substituted either alone (compound 65 and 66) or 
in combination (compound 67) the C=O and -NH2 groups with -CH2 and -CH3, respectively. A 
profound loss of biological activity (>1000-fold) was observed with all these analogs suggesting a 
pivotal role of the amide function of the Asn4 side chain for biological activity. In compounds 68 
and 69 this moiety was mono or dimethylated generating, also in this case, inactive peptides. These 
latter modifications reduced or eliminated the hydrogen bond donor properties of the amide 
function and at the same time progressively increased the steric hindrance of position 4. The relative 
importance of these factors in the loss of NPSR binding can not be clearly unravelled. Collectively, 
these results, together with previous Ala- and D-amino acid scan indications 18,76 underline the 
importance of Asn4 for the activity of NPS and suggest strict chemical requirements of the agonist 
binding pocket in NPSR allocating the side chain of this residue. 
 
.Table 6 Effects of NPS and [X4]NPS analogues in HEK293mNPSR cells 
N° Compound pEC50 (CL95%) Emax ± sem 
 NPS 7.99 (7.65-8.33) 234 ± 12 % 
61 [Asp4]NPS Crc incomplete  10 µM: 146 ± 6 % 
62 [Phe4]NPS Crc incomplete  10 µM: 118 ± 19 % 
63 [Thr4]NPS 6.99 (6.86-7.12) 253 ± 10 % 
64 [Gln4]NPS 6.25 (5.65-6.85) 210 ± 19 % 
65 [Dab4]NPS Crc incomplete  10 µM: 169 ± 18 % 
66 [NVal4]NPS Crc incomplete  10 µM: 240 ± 39 % 
67 [Ala4]NPS Crc incomplete  10 µM: 175 ± 27 % 
68 [Nmm4]NPS Crc incomplete  10 µM: 89 ± 12 % 
69 [Ndm4]NPS Crc incomplete  10 µM: 136 ± 17 % 
Data are means of at least 4 separate experiments.  
 
In conclusion, the SAR studies performed on position 2 of NPS demonstrated the following: 
(i) lipophilicity but not aromaticity is crucial, and a cyclic lipophilic side chain seems to be favored. 
(ii) both the size of the chemical moiety and its distance or position from the peptide backbone are 
important for biological activity. In particular, the size can be enlarged up to a naphthyl or reduced 
down to an isobutyl moiety while the distance can only be increased by one carbon atom without 
major changes of biological activity. (iii) finally, position 2 plays a role in both receptor binding and 
activation, as demonstrated by the reduction in efficacy displayed by [Bip2]NPS.  
Results related to position 3 suggest that (i) the guanidine moiety and its basic character are 
not crucial requirements, (ii) an aliphatic amino acid with a linear three carbon atom long side chain 
is sufficient to bind and fully activate NPSR, (iii) the receptor pocket allocating the side chain of 
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position 3 can accommodate slightly larger side chains at least to a certain degree [hArg, Arg(NO2) 
or Arg(Me)2 but not Arg(Tos)].  
Position 4 seems to be more sensitive to amino acids replacement compared to position 3; in 
fact, all the amino acid replacements investigated produced an important decrease of biological 
activity or generated inactive derivatives suggesting a pivotal role of the Asn4 side chain for NPS 
bioactivity. 
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3.2 Biological activity of NPS analogues modified in position 5 
 
In the context of  a conformation-activity study, [Aib5]NPS and [D-Ala5]NPS were 
identified as NPSR partial agonists 77. These results indicate that conformational changes induced 
by substituting Gly5 with the achiral α helix promoting amino acid Aib or with D-Ala are capable of 
reducing agonist efficacy. On these basis, we planned a SAR study on Gly5 and replaced it with a 
series of L and D amino acids characterized by hydrophobic aromatic and aliphatic side chains, 
including some Cys derivatives protected on the sulfhydryl group. Fifteen novel NPS analogues 
were synthesized and pharmacologically evaluated in the calcium mobilization assay using 
HEK293mNPSR and the fluorometric imaging plate reader FlexStation II. 
 
All data obtained investigating the SAR requirements of NPS positions 5 are summarized in 
table 7. In the calcium mobilization assay NPS increased the intracellular calcium leavels in a 
concentration-dependent manner with pEC50 and Emax values of 8.65 and 295% over basal, 
respectively. This result is in line with those previously reported. The substitution of Gly5 with 
natural amino acids containing hydrophobic aromatic side chains (compound 70 and 71) produced a 
drastic decrease (>300-fold) in peptide potency and, in the case of [Phe5]NPS, also an important 
reduction of efficacy. On the other hand, the replacement of Gly5 with natural amino acids with 
hydrophobic aliphatic side chains (compounds 72-75) generated NPSR full agonists with moderate 
to high potency. In particular, [Cys5]NPS was found to be only 6-fold less potent than the natural 
peptide, while increasing the size of the amino acid side chain produced a progressive decrease in 
potency with [Leu5]NPS being 100 fold less potent than NPS. These results suggest that position 5 
can tolerate substitutions with amino acids characterized by small side chains while larger side 
chains reduce agonist potency. Previous results obtained with [Ala5]NPS which behaves as a high 
potency NPSR full agonist 76-77 corroborate this suggestion. It should be emphasized that these 
analogues differ from the natural peptide not only by their position 5 side chain but also by the 
insertion of an L chiral centre, which substitutes the achiral Cα of Gly5. This chiral insertion, 
however, does not seem to significantly affect the pharmacological activity of the peptide 
analogues. Interestingly, this modification is compatible with the nascent helix spanning residues 74 
through 82 recently proposed as the bioactive conformation of NPS 18. To further investigate the 
possible role of chirality in this position, the D enantiomers of the same amino acids were used to 
generate compounds 76-81. The substitution of Gly5 with D amino acids with hydrophobic aromatic 
side chains (compound 76 and 77) produced a complete elimination of efficacy and, as in the case 
results and discussion 
 60
of their L enantiomers, an important reduction (approximately 100 fold) of potency. The 
replacement of Gly5 with D amino acids with hydrophobic aliphatic side chains (compound 78-81) 
generated NPSR partial agonists ([D-Leu5]NPS and [D-Cys5]NPS) or pure antagonists ([D-
Val5]NPS and [D-Met5]NPS) with moderate to high potency. These results clearly indicate that the 
insertion of a Cα chiral carbon with relative D-configuration in NPS position 5 produces, depending 
on the chemical features of the side chain, an important reduction of efficacy or its total elimination. 
Interestingly and corroborating this evidence, [D-Ala5]NPS behaves as an NPSR partial agonist 
while, as mentioned before, [Ala5]NPS is a full agonist 77. As far as peptide potency is concerned, 
the rank order of agonist potency obtained with L amino acid substitutions (Cys > Val > Met > Leu 
> Phe > Trp) is very similar to the rank order of antagonist potency obtained with the D 
enantiomers (Cys > Val > Leu > Met > Trp > Phe). On this basis, it can be proposed for position 5 
that the amino acid side chain size is very important for NPSR binding and inversely related to 
peptide potency, while the amino acid chirality has a crucial impact on the ability of the peptide to 
activate the receptor with L residues acting as partial/full agonists and D residues acting as low 
efficacy partial agonists or pure antagonists. Among [D-Xaa5]NPS derivatives, the partial agonist 
[D-Cys5]NPS was the most potent. In an attempt to increase peptide potency and particularly to 
reduce efficacy, some D-Cys side chain protected derivatives were used to substitute NPS Gly5 
(compound 82-84). These peptides behaved as pure antagonists. 
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Table 7 Effects of NPS and [X5]NPS analogues in HEK293mNPSR cells 
  agonist antagonist 
N° compound pEC50 (CL95%) Emax ± sem pKB (CL95%) 
 NPS 8.65 (8.55-8.75) 295 ± 22% ND 
70 [Phe
5]NPS 6.11 (5.35-6.90) 69 ± 8%* < 6 
71 [Trp
5]NPS Crc incomplete  10 µM: 30 ± 9 % < 6  
72 [Leu
5]NPS 6.64 (6.47-6.81) 214 ± 26% ND 
73 [Val
5]NPS 7.18 (6.57-7.79) 231 ± 68% ND 
74 [Met
5]NPS 7.06 (6.69-7.43) 240 ± 19% ND 
75 [Cys
5]NPS 7.86 (7.25-8.47) 280 ± 37% ND 
76 [D-Phe
5]NPS Inactive up to 10 µM 6.27 (5.88-6.66) 
77 [D-Trp
5]NPS Inactive up to 10 µM 6.79 (6.21-7.37) 
78 [D-Leu
5]NPS 7.05 (6.53-7.57) 118 ± 33%* 7.44 (6.96 – 7.94) 
79 [D-Val
5]NPS Inactive up to 10 µM 7.56 (7.12-8.00) 
80 [D-Met
5]NPS Inactive up to 10 µM 7.09 (6.31-7.87) 
81 [D-Cys
5]NPS 7.15 (6.39-7.91) 59 ± 13%* 7.84 (7.52-8.16) 
82 [D-Cys(Acm)
5]NPS Inactive up to 10 µM 6.47 (5.27-7.67) 
83 [D-Cys(Bzl)
5]NPS Inactive up to 10 µM 7.22 (7.01-7.43) 
84 [D-Cys(tBu)
5]NPS Inactive up to 10 µM 6.62 (6.40-6.84) 
Data are means of at least 4 separate experiments, made in duplicate. *p < 0.05 vs NPS Emax according to one-way 
ANOVA followed by the Dunnett test. 
 
In conclusion, the present study demonstrated a crucial role of the chirality of the amino acid 
residues of position 5 of NPS for peptide efficacy with L aminoacids favoring agonist and D 
aminoacids antagonist bioactive conformations. Moreover, in the frame of the present study we 
identified a series of NPS analogues devoid of efficacy and able to block agonist activity at NPSR 
with moderate to high potency: thus the first series of NPSR peptide antagonists has been 
discovered. 
 
The finding that  the replacement of Gly5 with a D aminoacid promotes  an antagonist 
bioactive conformations prompted us to further investigate NPS position 5 with the aim of 
understanding the chemical requirements of the D aminoacid side chains that are instrumental for 
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generating NPSR antagonism. In the context of this study eleven novel peptides were synthesized 
and pharmacologically evaluated in the calcium  mobilization assay. 
 
All data obtained from this study are summarized in table 8. Here [D-Val5]NPS was used as 
reference NPSR antagonist. It is worth of mention that, to facilitate drug diffusion into the wells in 
antagonist type experiments, the present studies were performed at 37 °C and three cycles of mixing 
were performed immediately after antagonist injection to the wells. This is different from previous 
calcium mobilization experiments, performed at room temperature and without mixing. NPS 
increased the intracellular calcium concentrations in a concentration-dependent manner with pEC50 
and Emax values of 8.32 and 295% over basal, respectively. Confirming previous findings, [D-
Val5]NPS did not evoke any effect per se but inhibited in a concentration dependent manner the 
stimulatory effect of 30 nM NPS, thus behaving as an NPSR antagonist. A pKB value of 6.54 was 
derived from these experiments. The replacement of the isopropyl group (as in Val) with a sec-butyl 
group (85 and 86) produced a similar moderate reduction of potency independently from the side 
chain chiral centre. Similar results were obtained substituting a methyl of the isopropyl group with 
an oxidril function (87 and 88). In this latter case, the side chain chiral centre seems to exert an 
effect on peptide efficacy, since [D-allo-Thr5]NPS behaves as a pure NPSR antagonist while [D-
Thr5]NPS as a low efficacy partial agonist. However, the difference in efficacy between 87 and 88 
([D-Thr5]NPS α = 0.08; [D-allo-Thr5]NPS α = 0) is too little to be meaningful. A linear three-
carbon side chain (89) produced an analogue that behaved as a NPSR low efficacy partial agonist 
10 fold less potent than [D-Val5]NPS. These findings indicated that the isopropyl moiety is highly 
important for NPSR antagonist binding and that the replacement of one of its methyl groups with 
ethyl or oxidril functions produced a reduction of potency. Moreover, the three carbon atoms of the 
D-Val side chain must have a ramified (isopropyl) rather than linear (n-propyl, as in 89) shape; in 
fact, the latter generates a clear reduction of peptide potency. The introduction in position 5 of a 
cyclohexyl or methylcyclohexyl moiety (90 and 91) generated inactive derivatives, while the 
introduction of a phenyl ring (92) produced only a 3 fold reduction in potency compared to the 
isopropyl moiety of [D-Val5]NPS. These data suggest that the increase in the side chain size (as in 
90 and 91) decreases peptide potency. This is further suggested by the results obtained with 92. In 
fact, the aromaticity of the phenyl ring of 92 reduced the side chain size and changed its shape 
compared with the cyclohexyl moiety of 90, and this may explain the moderate potency of [D-
Phg5]NPS compared to the inactivity of [cyclohexyl-D-Gly5]NPS. Next, the effect of the insertion 
in the D-Val5 isopropyl moiety of a CH3 (93) or SH (94) group was evaluated. In both cases the 
chemical change did not modify the pharmacological activity of the peptides; i.e., they behaved as 
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pure antagonists, with a 3 fold increase in potency. Finally, the insertion of a carbon atom between 
the tBu moiety and the peptide backbone (95) caused an important reduction of peptide potency 
associated with a clear increase in efficacy ([tBu-D-Gly5]NPS α = 0, pKB 7.06; [tBu-D-Ala5]NPS α 
= 0.35, pKB 6.32).  
 
Table 8 Effects of NPS and [X5]NPS analogues residues in HEK293mNPSR cells 
  agonist antagonist 
N° compound pEC50 (CL95%) Emax ± sem pKB (CL95%) 
 NPS 8.65 (8.55-8.75) 295 ± 22% ND 
 [D-Val
5]NPS Inactive up to 10 µM 6.54 (5.99-6.99) 
85 [D-Ile
5]NPS Inactive up to 10 µM 5.72 (5.10-6.34) 
86 [D-allo-Ile
5]NPS Inactive up to 10 µM 6.04 (5.52-6.56) 
87 [D-Thr
5]NPS 6.10 (5.79-6.41) 25 ± 5%* 6.09 (5.79-6.36) 
88 [D-allo-Thr
5]NPS Inactive up to 10 µM 6.04 (5.51-6.57) 
89 [D-Nva
5]NPS 5.57 (5.02-6.12) 24 ± 7%* 5.68 (5.38-5.98) 
90 [cyclohexyl-D-Gly
5]NPS Inactive up to 10 µM < 5 
91 [D-Cha
5]NPS Inactive up to 10 µM < 5 
92 [D-Phg
5]NPS 6.18 (5.81-6.55) 15 ± 2%* 6.79 (6.21-7.37) 
93 [
tBu-D-Gly5]NPS Inactive up to 10 µM 7.06 (6.48-7.64) 
94 [D-Pen
5]NPS Inactive up to 10 µM 7.08 (6.46-7.70) 
95 [
tBu-D-Ala5]NPS 5.78 (5.06-6.50) 104 ± 2%* 6.32 (5.63-7.01) 
Data are means of at least 4 separate experiments, made in duplicate. *p < 0.05 vs NPS Emax according to one-way 
ANOVA followed by the Dunnett test. 
 
In conclusion, the present study confirmed previous indications that the D relative 
configuration of amino acid residues at position 5 of NPS promotes antagonist activity, indicated 
that the peptide antagonist potency is inversely related to the D-Xaa5 side chain size, and 
demonstrated that the tBu (and its sulfhydryl derivative) directly linked to the Cα carbon atom is the 
best chemical moiety for increasing antagonist potency. [tBu-D-Gly5]NPS and [D-Pen5]NPS 
identified in the context of the present study represent the most potent NPSR peptide antagonists 
available up to now. 
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3.3  In vivo neuropeptide S actions in mice 
 
In the pivotal study by Xu et al. 9 it has been reported that the supraspinal administration of 
NPS (0.01- 1 nmol) stimulated locomotor activity, reduced all stages of sleep and promoted 
wakefulness. The same range of doses, supraspinal administration of NPS evoked clear anxiolytic-
like effects in mice subjected to the EPM, the light-dark box, the OF and the marble burying test 9. 
Thus, NPS was proposed as an unique neuropeptidergic signal: an activating anxiolytic. The 
observations by Xu 9 were subsequently confirmed and extended by Leonard 43, which reported 
NPS anxiolytic activity in three preclinical mouse models predictive of anxiolytic action: the four-
plate test, elevated zero maze, and SIH. 
 
In our laboratories we set up the experimental conditions to further evaluate the supraspinal 
NPS actions in vivo in a battery of mouse behavioural assay, including LA with naïve mice, mice 
habituated to the test cage and mice sedated with 5 mg/kg diazepam, recovery of RR following 
treatment with a hypnotic dose of diazepam (15 mg/kg), EPM, OF and SIH. The effects elicited by 
NPS in these behavioural assays were compared to those evoked under the same experimental 
conditions by reference drugs, such as caffeine and diazepam. 
 
Locomotor activity 
 
A first series of experiments to evaluate mouse LA activity was performed using Basile 
activity cages which consist of a four-channel resistance detector circuit, which converts the bridges 
‘broken’ by the animals paws into pulses that are summed by an electronic counter every 5 min. In 
these experiments NPS effects were compared to those evoked by caffeine (reference stimulant 
drug). Naïve mice injected with saline displayed a progressive reduction in spontaneous LA over 
the time course of the experiment. Their cumulative LA in 60 min was >1000 impulses. Mice 
habituated to the test cage for 60 min before the experiment showed an important reduction in LA 
with cumulative impulses <500. An even greater inhibitory effect was produced by i.p. 
administration of a sedative dose of diazepam (5 mg/kg), such that mice treated with the 
benzodiazepine displayed a cumulative LA of approx 250 impulses in 60 min. Caffeine 
administration promoted a robust and consistent increase in locomotion in naïve, habituated and 
diazepam treated mice (figure 13). The stimulatory effect of caffeine was more pronounced in 
habituated (327% of controls) and diazepam treated (310% of controls) animals than that in naïve 
mice (167% of controls). Similar results were obtained following i.c.v. injection of NPS in naïve, 
habituated and diazepam-treated mice (figure 14). NPS in the range of 0.01–1 nmol per mouse dose 
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dependently stimulated LA. At 0.01 nmol, the peptide was inactive whereas at 0.1 and 1 nmol, the 
peptide produced a robust stimulatory effect. However, in naïve and habituated animals, the effect 
produced by 0.1 nmol was higher than that produced by the 1 nmol dose. This was due to the fact 
that the onset of action of the latter dose of NPS was delayed (figure 14, top and middle panels). 
The maximal stimulatory effect of NPS was 162, 276 and 488% of controls in naïve, habituated and 
diazepam treated mice, respectively. 
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Figure 13 Locomotor activity assay. Effect of caffeine (20 mg/kg) in naïve (top panels), habituated (middle panels) and 
in diazepam treated (bottom panels) mice. Locomotor activity of mice is displayed over the time course of the 
experiment in the left panels and as cumulative impulses over the 60 min observation period in the right panels. Data 
are mean ± s.e.m. of 16 mice per group. *P<0.05 vs control, Student’s t-test for unpaired data. 
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Figure 14 Locomotor activity assay. Dose response curve to NPS in naïve (top panels), habituated (middle panels) and 
in diazepam treated (bottom panels) mice. Locomotor activity of mice is displayed over the time course of the 
experiment in the left panels and as cumulative impulses over the 60 min observation period in the right panels. Data 
are mean ± s.e.m. of 20 mice per group. *P<0.05 vs control, analysis of variance (ANOVA) followed by the Dunnett’s 
test for multiple comparison 
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In a second series of experiments NPS dose response cure was assessed using the video 
tracking system ANY-maze. These experiments were performed only in naïve mice. Results 
obtained with this methods were superimposable to the previous findings. Naïve mice injected with 
saline displayed a progressive reduction in spontaneous LA over the time course of the experiment. 
Their cumulative distance travelled in 60 min was approximately 60 m, their immobility time was 
around 1500 s and they reared 200 times. NPS in the range of 0.01–1 nmol per mouse dose 
dependently stimulated LA. At 0.01 nmol, the peptide was inactive whereas at 0.1 and 1 nmol, the 
peptide produced a robust stimulatory effect, increasing cumulative distance travelled by the 
animals, the number of rearings, and reducing the total immobility time in a statistically significant 
manner. The effect produced by 0.1 nmol was similar to that produced by the 1 nmol dose. Distance 
travelled by NPS 0.1 nmol treated mice was 100 m (167% of controls), their immobility time was 
700 s (47% of controls) and their number of rearing was 600 (300% of controls) (figure 15). 
 
5 10 15 20 25 30 35 40 45 50 55 60
0
3
6
9
12
15
18 Control
NPS 0.1 nmol
NPS 1 nmol
NPS 0.01 nmol
time (min)
D
is
ta
nc
e 
tra
ve
lle
d
(m
)
Control  0.01  0.1 1
0
25
50
75
100
125
*
*
NPS nmol, i.c.v.
C
um
ul
at
iv
e 
di
st
an
ce
 tr
av
el
le
d
(m
)
Control 0.01 0.1 1
0
300
600
900
1200
1500
1800
*
*
NPS nmol, i.c.v.
To
ta
l t
im
e 
im
m
ob
ile
(s
)
Control 0.01 0.1 1
0
100
200
300
400
500
600
700
*
*
NPS nmol, i.c.v.
R
ea
rin
g
(n
um
be
r o
f b
re
ak
s)
 
Figure 15 Locomotor activity assay. Dose response curve of NPS in naïve mice. The time course of NPS effects is 
shown in the top left panel, while the other panels display the cumulative effects exerted by the peptide over the 60 min 
observation period. Data are mean ± s.e.m. of 16 mice per group. *P<0.05 vs control, analysis of variance (ANOVA) 
followed by the Dunnett’s test for multiple comparison. 
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Recovery of righting reflex 
 
In RR test, the injection of diazepam at the hypnotic dose of 15 mg/kg produced loss of RR 
in 100% of the mice injected with saline. These mice needed around 80 min to regain the RR. Pre-
treatment with caffeine (20 mg/kg i.p.) decreased both the percentage of mice losing RR in response 
to the benzodiazepine and their sleeping time. Only 33% of caffeine treated mice lost RR and the 
sleeping time of those animals responding to diazepam was reduced to 28 min (35% of controls, 
figure 16, top panels). This arousal promoting effect of caffeine was mimicked by i.c.v. injection of 
NPS. Over the 0.01–1 nmol range, the peptide dose dependently reduced the proportion of animals 
responding to diazepam and their sleeping time. The maximal arousal promoting effect of NPS was 
obtained with the dose of 1 nmol, which reduced the percentage of animals showing loss of RR to 
50% and their sleeping time to 22 min (28% of controls, figure 16, bottom panels). 
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Figure 16 Recovery of righting reflex in mice. Effect of caffeine (20 mg/kg, i.p., top panels) and of NPS (0.01–1 nmol, 
bottom panels) on the per cent of animals losing the righting reflex in response to diazepam 15 mg/kg (left panels) and 
on their sleeping time (right panels). Sleeping time is defined as the amount of time between the loss and regaining of 
the righting reflex. Data are mean ± s.e.m. of 14 mice per group. *P<0.05 vs control, analysis of variance (ANOVA) 
followed by the Dunnett’s test for multiple comparison. 
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Elevated plus maze test 
 
In EPM, NPS effects were compared to those evoked by diazepam (reference anxiolytic 
drug) and caffeine (reference anxiogenic drug). In this test, saline injected mice spent about 35 s in 
the open arms (corresponding to 19% of the total time spent in open and closed arms) and their 
entries into open arms were approximately four (corresponding to 27% of the total entries into open 
and closed arms). Diazepam (1 mg/kg; i.p.) significantly increased both the percentage of time 
spent in and the number of entries into open arms (figure 17, top panels). Similar anxiolytic-like 
effects were promoted by i.c.v. injection of NPS (figure 17, bottom panels). In the range 0.001–1 
nmol, NPS dose dependently increased the time spent by animals in the open arms with a maximal 
effect, evoked at 1 nmol, equal to 157 s (corresponding to 68% of the total time spent in open and 
closed arms). This effect was associated with a statistically significant increase in entries into the 
open arms, which was, however, dose independent. Under the same experimental conditions, 
caffeine produced the opposite result reducing to 15 s, the time spent by animals in the open arms 
(corresponding to 11% of the total time spent in open and closed arms) and the number of entries 
into open arms to three (corresponding to 21% of the total entries into open and closed arms) (table 
9). All the behavioural parameters measured in the EPM in saline as well as drug-treated animals 
are summarised in table 9. 
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Figure 17 Elevated plus maze assay. Effects of diazepam (1 mg/kg i.p., top panels) and of i.c.v. injected NPS (0.001–1 
nmol, bottom panels) on the time spent in (left panel) and on the number of entries into the open arms (right panel). 
Data are mean ± s.e.m. of 16 mice per group. *P<0.05 vs control, analysis of variance (ANOVA) followed by the 
Dunnett’s test for multiple comparison. 
 
 
 
Table 9 Effects of diazepam, caffeine and NPS on various behavioural parameters displayed by mice subjected to the 
EPM 
Treatment Time in open 
arms (s) 
Entries in open 
arms 
Time in closed 
arms (s) 
Entries in 
closed arms 
Stretch attend 
posture 
Head-
dipping 
Rearing 
Control 34.9± 6.0 4.3± 0.5 161.6± 8.4 11.1± 1.3 8.1± 0.7 3.8± 0.7 11.1± 1.4 
Diazepam 1 
mg/kg 
107± 16.6* 12.1± 1.8* 111.9± 17.4* 13.3± 1.9 4.9± 1.2* 8.9± 1.0* 12.5± 1.4 
        
Control 39.8± 6.9 4.8± 0.9 129.7± 6.5 8.8± 0.8 4.1 ± 0.6 5.7± 0.9 11.8± 1.6 
Caffeine 20 
mg/kg 
14.8± 3.5* 2.7± 0.4* 125.4± 10.2 10.1± 0.7 7.5± 0.8* 4.5± 0.7 12.3± 1.6 
        
Control 48.9± 8.2 5.7± 0.8 133.6± 10.1 10.3± 0.7 5.3± 0.9 8.2± 1.2 10.3± 1.6 
NPS 0.001 
nmol 
84.2 ± 11.2 9.9± 1.4 111.8± 6.6 10.8± 0.7 3.2± 1.2 11.1± 1.7 12.0± 1.8 
NPS 0.01 nmol 114.4± 7.9* 9.7± 0.8* 107.2± 7.1 8.8± 0.8 1.8± 0.4* 14.9± 2.3 11.6± 1.9 
NPS 0.1 nmol 130.4± 11.6* 8.6± 0.7* 89.2± 10.6* 7.1± 0.5* 1.3± 0.3* 16.3± 2.8 8.6± 1.7 
NPS 1 nmol 156.6± 12.4* 9.2± 1.0* 68.2± 4.9* 6.1± 0.7* 0.5± 0.1* 18.8±4.4* 10.2± 1.5 
All values are expressed as mean ± s.e.m. of 12–16 mice per group. 
*P<0.05 vs control, analysis of variance (ANOVA) followed by the Dunnett’s test for multiple comparison. 
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Open field 
A first series of experiments were made to set up the experimental conditions of the OF test. 
In these experiments the effects of diazepam were assessed. Saline injected mice spent about 15 s in 
the central zone of the field (corresponding to 2.5% of the total time of the experiments) and their 
entries into the central zone were approximately 7. Diazepam (0.3 and1 mg/kg; i.p.) significantly 
increased both the time spent in and the number of entries into the central zone (figure 18). Similar 
anxiolytic-like effects were promoted by i.c.v. injection of NPS (figure 19). In the range 0.01–1 
nmol, NPS dose dependently increased the time spent by animals in the central zone with a 
maximal effect, evoked at 1 nmol, equal to 41 s (corresponding to 7% of the total duration of the 
experiment). This effect was associated with a statistically significant and dose dependent increase 
in entries into the central zone, with a maximal effect, evoked at 1 nmol, equal to 28. All the 
behavioural parameters measured in the OF in saline as well as drug-treated animals are 
summarised in table 10. 
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Figure 18 Open field assay. Effects of diazepam (1 and 3 mg/kg i.p.) on the number of entries into the central zone (left 
panel) and on the time spent in this area (right panel). Data are mean ± s.e.m. of 20 mice per group. *P<0.05 vs control, 
analysis of variance (ANOVA) followed by the Dunnett’s test for multiple comparison. 
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Figure 19 Open field assay. Effects of NPS (0.01- 1 nmol, i.c.v.) on the number of entries into the central zone (left 
panel) and on the time spent in this area (right panel). Data are mean ± s.e.m. of 20 mice per group. *P<0.05 vs control, 
analysis of variance (ANOVA) followed by the Dunnett’s test for multiple comparison. 
 
 
 
Table 10 Effects of diazepam and NPS on various behavioural parameters displayed by mice subjected to the OF 
Treatment Total distance 
travelled (m) 
Time immobile 
(s) 
Rearings (number 
of breaks) 
Entries in the 
central zone 
Time in the central 
zone (s) 
Control 16.79 ± 1.42 72.45 ± 14.28 71.40 ± 8.27 6.75 ± 1.44 14.50 ± 3.10 
Diazepam 0.3 mg/kg 22.83 ± 1.46 41.28 ± 9.20 88.94 ± 10.32 16.38 ± 2.85* 33.68 ± 7.01* 
Diazepam 1 mg/kg 27.20 ±  1.89* 69.05 ± 11.98 80.68 ± 10.35 18.53 ± 2.80* 34.99 ± 6.74* 
      
Control 24.47 ± 1.32 101.44 ± 12.17 85.58 ± 9.38 14.06 ± 1.35 18.45 ± 2.19 
NPS 0.01 nmol 27.92 ± 1.59 67.77± 9.68* 106.10 ± 8.36 18.57 ± 1.44 25.18 ± 3.39 
NPS 0.1 nmol 32.76 ± 2.78* 36.90± 5.54* 129.63 ± 9.78* 22.30 ± 1.90* 35.00 ± 2.98* 
NPS 1 nmol 30.96 ± 2.24 26.74± 6.69* 127.78 ± 11.39* 27.65 ± 2.11* 40.71 ± 4.21* 
All values are expressed as mean ± s.e.m. of 20 mice per group. 
*P<0.05 vs control, analysis of variance (ANOVA) followed by the Dunnett’s test for multiple comparison 
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Stress-induced hyperthermia test 
 
In control mice, stress induced by the measurement of body temperature evoked a 
significant increase in T2 compared with T1 corresponding to a ΔT of about 0.6 °C. Diazepam (1–
5mg/kg, i.p.) produced a dose-dependent reduction in baseline temperature, although this effect did 
not reach statistical significance (figure 8, top left panel). In the same dose range, the 
benzodiazepine reduced ΔT to negative values (figure 20, top right panel). These effects of 
diazepam were statistically significant at the doses of 3 and 5mg/kg. NPS (0.01-1 nmol, i.c.v.) 
mimicked the anxiolytic-like action of the benzodiazepine. It did not modify baseline temperature 
but produced a dose-related reduction in ΔT, which reached statistical significance at doses of 0.1 
and 1 nmol (figure 20, bottom panels). 
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Figure 20 Stress-induced hyperthermia test.  Effects of diazepam (1, 3 and 5mg/kg, i.p., top panels) and NPS (0.01–1 
nmol. i.c.v., bottom panels) on baseline temperature (T1, left panels) and SIH (T2–T1, right panels) in the mouse SIH 
test. Data are mean±s.e.m. of 14 mice per group. *P<0.05 vs control, analysis of variance (ANOVA) followed by the 
Dunnett’s test for multiple comparison. 
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Collectively, the present findings demonstrate that NPS was able to evoke a robust and 
consistent arousal response in mice. This stimulant effect was associated with a clear anxiolytic-like 
action. Thus, the present findings corroborate the proposal of NPS as a unique neuropeptidergic 
signal: an activating anxiolytic 9. In LA assays, NPS mimicked the stimulatory effect of caffeine 
and this effect is highly consistent across different experimental conditions, that is, naïve and 
habituated mice, and animals sedated with diazepam. Similar results in terms of degree of 
stimulation, NPS potency, onset and duration of action were previously reported both in mice 9 and 
in rats 35. This suggests that the locomotor stimulant effect of NPS is highly consistent among 
experimental conditions and animal species. The activating properties of NPS were further 
confirmed in the RR assay, where NPS mimicked the arousal-promoting action of caffeine in mice 
by reducing the number of animals losing RR in response to a hypnotic dose of diazepam and 
markedly decreasing the sleep time in those animals responding to the benzodiazepine. These 
findings parallel the results obtained by Xu et al. 9 in rats in electroencephalographic studies, where 
NPS given i.c.v. in the same dose range (0.1 and 1 nmol) increases the amount of wakefulness and 
decreases SWS1, SWS2 and REM sleep. These data demonstrated that the arousal-promoting action 
of NPS is a robust effect, which can be easily replicated in different laboratories and animal species. 
Collectively, our findings are in line with those already published, indicating that NPS behaves as 
an important signal in the brain to stimulate LA and wakefulness. In this respect, the effects of NPS 
are similar to those elicited by caffeine (and other psychostimulant drugs) and opposite to those of 
diazepam.  
In order to investigate NPS effects on anxiety, EPM and OF assays  were performed. EPM is 
based on natural aversion of rodents to open and unprotected spaces.  In this experiments, 1mg/kg 
diazepam produced clear anxiolytic like effects, increasing the time spent by mice in the open arms. 
In contrast, caffeine promoted anxiogenic like effects. These results validate our EPM experimental 
conditions. NPS induced a dose-dependent reduction in anxiety-like behaviour in this paradigms, 
increasing the number of entries and the time spent in open arms of the maze. OF is a paradigm of 
free exploratory behaviour in a novel environment. In this model, the supraspinal administration of 
NPS mimicked the effects of diazepam. It was found that NPS, in a dose dependent manner, 
significantly increased the number of entries and the time spent in central zone, which could 
indicate an anxiolytic-like effect. These results are similar to those obtained by Xu et al. 9 not only 
in the same assays but also in the light–dark test. Moreover, an anxiolytic like action of NPS was 
also reported in mice subjected to the four plate test and elevated zero maze 43. Thus, similar to the 
stimulant effects of NPS, its anxiolytic like action also seems to be a robust effect easily reproduced 
in different laboratories and in different species, using different assays. However, the stimulatory 
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action of NPS can bias the interpretation of results obtained in the above mentioned assays, in 
which anxiety levels are measured as inhibited behaviours. 
This prompted us to investigate NPS effects in the SIH assay, a model of anxiety, which is 
not sensitive to LA 90. As expected, in this assay, diazepam produced anxiolytic-like effects, that is, 
it counteracted the SIH response in a dose-dependent manner. However, higher benzodiazepine 
doses were required in this assay compared to EPM to elicit statistically significant effects. In 
addition, the effect of diazepam on body temperature (T1), although not statistically significant, may 
represent a bias for the analysis of its effect on SIH. However, this is unlikely because it has been 
clearly demonstrated using different mouse strains and several benzodiazepines (diazepam, 
oxazepam, alprazolam and chlodiazepoxide) that the decrease in ΔT is indeed independent of the 
effect of the drug on temperature T1 96. The action of caffeine was not evaluated in this assay 
because of the reported hyperthermic/hypothermic response of this drug 97 and because this assay 
failed to detect anxiogenic-like effects of several drugs, such as pentylenetetrazol, the beta-
carboline FG7142, meta-chlorophenylpiperazine 96. Thus, anxiogenic-like actions are extremely 
difficult to assess using this test, probably due to a ceiling effect of ΔT.  Under the same 
experimental conditions, NPS did not produce any modification of T1 but dose dependently 
prevented SIH. This same result has been independently replicated in a different laboratory 43. Thus 
the ability of NPS to counteract SIH, a physiological parameter insensitive to locomotion, indicates 
that the action of NPS should be considered as a genuine (that is, not merely dependent on 
experimental bias) anxiolytic-like effect. This proposal is corroborated by the anxiolytic-like effects 
measured in mice in response to NPS in the mouse marble burying assay 9 and in rat defensive 
burying test 44, two model where anxiety levels are measured as an active (marble and electric probe 
burying) behaviour. Collectively, the effects promoted by NPS in the EPM, OF and SIH assays are 
similar to those elicited by diazepam and opposite to those of caffeine. Collectively, the present 
study confirmed and extended previous findings 9 demonstrating that NPS produced a unique 
behavioural profile: stimulation associated with anxiolysis.  
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3.4 In vitro and in vivo pharmacological characterization of peptide NPSR antagonists  
 
The previously reported SAR studies focussed on NPS position 5 led to the identification of 
the first series of NPSR peptide antagonists. Based on the data reported in tables 7 and 8 the NPSR 
pure antagonists [D-Cys(tBu)5]NPS,  [D-Val5]NPS and [tBu-D-Gly5]NPS were selected for further 
in vitro and in vivo pharmacological characterization. 
In vitro, the antagonistic properties of these peptides were investigated in HEK239mNPSR 
cells by performing inhibition response curves against the effect elicited by 10 and 100 nM NPS, 
corresponding to submaximal and maximal concentrations, respectively, as well as by testing the 
peptides with the classical Schild protocol. In vivo, their NPSR antagonistic activity was assessed in 
the RR ([D-Cys(tBu)5]NPS and [tBu-D-Gly5]NPS) and LA ([D-Val5]NPS and [tBu-D-Gly5]NPS) 
assays. For the in vivo studies the NPS dose of 0.1 nmol was selected, based on previous results, as 
the lower dose producing statistically significant effects, to be challenged with the NPSR 
antagonists. 
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Calcium mobilization assay 
 
In the calcium mobilization assai performed in HEK239mNPSR cells [D-Cys(tBu)5]NPS 
concentration-dependently inhibited 10 and 100 nM NPS effects, with pIC50 values of 5.75 and 4.64 
(for the latter assuming a complete inhibition at higher concentrations), respectively. A [D-
Cys(tBu)5]NPS pKB value of 6.62 (CL95%, 6.40–6.84) was derived from these experiments (figure 
21). 
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Figura 21 Calcium mobilization assay performed on HEK293mNPSR cells. Inhibition response curve to [D-
Cys(tBu)5]NPS (0.1 nM–100 μM) against the stimulatory effect of 10 and 100 nM NPS. Data are mean±s.e.m of 4 
experiments made in duplicate. 
 
Next, to get information on the nature of the antagonist action exerted by [D-Cys(tBu)5]NPS, 
the classical Schild analysis was performed. As depicted in figure 22, left, [D-Cys(tBu)5]NPS, in the 
range 0.1 to 100 μM, did not have any effect per se but produced a rightward shift of the 
concentration response curve to NPS in a concentration-dependent manner, whereas the curves 
remained parallel to the control and reached similar maximal effects. The corresponding Schild 
plot, which was linear (r2 = 0.99) with a slope of  0.97 ± 0.07, is shown in figure 22, right. The 
extrapolated pA2 value was 6.44. Finally, [D-Cys(tBu)5]NPS selectivity of action was investigated 
by challenging the peptide against a panel of G protein-coupled receptors (table 11). These include 
native muscarinic receptors expressed in HEK293 cells, native PAR-2 receptors expressed in A549 
cells, and recombinant human NK-1, UT, and opioid receptors expressed in CHO cells. In these 
experiments, [D-Cys(tBu)5]NPS did not stimulate calcium mobilization up to 10 μM and did not 
modify the concentration response curves to receptor agonists (table 11). 
results and discussion 
 79
 
Table 11 Selectivity profile of [D-Cys(tBu)5]NPS at seven different G-protein coupled receptors. 
   Control [D-Cys(tBu)5]NPS  
10 µM  
Cell lines Receptor Agonist pEC50 Emax ± sem pEC50 Emax ± sem 
HEK293 native muscarinic carbachol 5.60 (5.21-5.69) 309 ± 31% 5.44 (4.82-6.06) 309 ± 33%   
CHO recombinant hNK-1 substance P 10.26 (9.88-10.64 122 ± 15%  10.10 (9.5-10.7) 110 ± 20%   
CHO recombinant hUT urotensin-II 8.31 (7.62-9.00) 224 ± 21%  8.37 (7.54-9.20) 225 ± 23%   
CHO-αqi5 recombinant hMOP dermorphin 7.98 (7.85-8.11) 186 ± 11%    7.80 (7.16-8.44) 194 ± 13%   
CHO-αqi5 recombinant hDOP DPDPE 8.63 (8.41-8.84) 169 ± 26%    8.65 (8.52-8.78) 155 ± 22%   
CHO-αqi5 recombinant hKOP dynorphin A 8.11 (7.72-8.50) 143 ± 12%    8.53 (8.00-9.06) 144 ± 12%   
A549 native hPAR2 SLIGKV-NH2 4.66 (4.43-4.89) 449 ± 25%    4.77 (4.31-5.23) 433 ± 37%   
Data are mean ± sem of three separate experiments performed in duplicate. The chimeric protein αqi5 98 was used to 
force opioid receptors to couple with the calcium pathway. 
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Figure 22 . Calcium mobilization assay performed on HEK293mNPSR cells. Concentration-response curve to NPS 
obtained in the absence (control) and in presence of increasing concentrations of [D-Cys(tBu)5]NPS (0.1-100 µM) (left 
panel); the corresponding Schild plot is shown in the right panel. Data are mean ± sem of 4 experiments made in 
duplicate. 
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Figure 23 left panel displays the results obtained by performing inhibition response curve to [D-
Val5]NPS (0.01 nM - 10 µM) against the stimulatory effect of NPS 10 and 100 nM. As mentioned 
before, [D-Val5]NPS was completely inactive per se up to 10 µM concentrations, however it 
produced a concentration dependent inhibition of NPS effects, with pIC50 values of 6.59 vs NPS 10 
nM and 5.96 (assuming full inhibition at concentration higher than 10 µM) vs NPS 100 nM. A [D-
Val5]NPS pKB value of 7.50 (CL95% 7.18– 7.82) was derived from these experiments. In order to get 
further information on the nature of the antagonist action exerted by [D-Val5]NPS the classical 
Schild analysis was also performed. As depicted in figure 23 right panel, [D-Val5]NPS in the range 
0.1–10 µM did not produced any effect per se but displaced to the right the concentration response 
curve to NPS in a concentration dependent manner; however this was associated to a slight but 
statistically significant decrease of the maximal effect elicited by NPS at the higher concentrations 
of antagonist (i.e. 1 and 10 µM). The extrapolated pKB values was 7.02. To investigate [D-
Val5]NPS selectivity of action, this peptide was challenged against the effect produced by carbachol 
via stimulation of endogenously expressed muscarinic receptors in HEK293mNPSR cells. Carbachol 
produced a concentration dependent stimulation of calcium levels with Emax and pEC50 values of 
305 ± 31% over the basal, and 5.58, respectively. The concentration response curve to carbachol 
was not significantly modified in the presence of [D-Val5]NPS 10 µM both in terms of efficacy 
(Emax 309 ± 33% over the basal) and potency (pEC50 5.69).  
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Figure 23 Calcium mobilization assay performed on HEK293mNPSR cells. Inhibition response curve to [D-Val5]NPS 
(0.1 nM–100 μM) against the stimulatory effect of 10 and 100 nM NPS (left panel). Concentration-response curve to 
NPS obtained in the absence (control) and in presence of increasing concentrations of [D-Val5]NPS (0.1-10 µM) (right 
panel). Data are mean ± sem of 4 experiments made in duplicate. 
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Finally the in vitro pharmacological profile of [tBu-D-Gly5]NPS was investigated. In order 
to compare [D-Val5]NPS and [tBu-D-Gly5]NPS antagonist potencies, the two peptides were tested 
in parallel, in the same series of experiments and under the same experimental conditions (37 °C; 
three cycles of mixing). Figure 24 displays the results obtained by performing inhibition response 
curve to [D-Val5]NPS and [tBu-D-Gly5]NPS (0.01 nM - 10 µM) against the stimulatory effect of 
NPS 30 nM. As mentioned before, [D-Val5]NPS and [tBu-D-Gly5]NPS were completely inactive 
per se up to 10 µM concentrations, however they produced a concentration dependent inhibition of 
NPS effects, with pKB values of 6.02 and 6.67 respectively. These data demonstrated that [tBu-D-
Gly5]NPS acted as a pure NPSR antagonist, 3 fold more potent than [D-Val5]NPS. 
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Figure 24 Calcium mobilization assay performed on HEK293mNPSR cells. Inhibition response curve to [D-Val5]NPS and 
[tBu-D-Gly5]NPS  (0.1 nM–100 μM) against the stimulatory effect of 30 nM NPS. Data are mean ± sem of 3 
experiments made in duplicate. 
 
To get further information on the nature of the antagonist action exerted by [tBu-D-
Gly5]NPS the classical Schild analysis was performed. Figure 25 summarizes the data obtained by 
determining concentration response curves to NPS in the presence of increasing concentrations (0.1 
- 10 µM) of [tBu-D-Gly5]NPS. This peptide produced a concentration dependent rightward shift of 
the concentration response curve to NPS which was associated with a slight but significant 
depression of NPS maximal effects. From these experiments a pKB of 6.78 (CL95% = 6.33 - 7.23) 
was derived using the equation described in section 2.6. To get information about the selectivity of 
action of [tBu-D-Gly5]NPS, the peptide was evaluated as agonist and antagonist in calcium 
mobilization experiments performed using the same unrelated human G protein-coupled receptors 
(table 12) used to determine the selectivity of [D-Cys(tBu)5]NPS. Moreover, this investigation was 
extended to  the bradykinin B2 receptor and to nociceptin/orphanin FQ peptide receptor (NOP) 
forced to couple with the calcium pathway by the chimeric protein αqi5 98. [tBu-D-Gly5]NPS up to 
results and discussion 
 82
10 µM neither stimulated calcium mobilization in these cells nor affected the stimulatory effects 
elicited by the reference receptor agonists (table 12).  
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Figure 25 Concentration-response curve to NPS obtained in the absence (control) and presence of increasing 
concentrations of [tBu-D-Gly5]NPS in calcium mobilization experiments performed in HEK293mNPSR cells. Data are 
mean ± sem of 4 experiments made in duplicate. 
 
 
 
Table 12 Selectivity profile of [tBu-D-Gly5]NPS at eight different G-protein coupled receptors. 
   Control [tBu-D-Gly5]NPS 10 µM  
Cell lines Receptor Agonist pEC50 Emax ± sem pEC50 Emax ± sem 
CHO recombinant hNK-1 substance P 10.24 (9.86-10.6) 122 ± 15%  10.31 (9.9-10.7) 113 ± 11%   
CHO recombinant B2 bradykinin 10.31 (10.2-10.3) 125 ± 2%  10.47 (9.9-11.0) 115 ± 11%   
CHO recombinant hUT urotensin-II 8.39 (7.50-8.88) 224 ± 21%  8.46 (8.19-8.73) 234 ± 19%   
CHO-αqi5 recombinant hMOP dermorphin 7.98 (7.85-8.11) 186 ± 11%    7.96 (7.71-8.21) 186 ± 15%   
CHO-αqi5 recombinant hDOP DPDPE 8.53 (8.23-8.73) 169 ± 26%    8.71 (8.65-8.77) 177 ± 11%   
CHO-αqi5 recombinant hKOP dynorphin A 8.20 (7.81-8.59) 143 ± 12%    8.63 (8.33-8.99) 139 ± 13%   
CHO-αqi5 recombinant hNOP N/OFQ 9.41 (9.26-9.56) 231 ± 12%    9.55 (9.11-9.99) 207 ± 30%   
A549 native hPAR2 SLIGKV-NH2 4.55 (4.06-5.04) 449 ± 25%    4.50 (3.96-5.04) 445 ± 30%   
Data are mean ± sem of three separate experiments performed in duplicate. The chimeric protein αqi5 98 was used to 
force opioid receptors to couple with the calcium pathway. 
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Recovery of righting reflex 
 
[D-Cys(tBu)5]NPS effects were evaluated in vivo in RR test. As shown in figure 26, i.p. 
injection of diazepam at the hypnotic dose of 15 mg/kg produced loss of the RR in 92% of the mice 
and approx 105 min were needed to regain this reflex. NPS injected i.c.v. at 0.1 nmol reduced the 
percentage of animals responding to diazepam to 58% and their sleep time to approx 50 min. On the 
contrary, the administration of [D-Cys(tBu)5]NPS at 1 and 10 nmol did not significantly modify the 
hypnotic effect of diazepam either in terms of percent of animals losing the RR or sleeping time. 
When [D-Cys(tBu)5]NPS 1 nmol was coinjected with NPS 0.1 nmol it did not significantly modify 
the action of the natural peptide, however when the higher dose of 10 nmol was used [D-
Cys(tBu)5]NPS prevented the arousal promoting effect of NPS (figure 26). 
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Figure 26 Recovery of righting reflex in mice. Effects elicited by i.c.v. injected NPS (0.1 nmol) and [D-Cys(tBu)5]NPS 
(1–10 nmol) alone or coinjected on the percentage of animals losing the righting reflex in response to 15 mg/kg i.p. 
diazepam (left) and on their sleep time (right). Sleep time is defined as the amount of time between the loss and 
regaining of the righting reflex. Data are mean ± sem of 16 mice per group. *P<0.05 vs saline, analysis of variance 
(ANOVA) followed by the Dunnett’s test for multiple comparison. 
 
With a second series of experiments the in vivo activity of [tBu-D-Gly5]NPS was assessed in 
the RR test. In line with previous findings, i.p. injection of diazepam at the hypnotic dose of 15 
mg/kg produced loss of the RR in 100% of the mice and approx 120 min were needed to regain this 
reflex. NPS injected i.c.v. at 0.1 nmol reduced the sleep time of mice responding to diazepam to 
approx 70 min. [tBu-D-Gly5]NPS up to 10 nmol did not significantly modify the hypnotic effect of 
diazepam either in terms of percent of animals losing the RR or sleep time. When [tBu-D-Gly5]NPS 
0.1 nmol was challenged with NPS it did not block the action of the natural peptide, however when 
the higher doses of 1 and 10 nmol were used [tBu-D-Gly5]NPS completely prevented the arousal 
promoting effect of NPS (figure 27). 
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Locomotor activity 
[D-Val5]NPS and [tBu-D-Gly5]NPS effects were investigated in vivo in LA test. In line with 
previous findings, NPS injected i.c.v. at 0.1 nmol evoked a stimulatory effect on mouse LA by 
increasing mice cumulative distance travelled and number of rearings, and reducing the total 
immobility time, in a statistically significant manner. [D-Val5]NPS injected i.c.v. at 10 nmol did not 
statistically modify the animal locomotor behaviour (figure 28). However, it is worthy of mention 
(although this effect did not reach the statistical level of significance) that there was a clear 
tendency of animals treated with 10 nmol [D-Val5]NPS to reduce their rearing behaviour. More 
importantly, [D-Val5]NPS completely prevented the locomotor stimulatory effect of 0.1 nmol NPS 
on all parameters detected (figure 28). 
 
 
 
Figure 27 Recovery of righting reflex in mice. Effects elicited by i.c.v. injected NPS (0.1 nmol) and [tBu-D-Gly5]NPS 
(0.1–10 nmol) on the percentage of animals losing the righting reflex in response to 15 mg/kg i.p. diazepam (left) and 
on their sleep time (right). Sleep time is defined as the amount of time between the loss and regaining of the righting 
reflex. Data are mean ± sem of 16 mice per group. *P<0.05 vs saline, analysis of variance (ANOVA) followed by the 
Dunnett’s test for multiple comparison. 
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Figure 28 Locomotor activity assay. Effects of 0.1 nmol NPS, 10 nmol [D-Val5]NPS and their coapplication. The time 
course of peptide effects is shown in the top left panel, while the other panels display the cumulative effects exerted by 
the peptides over the 60 min observation period. Data are mean ± sem of 16 mice per group. *P<0.05 vs saline, analysis 
of variance (ANOVA) followed by the Dunnett’s test for multiple comparison. 
 
[tBu-D-Gly5]NPS at 10 nmol did not affect per se the animal locomotion. When [tBu-D-
Gly5]NPS 1 nmol was challenged with NPS it did not significantly modify the action of the natural 
peptide, however when the higher doses of 3 and 10 nmol were given 15 min before NPS 
administration, [tBu-D-Gly5]NPS completely prevented, in a dose dependent manner, the 
stimulatory effects evoked by NPS (figure 29). 
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Figure 29 Locomotor activity assay. Effects elicited by i.c.v. injected NPS (0.1 nmol) and [tBu-D-Gly5]NPS (1–10 
nmol). The time course of the distance travelled is shown in the top left panel, while the other panels display the 
cumulative effects exerted by the peptides on distance travelled (top right panel), total time immobile (bottom left panel) 
and number of rearings (bottom right panel) over the 60 min observation period. Data are mean ± sem of 16 mice per 
group. *P<0.05 vs saline, analysis of variance (ANOVA) followed by the Dunnett’s test for multiple comparison. 
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[D-Cys(tBu)5]NPS at concentrations as high as 100 µM did not stimulate calcium 
mobilization in HEK293mNPSR cells but was able to completely inhibit, in a concentration dependent 
manner, the stimulatory effect of NPS. These results demonstrate that [D-Cys(tBu)5]NPS lacks 
efficacy and behaves as a pure NPSR antagonist. In addition, in inhibition response curve 
experiments [D-Cys(tBu)5]NPS antagonized NPS effects with pIC50 values (5.75 vs NPS 10 nM, 
4.64 vs NPS 100 nM) clearly influenced by the concentration of agonist, thus suggesting a 
competitive type of interaction 95. This was confirmed by classical Schild analysis where the 
peptide produced a concentration dependent rightward shift of the concentration-response curves to 
NPS without modifying its maximal effects. The estimated potency of [D-Cys(tBu)5]NPS in the two 
series of experiments, namely Schild plot (pA2 6.44) and inhibition experiments (pKB 6.62), is 
virtually superimposable and allows to classify this ligand as a moderate potency competitive 
antagonist. Under the same experimental conditions, [D-Cys(tBu)5]NPS 10 µM was found to be 
inactive both as agonist and antagonist at different G protein coupled receptors including 
muscarinic, opioid, NK-1, UT, and PAR2 receptors. These results certainly allow to exclude the 
possibility that the antagonist action of [D-Cys(tBu)5]NPS vs NPS can be due to a non-specific 
inhibitory effect on calcium signalling. However the panel of receptors used is probably not enough 
for firmly classifying [D-Cys(tBu)5]NPS as a selective NPSR antagonist. On the other hand, it is 
worthy of mention that [D-Cys(tBu)5]NPS was generated by substituting a single residue into a 20 
aminoacid long peptide characterized by high selectivity of action 9 and whose primary sequence is 
highly conserved among animal species 11. These considerations make the possibility that [D-
Cys(tBu)5]NPS maintains the same high selectivity of action as the natural peptide extremely likely. 
In calcium mobilization assay [D-Val5]NPS was completely inactive per se up to 10 µM, 
however it produced a concentration dependent inhibition of NPS effects. Thus [D-Val5]NPS 
clearly behaves in these experiments as a pure NPSR antagonist. As far as the type of antagonism 
exerted by [D-Val5]NPS vs NPS, it should be keep in mind that in inhibition curves experiments 
competitive antagonists are expected to display different pIC50 values depending on the 
concentration of agonist used while for non competitive antagonist similar pIC50 values are 
expected against different concentrations of agonist and pIC50 ≈ pKB. 95. In the present experiments 
[D-Val5]NPS displayed different pIC50 values dependent on agonist concentrations, i.e. 6.59 vs NPS 
10 nM and 5.96 (assuming full inhibition at concentration higher than 10 µM) vs NPS 100 nM. 
However, the increase of 1 log unit of agonist concentration produced a decrease of only 0.63 log 
unit in antagonist pIC50. Therefore, inhibition response data are not compatible with a simple 
competitive type of interaction between [D-Val5]NPS and NPS. A [D-Val5]NPS pKB value of 7.50 
(CL95% 7.18– 7.82) was derived from these experiments. In the classical Schild analysis [D-
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Val5]NPS displaced to the right the concentration response curve to NPS in a concentration 
dependent manner; however this was associated to a slight but statistically significant decrease of 
the maximal effect elicited by NPS at the higher concentrations of antagonist (i.e. 1 and 10 µM). 
The pattern of antagonist effect of [D-Val5]NPS vs NPS can be described as dextral displacement of 
the agonist concentration response curve with depression of maximum at high concentrations. Thus, 
in line with inhibition response data, the results obtained by Schild analysis are not compatible with 
competitive type of antagonism. A pKB values of 7.02 was derived from Schild analysis which is 
not too far from that obtained in inhibition experiments (7.50). To investigate [D-Val5]NPS 
selectivity of action, this peptide was challenged against the effect produced by carbachol via 
stimulation of endogenously expressed muscarinic receptors in HEK293mNPSR cells. [D-Val5]NPS at 
10 µM did not modify the stimulatory effect of carbachol. These results demonstrated that the 
antagonist effect of [D-Val5]NPS is selective for NPSR over muscarinic receptors and certainly 
does not derive from a non specific inhibitory effect of the peptide on calcium signalling. 
In order to compare [D-Val5]NPS and [tBu-D-Gly5]NPS antagonist potencies, the two 
peptides were tested in parallel, under the same experimental conditions. In this series of 
experiments, performed at 37°C and with three cycles of mixing, [D-Val5]NPS showed a pKB of 
6.02, so it was 10 fold less potent than in the previous study performed at room temperature and 
without mixing (pKB: 7.5). From these inhibition experiments a pKB of 6.67 was derived for [tBu-
D-Gly5]NPS. These data demonstrated that [tBu-D-Gly5]NPS represents the more potent pure 
peptide NPSR antagonist available up to now, being 3 fold more potent than [D-Val5]NPS. To get 
information on the nature of the antagonist action exerted by [tBu-D-Gly5]NPS the classical Schild 
analysis was performed. This peptide produced a concentration dependent rightward shift of the 
concentration response curve to NPS which was associated with a slight but significant depression 
of NPS maximal effects. From these experiments a pKB of 6.78 was derived. This value is close to 
that obtained in inhibition response curve studies (7.06, table 1). Thus, these experiments confirmed 
the pure and potent antagonist properties of [tBu-D-Gly5]NPS. However, these results are not 
compatible with a simple competitive interaction between [tBu-D-Gly5]NPS and NPS. Similar 
results (rightward shift associated with significant depression of agonist maximal effects) were 
previously reported for [D-Val5]NPS, which was tested at room temperature and without the three 
cycles of mixing. Under these same experimental conditions [tBu-D-Gly5]NPS caused a profound 
depression of NPS maximal effects (down to less than 50%) in a concentration dependent manner 
(data not shown). This depression of Emax was strongly reduced even if not completely eliminated 
performing the experiments at 37 °C and introducing the three cycles of mixing. Collectively these 
findings suggest that the depression of NPS Emax caused by NPSR antagonists in the calcium 
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mobilization assay may likely come from hemiequilibrium conditions due to lack of stirring rather 
than from a real insurmountable type of antagonism 95. Under the same experimental conditions, 
[tBu-D-Gly5]NPS 10 µM was found to be inactive both as agonist and antagonist at different G 
protein coupled receptors including muscarinic, opioid, NK-1, UT, B2 and PAR2 receptors. These 
results suggest that [tBu-D-Gly5]NPS behaves as a selective NPSR antagonist. However, the panel 
of receptors investigated is probably too limited to draw final conclusions about compound 
selectivity at this time. 
NPS produces a clear arousal promoting effect and a strong locomotion stimulant effect 
when administered supraspinally in rodents. These findings are robust and were independently 
replicated in different laboratories (see sections 3.3) 9. Thus, we used the mouse RR and LA assays 
for investigating the in vivo action of [D-Cys(tBu)5]NPS (RR), [D-Val5]NPS (LA) and [tBu-D-
Gly5]NPS (RR and LA). For these studies, the NPS dose of 0.1 nmol was selected based on 
previous dose-response studies 99 as the lower dose producing statistically significant effects, to be 
challenged with the NPSR antagonists.  
In line with previous findings, NPS 0.1 nmol produced a clear arousal promoting effect in 
the mouse RR assay. [D-Cys(tBu)5]NPS tested at 1 nmol was found inactive per se and vs the effect 
elicited by NPS. At 10 fold higher doses, [D-Cys(tBu)5]NPS did not modify per se the hypnotic 
effect of diazepam but fully prevented the arousal promoting action of NPS. This result confirmed 
in vivo the antagonistic properties of [D-Cys(tBu)5]NPS. The in vivo dose range of activity of [D-
Cys(tBu)5]NPS perfectly matches its in vitro potency at NPSR. In fact the peptide was active when 
tested vs NPS in a 100/1 but not 10/1 dose ratio and its in vitro antagonist potency (≈ 6.5) is 100 
fold lower than NPS agonist potency (≈ 8.5). Similarly, [tBu-D-Gly5]NPS tested at 10 nmol did not 
modify per se the hypnotic effect of diazepam. However it was able to completely block the arousal 
promoting action of NPS from the dose of 1 nmol. 
NPS 0.1 nmol had a strong stimulant action on mice LA, in all parameters detected. Because 
the in vitro ratio of potency NPS/[D-Val5]NPS is approximately 1/30, [D-Val5]NPS was tested in 
vivo at 10 nmol (agonist/antagonist ratio 1/100). [D-Val5]NPS injected i.c.v at the doses of 10 nmol 
did not statistically modify the animal locomotor behaviour. However it is worthy of mention 
(although this effect did not reach the statistical level of significance) that there was a clear 
tendency of animals treated with [D-Val5]NPS 10 nmol to reduce their rearing behaviour. 
Interestingly enough, this effect is opposite to that of NPS which produces a statistically significant 
increase in number of rearings. More importantly [D-Val5]NPS completely prevented the locomotor 
stimulatory effect of 0.1 nmol NPS and this applies to all the parameters investigated (cumulative 
distance travelled, number of rearings, and total immobility time). These results confirmed and 
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extended to an in vivo assay the NPSR antagonist properties of [D-Val5]NPS. [tBu-D-Gly5]NPS 
injected i.c.v at the doses of 10 nmol did not statistically modify the animal locomotor behaviour. 
At the doses of 1 nmol it did not counteract the stimulant NPS action but at the higher doses of 3 
and 10 nmol it was able to block, in a dose dependent manner the stimulant NPS actions. These 
results confirmed the NPSR antagonist proprieties of [tBu-D-Gly5]NPS in two in vivo assays. From 
these studies [tBu-D-Gly5]NPS was demonstrated to be the most potent peptide NPSR antagonist 
available up to now. In fact in RR test it was able to completely counteract the NPS arousal 
promoting action at the dose of 1 nmol, being 10 fold more potent than [D-Cys(tBu)5]NPS (active at 
10 nmol) and in LA test [tBu-D-Gly5]NPS was able to block the NPS stimulant effects at the dose 
of 3 nmol, being 3 fold more potent than [D-Val5]NPS (active at 10 nmol). The in vivo dose range 
of activity of [tBu-D-Gly5]NPS perfectly matches its in vitro potency at NPSR and the in vitro ratio 
of potency [D-Val5]NPS/[tBu-D-Gly5]NPS. 
The neurobiological implications of these experiments are twofold. First, with the use of [D-
Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS we demonstrated that the stimulant and arousal 
promoting effects  of NPS are exclusively due to NPSR activation. These results are in line with 
previous reports about the stimulatory effect of NPS on LA using the non peptide antagonist SHA 
68 33 and the peptide partial agonist [Ala3]NPS 100. Second, the lack of effect of this NPSR 
antagonists per se at doses able to prevent the action of exogenously applied NPS suggests that 
endogenous NPS signalling is not activated under the present experimental conditions. It is worthy 
of mention (although this effect did not reach the statistical level of significance) that there was a 
clear tendency of animals treated with [D-Val5]NPS 10 nmol to reduce their rearing behaviour. This 
effect is opposite to that of NPS which produces a statistically significant increase in number of 
rearings. Interestingly SHA 68 at doses able to counteract the stimulatory effect of exogenously 
applied NPS produced per se a selective reduction of mouse vertical activity 33. These results 
together with the present findings obtained with [D-Val5]NPS might implicate a tonic control of the 
endogenous NPS/NPSR system on this particular animal behaviour. Clearly further studies are 
needed to firmly understand the role of the endogenous NPS/NPSR system in the regulation of 
locomotion, wakefulness and sleep functions. 
In conclusion, [D-Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS were 
pharmacologically characterized in vitro and in vivo. These molecules were demonstrated to be pure 
and selective NPSR antagonists, with [D-Cys(tBu)5]NPS and [D-Val5]NPS characterized by a 
moderate potency, while [tBu-D-Gly5]NPS represents the most potent NPSR peptide antagonist 
available up to now. Moreover  it has been demonstrated that the stimulant and arousal promoting 
action of NPS is due to the selective activation of the NPSR protein. These peptide molecules 
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together with the recently discovered NPSR non peptide antagonist SHA 68 represent very 
important tools needed for understanding which and how biological functions are controlled by the 
NPS/NPSR system; in addition these NPSR ligands might be instrumental for identifying 
innovative strategies for treating neurological as well as psychiatric diseases. 
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3.5 In vitro and in vivo pharmacological characterization of the non peptide NPSR antagonist 
SHA 68 
 
SHA 68, i.e. the racemic mixture (9R/S)-3-oxo-1,1-diphenytetrahydro-oxazolo[3,4-
a]pyrazine-7-carboxylic acid 4-fluorobenzylamide has been identified by Takeda researchers and 
characterized pharmacologically in vitro and in vivo by Okamura et al. 33. In radioligand 
([125I][Tyr10]NPS) binding experiments performed in HEK293hNPSR cells SHA 68 displayed high 
affinity (pKi 7.3). In calcium mobilization experiments SHA 68 was inactive per se while 
antagonizing NPS stimulatory effects in a concentration-dependent and competitive manner. 
Similar high pA2 values were obtained with SHA 68 at Ile107 (7.6) and Asn107 (7.8) hNPSR 
isoforms expressed in HEK293 cells 33. SHA 68 appeared to be selective for NPSR since it did not 
affect signaling at 14 unrelated GPCR. In vivo in mice SHA 68 reached pharmacologically relevant 
levels in plasma and brain after i.p. administration 33. Despite this, SHA 68 (50mg/kg i.p.) was only 
able to partially counteract NPS induced stimulation of LA 33. In the present study the 
pharmacological profile of SHA 68 was further investigated in vitro in calcium mobilization 
experiments performed on HEK293mNPSR cells and in vivo in LA, RR and OF tests in mice. 
 
Calcium mobilization assay 
 
In the calcium mobilization assay performed on HEK293mNPSR cells, NPS increased the 
intracellular calcium concentrations in a concentration-dependent manner with pEC50 and Emax 
values of 8.30 and 236±15% over the basal values, respectively. Inhibition response curve to SHA 
68 (0.01 nM–10 μM) were performed against the stimulatory effect of 30 nM NPS, approximately 
corresponding to the EC80 value for the agonist. As shown in figure 30, SHA 68 concentration-
dependently inhibited 30 nM NPS stimulatory effects with a pIC50 value of 7.37. A pKB value of 
7.74 (CL95% 7.44–8.04) was derived for SHA 68 from these experiments.  
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Figure 30 Calcium mobilization assay performed on HEK293mNPSR cells. Inhibition response curve to SHA 68 (0.01 
nM–10 μM) against the stimulatory effect of 30 nM NPS. Data are mean±s.e.m of 4 experiments made in duplicate. 
 
 
In order to investigate the nature of the antagonist action exerted by SHA 68 the classical 
Schild analysis was performed. As depicted in figure 31, left panel, SHA 68 in the range of 10–
1000 nM did not produce any effect per se but displaced the concentration response curve to NPS to 
the right in a concentration-dependent and parallel manner. A slight but significant depression of 
NPS Emax was recorded in the presence of the highest concentrations of antagonist (i.e. 100 and 
1000 nM). The corresponding Schild plot, which was linear (r2 = 0.97) with a slope of 1.00±0.18, is 
shown in the right panel of figure x. The extrapolated pA2 value was 8.06. 
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Figure 31. Calcium mobilization assay performed on HEK293mNPSR cells. Concentration-response curve to NPS 
obtained in the absence (control) and in presence of increasing concentrations of SHA 68 (10-100 nM) (left panel); the 
corresponding Schild plot is shown in the right panel. Data are mean ± sem of 4 experiments made in duplicate. 
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Locomotor activity 
 
As shown in figure 32 and in line with previous findings, NPS injected i.c.v. at 0.1 nmol 
evoked a stimulatory effect on mouse LA by increasing cumulative distance travelled by the 
animals and their number of rearings, and reducing the total immobility time, in a statistically 
significant manner. SHA 68 at 50mg/kg did not modify per se the animal behaviour (figure 
32).When challenged with NPS, SHA 68 at 10mg/kg displayed a trend toward inhibition of the 
stimulatory effects evoked by the peptide. Statistically significant effects were obtained with SHA 
68 50mg/kg (figure 32) although the antagonist did not fully prevented the effects elicited by the 
peptide.  
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Figure 32 Locomotor activity assay. Effects of NPS and SHA 68. Time course of the distance traveled is shown in the 
top left panel, while the other panels display the cumulative effects exerted by the peptide and SHA 68 on distance 
traveled (top right panel), total time immobile (bottom left panel), and number of rearings (bottom right panel) over the 
60 min observation period. Data are mean ± sem of 4 separate experiments (total 16 mice per group). *p<0.05 vs 
control, #p<0.05 vs NPS 0.1 nmol according to two-way ANOVA followed by the Bonferroni test for multiple 
comparisons. 
 
 
In order to investigate the in vivo selectivity of action of SHA 68, the NPSR antagonist was 
tested against the effect of caffeine in LA experiments. Caffeine at 20 mg/kg evoked a clear 
stimulatory effect on mouse locomotor activity by increasing cumulative distance travelled by the 
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animals and reducing the total time immobile, in a statistically significant manner. SHA 68 at 
50mg/kg did not affect the stimulatory effects of caffeine (figure 33). 
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Figure 33 Locomotor activity assay. Effects of caffeine and SHA 68. Time course of the distance travelled is shown in 
the top left panel, while the other panels display the cumulative effects exerted by the peptide and SHA 68 on distance 
traveled (top right panel), total time immobile (bottom left panel), and number of rearings (bottom right panel) over the 
60 min observation period. Data are mean ± sem of 4 separate experiments (total 16 mice per group). *p<0.05 vs 
control, #p<0.05 vs NPS 0.1 nmol according to two-way ANOVA followed by the Bonferroni test for multiple 
comparisons. 
 
 
Recovery of righting reflex 
 
As shown in figure 34 and in line with previous findings, i.p. injection of diazepam at the 
hypnotic dose of 15mg/kg produced loss of the RR in all treated mice and approximately 100 min 
were needed to regain this reflex. NPS injected i.c.v. at 0.1 nmol reduced both the percent of 
animals responding to diazepam below 75% and their sleep time to approximately 50 min. The 
administration of SHA 68 (10 and 50mg/kg) did not significantly modify the hypnotic effect of 
diazepam either in terms of percent of animals losing the RR or duration of their sleep time (figure 
34).When SHA 68 (10 mg/kg) was co-administered with 0.1 nmol NPS, it prevented the NPS 
mediated reduction in the percent of mice responding to diazepam but did not modify their sleep 
time. On the contrary, SHA 68 50 mg/kg fully prevented the arousal promoting effect of NPS; in 
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fact results obtained in mice treated with NPS plus SHA68 50 mg/kg were superimposable to those 
of vehicle-treated animals (figure 34).  
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Figure 34 Recovery of righting reflex in mice. Effects elicited by NPS (0.1 nmol) and SHA 68  (10–50 mg/kg) on the 
percentage of animals losing the righting reflex in response to 15 mg/kg i.p. diazepam (left) and on their sleep time 
(right). Sleep time is defined as the amount of time between the loss and regaining of the righting reflex. Data are mean 
± sem of 16 mice per group. *p<0.05 vs control, #p<0.05 vs NPS 0.1 nmol according to two-way ANOVA followed by 
the Bonferroni test for multiple comparisons. 
 
In order to investigate the possible effects of the NPSR antagonist on the hypnotic action of 
diazepam, a separate series of experiments were performed by testing SHA 68 50 mg/kg against 
different doses of the benzodiazepine. As shown in figure 35, 5 mg/kg diazepam was inactive in the 
RR paradigm. At 10 mg/kg the benzodiazepine produced loss of the RR in 70% of the treated mice 
and approximately 25 min were needed to regain the reflex. Diazepam at 15 mg/kg produced loss of 
the RR in all treated mice and they sleep time was approximately 110 min. At 50 mg/kg SHA 68 
did not modify the dose response curve to diazepam; in fact superimposable results were obtained 
in animals treated with saline or SHA 68 both in terms of percent of animals losing the RR and 
regarding their sleep time (figure 35). 
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Figure 35 Recovery of righting reflex in mice. Effect of i.p. injection of SHA 68 (50mg/kg) on the percent of animals 
losing their righting reflex (left panel) and on their sleep time (right panel) in response to diazepam 5, 10, and 15mg/kg 
i.p. Sleep time is defined as the amount of time between the loss and regaining of the righting reflex. Data are mean ± 
sem of 16 mice per group. 
 
Open field 
 
As shown in figure 36 and in line with previous findings, NPS injected i.c.v. at 0.1 nmol 
evoked an anxiolytic like effect on mouse OF, by increasing number of entries in the central zone 
and the time spent by mice in this area of the field. SHA 68 50 mg/kg did not significantly modify 
per se the behaviour of mice subjected to the OF assay. Moreover, SHA 68 50mg/kg only 
counteracted the effects elicited by NPS on time in the central area but not on the number of entries 
(figure 36). 
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Figure 36 Open field assay in mice. Effects of NPS and SHA 68 on the number of entries in the central zone (left 
panel) and the time spent in this are of the field (right panel). Data are mean ± sem of 20 mice per group. *p<0.05 vs 
control, #p<0.05 vs NPS 0.1 nmol according to two-way ANOVA followed by the Bonferroni test for multiple 
comparisons. 
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In the present study the in vitro and in vivo pharmacological profile of the NPSR ligand 
SHA 68 was investigated. Our findings confirmed and extended previous results 33 demonstrating 
that SHA 68 behaves in vitro as a pure and potent NPSR antagonist. In vivo, in mice, SHA 68 was 
investigated in a panel of assays sensitive to the stimulatory and arousal promoting (LA and RR), 
and anxiolytic-like (OF) actions of NPS. Depending on the assay, SHA 68 displayed different 
effectiveness: it fully blocked NPS effects in the RR, partially counteracted the actions of the 
peptide in the LA and was barely active in the OF assay. The reasons for this different pattern of 
action of SHA 68 are not known but they may likely be attributed to its poor pharmacokinetic 
profile 33. In HEK293mNPSR cells SHA 68 behaved as a pure antagonist. Similar high values of 
potency were obtained in inhibition curve experiments (pKB 7.74) and by performing the classical 
Schild protocol (pA2 8.06). Results obtained in the latter assay are however not compatible with a 
simple competitive interaction between SHA 68 and NPS since the antagonist at the highest 
concentration tested produced a slight but significant depression of NPS maximal effects. However, 
the following considerations suggest that the depression of NPS Emax caused by SHA 68 in the 
calcium  mobilization assay probably derives from hemiequilibrium conditions rather than from a 
real insurmountable type of antagonism. In fact in a pilot series of experiments performed at room 
temperature and without three cycles of mixing, SHA 68 caused, in a concentration dependent 
manner, a profound depression of NPS maximal effects (down to less than 50% Emax). This 
depression of Emax was strongly reduced even if not completely eliminated (see figure 23) by 
performing the experiments at 37 °C and introducing three cycles of mixing. Similar results were 
obtained investigating the NPSR antagonist properties of the NPS related peptide [tBu-D-Gly5]NPS. 
Thus, the fact that antagonist induced depression of agonist maximal effects is highly sensitive to 
procedures which facilitate drug diffusion (i.e. increase in temperature and cycles of mixing) 
strongly suggests that this phenomenon is due to hemiequilibrium conditions due to lack of stirring 
and not to a real insurmountable type of antagonism 95. The value of SHA 68 potency at mouse 
NPSR obtained in the present study is superimposable to those measured at human NPSR isoforms 
Asn107 (pA2 7.77) and Ile107 (pA2 7.55) 33 indicating that this NPSR ligand does not discriminate 
between NPSR species-specific proteins and isoforms. This is in contrast to findings for NPS 17-18  
and NPS-related peptides 101 that displayed significantly higher agonist potencies at hNPSR Ile107 
and mNPSR (that contains Ile at position 107) than at the hNPSR Asn107 isoform. It would be 
interesting in future studies to analyze and compare the pharmacological profile of NPSR peptide 
antagonists (i.e. [D-Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS) and non-peptide agonists 
(that are not yet described in the literature) at NPSR species-specific proteins and isoforms. Such 
studies may help to identify the specific binding site(s) recognized by peptide and non-peptide 
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ligands able of block or activate NPSR and thus facilitate molecular modeling studies and the 
rational design of novel potent NPSR ligands. 
In vivo SHA 68 was first challenged against the LA stimulatory effect of NPS. This action of 
NPS has been independently replicated in several different laboratories (see for a review Guerrini et 
al. 100). Data obtained in LA experiments with SHA 68 are virtually superimposable to those 
previously published by Okamura et al. 33. SHA 68 at the higher dose tested (50 mg/kg) was 
inactive per se and only partially counteracted the stimulatory effect elicited by the supraspinal 
injection of NPS. The absence of a full block of NPS effects despite the relatively high dose of 
antagonist used may likely be linked to the poor pharmacokinetic properties of this molecule, in 
particular its very high lipophilicity 33 that may reduce the ability of this molecule to reach its target. 
Recent findings obtained by industrial investigators corroborate this view 102. In fact, ex vivo 
binding studies demonstrated that only approximately 50% of [125I]NPS binding to brain sections is 
inhibited by treating mice with SHA 68 50 mg/kg. The results obtained with the peptide NPSR 
antagonists [D-Val5]NPS and [tBu-D-Gly5]NPS that fully blocked NPS stimulatory effects but 
being per se inactive parallel those of SHA 68. Thus findings obtained from different laboratories 
using chemically unrelated molecules demonstrated that the stimulatory effect of NPS on LA is 
solely due to NPSR activation. This has been recently confirmed by knockout studies that 
demonstrated that NPS can stimulate LA in NPSR(+/+) but not in NPSR(-/-) mice 36.  
In line with in vitro findings (SHA 68 does not affect signaling at 14 unrelated G protein-
coupled receptors, 33), the present in vivo results confirmed that SHA 68 antagonist properties are 
selective for the NPSR since the stimulatory effect of caffeine on LA was not affected by this 
molecule.  
The supraspinal administration of NPS elicits a robust arousal promoting action in rodents. 
SHA 68 was able to fully prevent this NPS effect in the mouse RR assay. This implies that NPSR 
regulating arousal might be more accessible to the antagonist than those stimulating LA. This result 
parallels previous data obtained under the same experimental conditions using the NPSR antagonist 
[D-Cys(tBu)5]NPS and investigating the phenotype of NPSR(-/-) mice. [D-Cys(tBu)5]NPS blocked 
the arousal promoting effect of NPS and NPS elicited its stimulatory effects in NPSR(+/+) but not 
in NPSR(-/-) mice. In addition, NPSR(+/+) and NPSR(-/-) animals were similarly sensitive to the 
hypnotic effect of diazepam and the peptide NPSR antagonist did not modify per se the effect of the 
benzodiazepine. This latter result has been confirmed and extended in the present study by 
challenging SHA 68 versus increasing doses of diazepam. Thus, collectively these results 
demonstrated that i) NPSR activation is involved in the arousal promoting action of NPS, and ii) 
endogenous NPSR is not tonically activated under the present experimental conditions. Obviously 
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this does not preclude the possibility that the endogenous NPS/NPSR system might be important for 
controlling circadian sleep/wakefulness cycles. In fact, NPSR(-/-) mice displayed reduced late peak 
wheel running (an index of activity of the internal clock) compared to NPSR(+/+) mice 36 and, more 
importantly, the functional hNPSR polymorphism Ile107 has been associated with delayed average 
bedtime in humans 20.  
In line with previous findings the present data confirmed that the supraspinal injection of 
NPS elicited dose-dependent anxiolytic-like actions in rodents. In fact, NPS 0.1 nmol increased the 
time spent in and the number of entries into the central area of the OF in mice. SHA 68 slightly and 
non-significantly reduced the effects of the peptide in the mouse OF. The reasons for these weak 
SHA 68 effectiveness are not completely known, however they may likely be attributed to the 
pharmacokinetic rather than pharmacodynamic properties of this molecule. In fact, SHA 68 was 
reported to be able to prevent the anxiolytic NPS actions in rat EPM and defensive burying assays 
103 and these data support the hypothesis that the anxiolytic-like actions evoked by NPS in rodents 
are due to the selective activation of the NPSR protein. Probably the lack of effectiveness of SHA 
68 given systemically in the mice OF test may derive from an incomplete occupation of brain NPSR 
controlling fear and anxiety levels which are most probably located in the amygdala 25-26,28. Since 
SHA 68 50 mg/kg was not able to block the anxiolytic effect of exogenous given NPS, the present 
study did not provide any indication about the role of endogenous NPS/NPSR system in controlling 
anxiety behaviours. Clearly further studies performed with different NPSR selective antagonists and 
with NPSR(-/-) mice are needed before drawing firm conclusion on the role of the endogenous 
NPS/NPSR system in the control of fear and anxiety.  
In conclusion, this study confirmed and extended previous findings demonstrating that the 
bicyclic piperazine derivative SHA 68 behaves as a selective NPSR antagonist in vitro and in vivo. 
However the usefulness of this research tool is limited by its poor pharmacokinetic properties. This 
may likely be one reason for the variable effectiveness of SHA 68 in the different NPS sensitive 
assays examined in the present study. Nevertheless SHA 68 can be successfully used as a template 
for the identification of non-peptide NPSR selective antagonists characterized by better 
pharmacokinetic features. These kind of molecules should be used together with the available 
NPSR peptide ligands 100 and genetic models 83 for performing detailed target validation studies that 
will hopefully allow to firmly identify the therapeutic potential of innovative drugs acting at NPSR. 
results and discussion 
 101
3.6 Behavioural characterization of NPSR knock out mice   
 
Up to now little information is available about the physiological functions modulated by the 
endogenous NPSergic pathways. For this reason, NPSR(-/-) mice represent a useful and powerful 
tool  for the elucidation of the biological roles played by this new peptidergic system. Moreover 
time these mice can be used to investigate the involvement of the NPSR receptor in the well known 
activities promoted by exogenously given NPS and, when they will be available, by non peptide 
NPSR agonists. NPSR(-/-) mice were generated on a 129S6/SvEv genetic background as described 
in Allen et al. 83. 129S6/SvEv derived embryonic stem cells were choose as they are the most useful 
cell type for gene modification purposes. However the 129S6/SvEv strain provide an unfavourable 
genetic background, as these mice are characterized by poor reproductive performance and 
behavioural abnormalities including low locomotor activity, high anxiety levels and depressive-like 
behaviours 104-107. The need to avoid a strain with extreme traits, in this case very low locomotor 
activity associated to high anxiety levels, which could produce ceiling or floor effects that mask the 
outcome of the mutation, prompted us to change the genetic background of NPSR(-/-) mice from 
129S6/SvEv to CD-1. This has been achieved by performing 8 cycles of backcross to the CD-1 
strain.  
Since NPS is reported to have stimulant and arousal promoting affects and at the same time 
a clear anxiolytic-like action 9,43 (see also section 3.3), we investigated the behaviour of NPSR(+/+) 
and NPSR(-/-) mice in LA, RR, EPM, OF and SIH assays. Furthermore, to understand if the 
NPS/NPSR system plays a role in controlling depressive-like behaviours we performed the FS test. 
NPS is also able to facilitate memory 67-69 and to reduce pain transmission 71, thus we studied 
NPSR(-/-) mice phenotype in the NOR test and in the formalin test. 
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Behavioural comparison of  129S6/SvEv and CD-1 mice 
 
As mentioned before, we backcrossed for 8 generations 129S6/SvEv NPSR(+/-) mice to the 
CD-1 strain, that is the inbred strain we routinely use for our experiments. A congenic strain is a 
mouse strain that is isogenic to an inbred strain, but contains a chromosomal segment from another 
background. Thus after 8 backcross cycles we obtained a CD-1 congenic colony (mice which are 
99.61% CD-1 pure) and then we split it into two separate colonies, NPSR(+/+) and NPSR(-/-) mice. 
As the two colonies differ only for the presence or the absence of a functional NPSR gene, they can 
be directly compared in phenotype studies. Figure 38 compares the behaviour of 129S6/SvEv 
NPSR(+/+) mice with that of CD-1 congenic NPSR(+/+) mice obtained at the end of backcross in 
the OF assay. Unpaired t-test revealed that CD-1 mice shown a significant increase in locomotor 
activity, both in terms of total distance travelled and number of rearing, compared to 129S6/SvEv 
mice. In addition, CD-1 mice resulted less anxious than 129S6/SvEv mice as they did significantly 
more entries in and spent more time into the central zone of the field. 
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Figure 37 Open field assay in 129S6/SvEv and CD-1 mice. Effects of genetic background on the total distance travelled 
(top left panel), number of rearings (top right panel), number of entries in the central zone (bottom left panel) and the 
time spent in this are of the field (bottom right panel). Data are mean ± s.e.m. of 8 mice per group. *P<0.05 vs 
129S6/SvEv, Student’s t-test for unpaired data. 
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Locomotor activity 
 
Locomotor activity test was performed both with naïve mice and with mice habituated for 
60 min to the test chamber. In this test, naïve NPSR(-/-) mice did not show any difference in the 
total distance travelled, in the total time immobile and in the number of rearings compared to 
NPSR(+/+) mice (figure 38).  
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Figure 38 Locomotor activity assay performed in NPSR(+/+) and NPSR(-/-) mice. Effect of genotype on the time 
course of distance travelled (top left panel), on the cumulative total distance travelled (top right panel), immobility time 
(bottom left panel) and number of rearings (bottom right panel). Data are mean ± s.e.m. of 21 mice per group.  
 
Similar results were obtained comparing the LA of NPSR(+/+) and NPSR(-/-) mice after 60 
min of habituation to the test cage. A shown in figure 39, after the habituation period, NPSR(+/+) 
mice showed an important reduction in LA with total distance travelled < 50 m, total time immobile 
> 1500 s and number of rearing ~ 300. NPSR(-/-) did not display any alteration in locomotion 
compared to NPSR(+/+) mice (figure 39).  
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Figure 39 Locomotor activity assay performed in NPSR(+/+) and NPSR(-/-) mice habituated to the test cage. Effect of 
genotype on the time course of distance travelled (top left panel), on the cumulative total distance travelled (top right 
panel), immobility time (bottom left panel) and number of rearings (bottom right panel). Data are mean ± s.e.m. of 21 
mice per group.  
 
To investigate the involvement of the NPSR receptor in the NPS stimulant affects, 
NPSR(+/+) and NPSR(-/-) were treated with saline or NPS and their LA measured. No differences 
were found between NPSR(+/+) and NPSR(-/-) mice treated with saline. The i.c.v. injection of NPS 
1 nmol caused a significant increase in mice horizontal and vertical activity and a decrease of mice 
immobility time in NPSR(+/+) but not NPSR(-/-) mice (figure 40).  
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Figure 40 Locomotor activity assay performed in NPSR(+/+) and NPSR(-/-) mice. Effect of NPS 1 nmol on the time 
course of distance travelled (top left panel), on the cumulative total distance travelled (top right panel), immobility time 
(bottom left panel) and number of rearings (bottom right panel), Data are mean ± s.e.m. of 9 mice per group. *p<0.05 vs 
control according to two-way (treatment and genotype) ANOVA followed by the Bonferroni test for multiple 
comparisons. 
 
 
Recovery of righting reflex 
 
A first series of experiments was performed with NPSR(+/+) and NPSR(-/-) littermates 
obtained by mating heterozygous NPSR(+/-) 129S6/SvEv mice from Taconic. These mice were 
investigated for their phenotype and sensitivity to NPS in the RR assay. The i.p. injection of 
diazepam at 15 mg/kg produced loss of the RR in 100% of both NPSR(+/+) and NPSR(-/-) mice 
and 180 ± 18 and 211 ± 19 min were needed to regain this reflex in NPSR(+/+) and NPSR(-/-) 
mice, respectively (figure X). In NPSR(+/+) mice, NPS injected i.c.v. at the dose of 1 nmol did not 
modify the percent of animals responding to diazepam, however it clearly reduced their sleeping 
time to 67 ± 9 min. On the contrary, NPS 1 nmol failed to modify the hypnotic effect of diazepam 
in NPSR(-/-) mice (figure 41).  
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Figure 41 Recovery of righting reflex in NPSR(+/+) and NPSR(-/-) mice. Effect of 1 nmol i.c.v. injected NPS on the 
sleep time of animals losing of the righting reflex in response to diazepam 15 mg/kg i.p. Sleeping time is defined as the 
amount of time between the loss and regaining of the righting reflex. Data are mean ± sem of 10-12 mice per group. 
*p<0.05 vs control, according to two-way (treatment and genotype) ANOVA followed by the Bonferroni test for 
multiple comparisons. 
 
 
Subsequently the phenotype of NPSR(+/+) and NPSR(-/-) mice backcrossed on the CD-1 
strain was investigated in the same assay. CD-1 mice were less sensitive to the hypnotic effects of 
diazepam compared to 129S6/SvEv mice. In fact after diazepam administration at the dose of 15 
mg/kg, only the 85% of CD-1 mice lost the RR and the sleep time of mice responding to 
benzodiazepine was ~ 80 min. As shown in figure 42, no differences between NPSR(+/+) and 
NPSR(-/-) mice were recorded both in terms of percentage of animals responding to diazepam and 
in terms of sleep time (figure 42). 
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Figure 42 Recovery of righting reflex in NPSR(+/+) and NPSR(-/-) mice. The percent of animals losing the righting 
reflex in response to diazepam 15 mg/kg  is displayed on the left panels, their sleep time is displayed on right panels. 
Sleep time is defined as the amount of time between the loss and regaining of the righting reflex. Data are mean ± s.e.m. 
of 10 mice per group. 
 
 
Elevated plus maze 
The behaviour of NPSR(+/+) and NPSR(-/-) mice was investigated in the EPM test. In this 
test, the average time spent in and the number of entries into open arms by NPSR(+/+) mice were 
34.1 ± 6.4 s (corresponding to 21.4 ±3.6 % of the total time spent in open and closed arms) and 3.6 
± 0.7 (corresponding to 22.5 ± 3.9 % of the total entries into open and closed arms), respectively. 
Mice lacking the NPSR receptor did not exhibit any difference compared to NPSR(+/+) mice 
(figure 43). All the behavioural parameters measured in the EPM in NPSR(+/+) and NPSR(-/-) 
animals are summarised in table 13. Interestingly enough, NPSR(-/-) mice displayed a significant 
decreased number of rearings compared to NPSR(+/+) mice. No differences in the frequency of 
stretch attend postures, grooming, and head dipping were observed.  
NPSR(+/+) and NPSR(-/-) mice were injected with saline or NPS 1 nmol and their 
behaviour was investigated in the EPM test. No genotype related differences were observed in mice 
treated with saline (figure 44). NPS 1 nmol had a significant anxiolytic action in NPSR(+/+) mice 
increasing both the number of entries in and the time spent in the open arms. On the contrary the 
peptide was inactive when given to NPSR(-/-) animals. All the measured EPM parameters are 
summarised in table 14.  
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Figure 43 Elevated plus maze test performed with NPSR(+/+) and NPSR(-/-) mice. Effects of genotype on the time 
spent in (left panel) and on the number of entries into the open arms (right panel). Data are mean ± s.e.m. of 22 mice per 
group.  
 
 
 
Table 13 Effects of genotype on various behavioural parameters displayed by NPSR(+/+) and NPSR(-/-) mice 
subjected to the EPM 
Genotype Time in 
open 
arms (s) 
Entries in 
open arms 
Time in closed arms 
(s) 
Entries in 
closed 
arms 
Stretch 
attend 
posture 
Head-
dipping 
Rearing 
NPSR(+/+) 
 
34.1±6.4 3.6±0.7 110.9±5.9 10.2±0.8 21.5±1.6 9.7±1.5 20.7±1.8 
NPSR(-/-) 
 
35.5±6.5 3.9±0.6 107.8±4.4 11.8±1.1 21.5±1.5 7.4±1.0 14.1±1.5* 
All values are expressed as mean ± s.e.m. of 22 mice per group. 
*P<0.05 vs NPSR(+/+), Student’s t-test for unpaired data. 
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Figure 44 Elevated plus maze test performed with NPSR(+/+) and NPSR(-/-) mice. Effects of genotype and NPS (1 
nmol, i.c.v.) on the time spent in (left panel) and on the number of entries into the open arms (right panel). Data are 
mean ± s.e.m. of 9 mice per group. *p<0.05 vs control, according to two-way (treatment and genotype) ANOVA 
followed by the Bonferroni test for multiple comparisons. 
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Table 14 Effects of genotype and treatment on various behavioural parameters displayed by NPSR(+/+) and NPSR(-/-) 
mice subjected to the EPM 
Genotype Treatment Time in 
open arms 
(s) 
Entries 
in open 
arms 
Time in closed 
arms 
(s) 
Entries in 
closed 
arms 
Stretch 
attend 
posture 
Head-
dipping 
Rearing 
NPSR(+/+)  
 
control 18.5±10.0 2.0±0.9 106.1±20.1 7.3±1.7 25.8±3.2 9.3±1.3 10.8±3.6 
NPSR(+/+)  
 
NPS 1 
nmol 
149.7±18.0* 17.3±3* 52.3±6.8* 9.7±1.2 5.0±1.6* 33.3±5.2* 16.4±2.7 
NPSR(-/-)  
 
control 40.2±12.9 5.3±1.6 92.7±14.1 9.9±1.3 21.4±3.2 13.2±2.3 10.0±3.1 
NPSR(-/-) 
 
NPS 1 
nmol 
65.6±24.2 7.4±2.1 76.0±16.4 9.9±1.4 11.0±3.1 19.1±4.7 11.9±0.6 
All values are expressed as mean ± s.e.m. of 9 mice per group. 
*p<0.05 vs control, according to two-way (treatment and genotype) ANOVA followed by the Bonferroni test for 
multiple comparisons. 
 
 
Open field 
 
When evaluated in the OF test no differences were observed between NPSR(+/+) and 
NPSR(-/-) mice in the total distance travelled, number of entries in and time spent in the central 
zone of the field (figure 45). However the frequency of rearing was significantly reduced in NPSR(-
/-) mice compared to NPSR(+/+) mice (figure 45). 
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Figure 45 Open field assay in NPSR(+/+) and NPSR(-/-) mice. Effects of genotype on the total distance travelled (top 
left panel), number of rearings (top right panel), number of entries in the central zone (bottom left panel) and the time 
spent in this are of the field (bottom right panel). Data area mean ± s.e.m. of 20 mice per group. *P<0.05 vs NPSR(+/+), 
Student’s t-test for unpaired data. 
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Next we evaluated NPS 1 nmol effects in the OF assay in NPSR(+/+) and NPSR(-/-) mice. 
NPSR(-/-) mice injected with saline displayed a significant decrease in the number of entries in the 
central zone of the field compared to NPSR(+/+) mice. No significant genotype effect were 
recorded in the other parameters detected. However there was a trend for of NPSR(-/-) animals 
towards reduced rearing behaviour, number of entries and time spent in the central zone of the field. 
NPS 1 nmol had an anxiolytic-like action in NPSR(+/+) mice and was able to increase their vertical 
activity and their frequency and the length of the visits in the central area of the OF. No significant 
effects were recorded in NPSR(-/-) mice in response to NPS injection (figure 46). 
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Figure 46 Open field assay in NPSR(+/+) and NPSR(-/-) mice. Effects of genotype and  NPS (1 nmol, i.c.v.) on the 
total distance travelled (top left panel), number of rearings (top right panel), number of entries in the central zone 
(bottom left panel) and the time spent in this area of the field (bottom right panel). Data are mean ± s.e.m. of 9 mice per 
group. *p<0.05 vs control, # p<0.05 vs NPSR(+/+) according to two-way (treatment and genotype) ANOVA followed 
by the Bonferroni test for multiple comparisons. 
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Stress-induced hyperthermia test 
Stress induced by the measurement of body temperature evoked an increase in T2 compared 
with T1 temperature in NPSR(+/+) and NPSR(-/-) mice. No differences were recorded in baseline 
temperature and in the SIH between NPSR(+/+) and NPSR(-/-) mice (figure 47). 
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Figure 47 Sress-induced hyperthermia test in NPSR(+/+) and NPSR(-/-) mice. Effects of genotype on baseline 
temperature (T1, left panels) and SIH (T2–T1, right panels). Data are mean ± s.e.m. of 7-10 mice per group.  
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Novel object recognition 
 
The NPSR(+/+) and NPSR(-/-) performances were evaluated in the NOR test. In the sample 
trial no significant differences were observed in the time spent by mice exploring the two objects, 
both in NPSR(+/+)and NPSR(-/-) mice. Moreover the total time spent by NPSR(+/+) and NPSR(-/-) 
mice exploring the objects was superimposable (data not shown). After a 3 h delay, both 
NPSR(+/+) and NPSR(-/-) mice spent significantly more time exploring the new object. No 
alterations were observed in the NOR in NPSR(-/-) compared to NPSR(+/+) mice (figure 48). 
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Figure 48 Novel object recognition test in NPSR(+/+) and NPSR(-/-) mice. Effects of genotype on time spent exploring 
the old and the new object during the test session. *p<0.05 vs old object, according to two-way (genotype and object) 
ANOVA followed by the Bonferroni test for multiple comparisons. 
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Forced swimming test 
 
No differences were measured between the behaviour of NPSR(+/+) and NPSR(-/-) mice 
subjected to the FST (figure 49). 
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Figure 49 Forced swimming test in NPSR(+/+) and NPSR(-/-) mice. Effects of genotype on immobility time. Data are 
mean ± s.e.m. of 8-10 mice per group. 
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Formalin test 
 
The intraplantar injection of 30 µl of 1.5% formalin solution into the dorsal surface of the 
right hind paw produced a biphasic nociceptive response both in NPSR(+/+) and NPSR(-/-) mice. 
As shown in figure 51 the first phase started immediately after formalin injection and lasted for 10 
min, while the second phase was prolonged, starting approximately 15 min after the injection and 
lasting for about 30 min. No differences were observed between the nociceptive behaviours of 
NPSR(+/+) and NPSR(-/-) mice, both in the first and second phase (figure 50). 
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Figure 50 Formalin test in NPSR(+/+) and NPSR(-/-) mice. Effect of genotype on the time course of formalin-induced 
pain behaviour (left panel) and on the cumulative formalin-induced pain behaviour during the I° and II° phase (right 
panel). Data are mean ± s.e.m. of 8-10 mice per group. 
 
 
The present study reports the behavioural phenotype of mice lacking the NPSR receptor 
gene. Specifically we assessed the effects of the NPSR absence in locomotion, benzodiazepine 
induced sleep, anxiety, depression, memory and pain. Subsequently we evaluated the involvement 
of NPSR in NPS induced iperlocomotion, arousal and anxiolytic-like effects. 
What is unique in the present work is the use of NPSR(-/-) mice backcrossed to CD-1 strain. 
In fact the previously published phenotype studies were performed with 129S6/SvEv 36 and 
C57BL/6 37-38 NPSR(-/-) mice. It is well know that the strain of mouse can greatly affect the 
behavioural phenotype and this fact must be taken into account before the behavioural screening 
starts. In particular, we decided to avoid the use of 129S6/SvEv mice obtained from Taconic 
because of their low locomtor activity and their high anxious profile. After 8 cycles of backcross to 
CD-1 strain we obtained mice more active and less anxious in the OF test. The behaviour of these 
mice is similar to that of the CD-1 mice we used to set up our experimental conditions and to 
evaluate the effects of selective NPSR ligands (see section 3.3).  
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NPSR(+/+) and NPSR(-/-) mice were tested in a battery of tests to characterize their 
phenotype. To minimize the influence of experience of one behavioural test to another, we divided 
mice in two group (see section 2.5.1) and we arranged the tests in order from the least to the most 
stressful. The behaviour of  NPSR(+/+) mice in each test was very similar to that of CD-1 naïve 
mice, suggesting the absence of significant carry over effects of one test to another. 
No differences were observed between NPSR(+/+) and NPSR(-/-) mice in terms of 
locomotor activity, both in naïve and in habituated mice. These data suggest that the NPS/NPSR 
system does not tonically control locomotion. The present results are in line with what reported by 
other research groups 36-38 and they match the data obtained with the NPSR antagonists [D-
Val5]NPS, [tBu-D-Gly5]NPS and SHA 68 (see sections 3.4 and 3.5). In fact the absence of 
differences between NPSR(+/+) and NPSR(-/-) mice parallels the lack of effects of the NPSR 
antagonists per se in LA test and corroborate the hypothesis that NPS signalling is not activated 
under the present experimental conditions. When NPS 1 nmol is given i.c.v., it produced an increase 
in mice locomotion (horizontal and vertical) in NPSR(+/+) mice but not in NPSR(-/-) mice. Thus, 
the present study give evidence that the mechanism by which NPS promotes stimulation of LA is 
the selective activation of the NPSR protein. This results are consistent with the results obtained in 
several laboratories with  the NPSR(-/-) mice 36-38 and with the NPSR antagonists [D-Val5]NPS, 
[tBu-D-Gly5]NPS and SHA 68, that inhibited the stimulatory effect of NPS on LA 33 (see sections 
3.4 and 3.5). 
Similarly, in  the RR test, NPSR(+/+) and NPSR(-/-) shown the same sensitivity to 
diazepam, both in terms of percentage of mice losing RR and in terms of sleep time. These results 
were in a first series of experiments obtained with 129S6/SvEv mice and then confirmed with CD-1 
mice. 129S6/SvEv mice were more sensitive than CD-1  mice to the hypnotic effect of 
benzodiazepine as suggested by the difference in percentage of mice losing the RR (~ 100% vs ~ 
85%, respectively) and particularly in sleep time (~ 200 vs ~ 80 min, respectively). This diverse 
diazepam sensitivity can be due by the difference in genetic background (CD-1 vs 129S6/SvEv) 
and/or age (3 vs 6 months). However the results obtained with the two different mice strains in 
terms of lack of phenotype  were perfectly superimposable. Furthermore, NPS was able to reduce 
the sleep time only  in NPSR(+/+) and not in NPSR(-/-), demonstrating that the NPSR receptor is 
required for the NPS arousal promoting effect. Also in this case the data from knockout studies 
exactly match the results obtained with the NPSR antagonists [D-Cys(tBu)5]NPS, [tBu-D-Gly5]NPS 
and SHA 68 (see section 3.4 and 3.5). All these NPSR antagonists were in fact inactive per se in 
RR test, suggesting that the NPSR receptor is not tonically activated under the present experimental 
conditions, but, they were able to block the NPS wake promoting action, corroborating the proposal 
results and discussion 
 116
that the mechanism by which NPS induces arousal is the selective NPSR activation. Obviously our 
data are limited to the mice sensitivity to diazepam and do not exclude the possibility that the 
endogenous NPSergic pathways can be activate to promote wakefulness and control circadian 
sleep/wakefulness cycles. In fact it has been recently reported that thiopental and ketamine 
anaesthesia time is reduced by NPS while enhanced by the NPSR antagonist [D-Cys(tBu)5]NPS. 
Moreover NPSR(-/-) mice displayed reduced late peak wheel running (an index of activity of the 
internal clock) 36 and reduced LA during the dark phase 37 compared to NPSR(+/+) mice. 
Furthermore the functional hNPSR polymorphism Ile107 has been associated with delayed average 
bedtime in humans 20. Thus it seems that the endogenous NPS system can be activated under 
defined situations/conditions to promote wakefulness. 
Since NPS produces a clear anxiolytic-like action when administered supraspinally in rodent 
9,43-44 (see section 3.3), we evaluated the behavior of NPSR(+/+) and NPSR(-/-) mice in a battery of 
paradigms predictive of anxiety, including EPM, OF and SIH assays. The behaviour of NPSR(+/+) 
and NPSR(-/-) mice in the EPM, OF and SIH tests was superimposable, indicating that the absence 
of NPSR receptor does not alter anxiety levels under basal conditions. The results of our studies are 
in line with that reported by Zhu et al. in the OF and elevated zero maze tests 38 and Fendt et al. 37 
in the OF and EPM assays. However they are in contrast to the data published by Duangdao 36, who 
reported an anxiogenic-like phenotype in NPSR(-/-) mice in the EPM, OF and light-dark box 
assays. This discrepancy can be explain by the fact that the present study was performed with mice 
backcrossed on CD-1 strain, instead Duangdao and colleagues used mice on a 129S6/SvEv genetic 
background. This difference is of particular importance because of 129S6/SvEv mice display high 
anxiety-levels 105, as demonstrated by the few time spent in the open arms of the EPM (< 6 s) and in 
the central zone of the OF (< 5 s) by Duangdao 129S6/SvEv mice 36 compared to our CD-1 mice ( ~ 
35 s;  ~ 30 s, respectively). It may be that the endogenous NPS/NPSR system modulates anxiety 
levels only in case of high anxiety basal conditions (129S6/SvEv mice) but not in case of normal 
anxiety basal conditions (CD-1 mice). This hypothesis  is supported by the results obtained by Zhu 
et al. and Fendt et al. 37-38 using C57BL/6, who reported no differences between NPSR(-/-) and 
NPSR(+/+) mice in different models of anxiety. Furthermore, when we evaluated the behaviour of 
NPSR(-/-) and NPSR(+/+) mice treated with an i.c.v. injection of saline or NPS in the OF test, an 
effect of genotype was recorded. In fact control mice lacking the NPSR receptor displayed a 
tendency to a more anxious behaviour compared to wild type animals. This discrepancy between 
the data obtained with naïve and i.c.v. treated mice can be possibly explained considering that the 
injection evokes a significant stress for mice. This may increase mice anxiety levels, in fact naïve 
mice spent  ~ 30 s in the central zone of the OF, instead i.c.v. injected mice spent less then 14 s in 
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this zone (figures 46 and 47).  Thus it might be possible that the endogenous NPS system is 
activated in high anxious mice (i.e. 129S6/SvEv mice and i.c.v. treated mice) but not in middle 
anxious mice (i.e. C57BL/6 mice and CD-1 naïve mice). Further studies are needed to firmly 
identify the conditions under which the endogenous NPS signalling is activated.  
NPS 1 nmol failed to elicit anxiolytic-like effects in NPSR(-/-) mice, both in the EPM and in 
the OF test. Thus, with the present study we demonstrated that the NPSR protein is required for the 
NPS anxiolytic-like action. Our data are consistent with the results reported by Zhu and colleagues 
38 in the OF and elevated zero maze assays. Up to now no data with NPSR antagonists in anxiety 
paradigms are available in mice. However SHA 68 and [tBu-D-Gly5]NPS are reported to be able to 
completely inhibit the NPS effects in the EPM in rats 47, corroborating the hypothesis that the 
mechanism by which NPS promotes anxiolysis is the selective activation of the NPSR receptor. 
Interestingly, NPSR(-/-) mice displayed a significantly reduced rearing behaviour, both in 
the EPM and in the OF test. Rearing  is  an  exploratory  act  displayed  by mice  when  placed  in  a  
novel  situation such as the EPM and the OF tests. Actually, there is not an unique interpretation of 
this kind of spatial exploration, however it seems to represent a response to novelty 108. Thus, we 
can suppose a tonic control of the NPS/NPSR system on this particular animal behaviour. Our 
hypothesis is consistent with pharmacological studies with the NPSR antagonists, in fact there was 
a clear tendency of animals treated with [D-Val5]NPS 10 nmol to reduce their rearing behaviour 
(see section 3.4), furthermore, SHA 68 at doses able to counteract the stimulatory effect of 
exogenously applied NPS produced per se a reduction of mouse vertical activity 33. 
NPS facilitates spatial memory acquisition 67 and enhances aversive and non aversive 
memory consolidation 69. Thus, we investigated the NPSR(-/-) and NPSR(+/+) mice performance in 
the NOR paradigm. In the sample trial animals explored the two equal objects for the same time and 
no differences were recorded between NPSR(-/-) and NPSR(+/+) mice in this phase.  After 3 hours, 
when tested for memory retention, both NPSR(-/-) and NPSR(+/+) mice spent more time with the 
novel object, indicating that they have memorized the familiar object. Also in this trial, the 
performance of NPSR(-/-) mice was superimposable to that of NPSR(+/+) mice, suggesting that the 
endogenous NPS system does not modulate learning and memory in the NOR paradigm, at least 
under the present experimental conditions. Our data are in contrast to those reported by Okamura et 
al. 69, who observed a deficit in NPSR(-/-) mice memory, not only in the NOR test, but also in the 
inhibitory avoidance paradigm, demonstrating that the NPS/NPSR system is required for memory 
consolidation. Of note, the experimental protocol adopted by Okamura et al. is different from the 
our protocol. In fact Okamura et al. performed the second trial after 24 hours from the first trial 69, 
instead we performed the second trial only 3 hours from the first trial. Thus it is possible that 
results and discussion 
 118
NPSergic pathways have a role in modulating long term (24 hours delay) but not short term (3 
hours delay) memory consolidation. The discrepancy between our and Okamura et al. data can also 
be due to the different mice strain used (129S6/SvEv vs CD-1). On note, our results are in line with 
that reported by Zhu and colleagues 38, which recorded no differences between NPSR(+/+) and 
NPSR(-/-) mice in spatial learning and memory evaluated in the Morris water maze task. Obviously, 
further studies are needed to firmly establish the role of played by the endogenous NPS in 
regulating memory acquisition, consolidation and retrieval. 
The FST was used to assess depressive-like behaviours. During this test NPSR(+/+) and 
NPSR(-/-) mice spent the same amount of time immobile, indicating that  the lack of the NPSR 
receptor does not influence this kind of behaviour in mice. This results is consistent to that reported 
by Okamura et al. 69 but it is in contrast with the results reported by  Zhu et al. 38, who observed that 
NPSR(-/-) mice display an enhanced depressive behaviour compared to NPSR(+/+) mice. It is 
worthy of note that this different phenotype was detected only in male but not in female mice and 
only in the FST but not in the tail suspension test 38.  
NPS was reported to be able to reduce pain transmission in different mice models, including 
the tail withdrawal test, the hot-plate test 71 and the formalin test 72. Thus, we decided to investigate 
the sensitivity of NPSR(+/+) and NPSR(-/-) mice in the formalin test. No differences were recorded 
between wild type and knock out animas, demonstrating that the endogenous NPS signalling is no 
activated during the formalin test. This results parallel the results obtained with the peptide NPSR 
antagonists [D-Cys(tBu)5]NPS and  [D-Val5]NPS. In fact [D-Cys(tBu)5]NPS did not induce 
hyperalgesia or antinociception per se in the tail withdrawal test and in the hot-plate test 71; 
similarly [D-Val5]NPS was found inactive per se in the formalin test 72. These data obtained with 
the NPSR antagonists corroborate the hypothesis that NPSergic pathways do not tonically modulate 
pain transmission. 
In conclusion the present study indicate that the endogenous NPSergic pathway does not 
modulate locomotion, sensitivity to benzodiazepine, anxiety, memory, depressive-like behaviours 
and pain transmission in mice. However we demonstrated that the NPS/NPSR system has role in 
controlling mice rearing behaviour in a novel environment. Furthermore our results clearly show 
that the NPSR protein is not a redundant receptor for NPS in the brain; on the contrary, it represents 
the mandatory protein for all the biological effects of NPS so far described.
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4. GENERAL CONCLUSIONS 
 
The present thesis summarizes the work we performed in the last three years in the field of 
NPS and its receptor. Following the identification in 2004 of NPS as the endogenous ligand of the 
NPSR receptor an extensive research has started, both in academic and industrial laboratories, to 
assess the biological functions regulated by this new peptidergic system and to foresee the possible 
therapeutic indications of drugs interacting selectively with the NPSR receptor. To this aim, 
different group focused their attention to the identification of selective NPSR ligands, particularly 
antagonists, since they represent a tool of paramount importance to elucidate which biological 
functions and how they are controlled by the NPS/NPSR system and the neurobiological 
mechanisms of NPS actions. Another important tool instrumental for investigating this new 
peptidergic system is represented by NPSR knockout animals. In fact the study of their phenotype is 
useful to elucidate the biological functions tonically regulated by endogenous NPS, furthermore 
they can be used to demonstrate the in vivo selectivity of action of NPS and synthetic NPSR 
agonists. 
 
The aim of our research was to contribute to the study of the pharmacology and the 
neurobiology of this new petidergic system. We performed parallel studies aimed at the 
identification of new and interesting peptide NPSR ligands, in particular antagonists, and at the 
determination of the biological actions elicited by NPS in mice. New identified NPSR antagonists 
as well as NPSR(-/-) mice were used to deeply investigate the neurobiology of the NPS/NPSR 
system. 
 
Our major achievements in this field were: 
1. systematic structure and conformation activity studies that allowed the identification 
of the first generation of peptide NPSR antagonists 
2. detailed investigation of NPS actions in mice 
3. first in vitro and in vivo characterization of NPSR antagonists 
4. generation of a CD-1 congenic NPSR(-/-) mouse colony and first investigation of 
their phenotype and NPS sensitivity 
 
The studies focused on NPS position 2, 3 and 4, that represent the peptide message domain, 
revealed the chemical characteristics needed for high potency binding to NPSR. However no useful 
and interesting NPSR ligands were identified in the context of such studies. The SAR studies 
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focused on NPS position 5 demonstrated that peptide efficacy was not modified by L amino acid 
residues while being strongly reduced or even abolished by D residues. This clearly suggests that 
modifications of the relative spatial disposition of the N- (message) and C-terminal domains of NPS 
induced by chirality changes in position 5 have little effect on peptide potency while having a 
profound impact on peptide efficacy, with L amino acid favouring agonist and D amino acids 
inducing antagonist bioactive conformations. Thus these studies led to the identification of the first 
generation of peptide NPSR antagonists, that derived from the substitution of Gly5 with D amino 
acids with a  short lipophilic-branched side chain. The most important chemical modifications 
applied in NPS position 5 that were instrumental for the identification of NPSR peptide antagonists 
are displayed in figure 52. The most potent NPSR pure antagonists identified were the compounds 
[D-Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS.  
 
 
 
Figure 51 Chemical modifications of NPS Gly5: critical steps toward the identification of NPSR peptide antagonists. 
 
 
Knowledge derived from the SAR studies focused on NPS sequence are summarized in 
figure 53. 
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Figure 52. Summary of SAR studies on NPS. The message domain  is crucial for NPSR binding and activation. The 
conformation inducing domain plays a critical role in shaping the bioactive conformations of NPS. The C-terminal 
domain is required for in vivo biological activity. 
 
 
 
We successfully set up the experimental conditions to study NPS actions in vivo and we 
provided further evidence that NPS, given supraspinally in mice, elicits an unique pattern of 
biological effects: stimulation associated with anxiolysis. We demonstrated that NPS increases mice 
locomotion and reduces benzodiazepine induced sleep. Moreover NPS has a clear anxiolytic effect 
in different mice models, such as EPM, OF and SIH tests. In LA and RR assays, NPS mimics the 
stimulatory effect of caffeine, instead in EPM, OF and SIH tests NPS mimics the anxiolytic effect 
of diazepam. Our data corroborate and extend the findings obtained in the pivotal study by Xu and 
colleagues 9, that reported that NPS is able to increase mice locomotion and to stimulate 
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wakefulness in rat and at the same time it shows clear anxiolytic-like actions in EPM, OF light-dark 
box and marble burying tests. The locomotor stimulant effect of NPS seems to be highly consistent 
among experimental conditions and animal species, in fact it was replicated in different laboratories 
9,32-34, not only in mice but also in rats 31,35. We also demonstrated that NPS has arousal promoting 
proprieties in the RR assay, since it is able to reduce the number of animals losing RR in response 
to an hypnotic dose of diazepam and markedly decrease the sleep time in those animals responding 
to the benzodiazepine. Our findings were recently confirmed by Kushikata et al. 40 who reported 
similar NPS effects in rats anesthetized with ketamine or thiopental. Finally, we demonstrated that 
NPS acts as an anxiolytic drug in the EPM, OF and SIH assays, confirming the data previously 
reported by Xu et al. 9. During the last few years the NPS anxiolytic effects were replicated in 
different laboratories 25,34,38,43 and extended to rats 44,47  Thus, similar to the stimulant effects of 
NPS, its anxiolytic like action also seems to be a robust effect easily reproduced in different 
laboratories, species and assays. Collectively the present work confirms and extends the hypothesis 
of NPS as a unique neuropeptidergic signal: an activating anxiolytic. Furthermore we successfully 
set up the experimental conditions to evaluate the in vivo actions of new synthesized NPSR ligands 
in a battery of behavioural assays. The results of this study suggest that the NPS/NPSR system can 
represent an innovative and unique pharmacological target for the treatment of sleep and anxiety 
disorders. 
 
Our major goal was, in the frame of the SAR studies focused on NPS position 5, the 
discovery of the first generation of peptide NPSR antagonists, including the compounds [D-
Cys(tBu)5]NPS,  [D-Val5]NPS and [tBu-D-Gly5]NPS. We performed an extensive in vitro and in 
vivo pharmacological characterization of the actions of these new NPSR antagonists. In calcium 
mobilization assay [D-Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS acted as pure and 
selective NPSR  antagonists, with the following rank order of potency [tBu-D-Gly5]NPS > [D-
Val5]NPS > D-Cys(tBu)5]NPS. The NPSR antagonistic action of these molecules was also 
confirmed in vivo in the LA ([D-Val5]NPS and [tBu-D-Gly5]NPS) and RR ([D-Cys(tBu)5]NPS and 
[tBu-D-Gly5]NPS) tests. From these studies [tBu-D-Gly5]NPS resulted the most potent peptide 
NPSR antagonist available up to now. Both [D-Val5]NPS and [tBu-D-Gly5]NPS were able to 
completely prevent the stimulant NPS effects in LA test, with [tBu-D-Gly5]NPS 3 fold more potent 
than [D-Val5]NPS, but the peptide injected alone did not change mice locomotion. Similar results 
were obtained in the RR test, where [D-Cys(tBu)5]NPS and [tBu-D-Gly5]NPS counteracted NPS 
arousal promoting action, with [tBu-D-Gly5]NPS being 10 fold more potent than [D-
Cys(tBu)5]NPS. Thus we provided first evidence that the NPS stimulant and arousal promoting 
general conclusions 
 123
actions are selectively due to the NPSR receptor activation and that the endogenous NPSergic 
pathway is not involved in the control of mice locomotion and sensitivity to benzodiazepine under 
the present experimental conditions. [D-Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS 
represent pharmacological tools, available to the scientific community, of paramount importance to 
investigate which biological functions  are controlled by the NPS/NPSR system and to elucidate the 
role plays by NPSR in the actions evoked by NPS. In fact, as summarized in table 15, the NPSR 
antagonists we identified were largely used by different research groups in the world. Specifically, 
using [D-Cys(tBu)5]NPS, [D-Val5]NPS and [tBu-D-Gly5]NPS different laboratories demonstrated 
that the NPS anorectic effects are selectively due to the NPSR activation and that the endogenous 
NPS does not modulate feeding behaviours both in mice and in rat 63-65. [D-Cys(tBu)5]NPS and [D-
Val5]NPS were instrumental to shown that the NPS induced antinociception is selectively mediated 
by the NPSR protein and that the NPS/NPSR system does not control this biological function 71-72. 
Moreover, [D-Val5]NPS was useful to demonstrate that the inhibition of mouse colonic transit 
caused by NPS is due to the NPSR activation and that endogenous NPS does not control colonic 
transit 73. Finally, Kushikata and colleagues 40reported that [D-Cys(tBu)5]NPS was able to 
counteract the NPS arousal promoting action in ketamine and thiopental induced anaesthesia, 
demonstrating that NPS actions in RR test are due to the NPSR activation. [D-Cys(tBu)5]NPS 
prolonged per se anaesthesia duration, suggesting that the NPS/NPSR system tonically controls the 
anaesthesia state 40. Of note the data by Kushikata et al. are opposite to our findings, in fact neither 
[D-Cys(tBu)5]NPS  nor [tBu-D-Gly5]NPS increased diazepam induced sleep time under our 
experimental conditions. This discrepancy may be possible due the differences in anaesthetics used 
and in animal species (mouse vs rat). However, based on Kushikata findings, NPSR may represent a 
pharmacological target for developing novel anaesthetic.  
 
SHA 68 has been identified as a novel non peptide selective NPSR antagonist 33. We 
performed a complete pharmacological characterization of the actions of this interesting molecule. 
We confirmed and extended previous findings demonstrating that SHA 68 behaves as a selective 
NPSR antagonist in vitro and in vivo. In calcium mobilization assay SHA 68 resulted 10 fold more 
potent than the most potent peptide NPSR antagonist [tBu-D-Gly5]NPS. Despite its high potency at 
the mNPSR in vitro, in vivo SHA 68 at high doses was able to completely prevent only the NPS 
arousal promoting effect in the RR test, instead in the LA test it only partially counteracted NPS 
actions. SHA 68 did not antagonize NPS anxiolytic-like effects in the OF assay. Those differences 
between in vitro and in vivo effectiveness are likely due to the poor pharmacokinetic features of 
SHA 68. Thus the usefulness of SHA 68 as pharmacological tool for the investigation of the 
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NPS/NPSR system is limited. During the last few years new non peptide NPSR antagonists were 
identified by industrial research groups and others will be available in the next future. The 
comparison of the biological effects of these molecules, characterized by unrelated chemical 
structures, will allow a specific determination of the therapeutic indications of this new drug class.  
However SHA 68 may represent an useful template for the identification of NPSR selective 
antagonists characterized by better pharmacokinetic features. As summarized in table 15 and similar 
to peptide NPSR antagonists, SHA 68 was used during these years by different research groups to 
investigate the mechanisms of NPS actions and the biological functions controlled by the 
NPS/NPSR system. 
 
Interestingly, in a recent study Kallupi et al. 59 demonstrated that [D-Cys(tBu)5]NP and SHA 
68 injected alone are able to prevent cue-induced drug  seeking. This evidence suggests  that the 
NPS/NPSR system may have a role in the pathophysiology of drug relapse and that NPSR receptor 
may represent an important and unique target for the treatment of drug craving and the prevention 
of relapses in addicted patients. 
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Table 15. Summary of  NPSR antagonist in vivo studies 
Assay 
 
NPS effects 
(dose) 
Antagonist Antagonist actions 
(dose) 
Reference
Mouse RR 
(diazepam) 
Arousal promoting 
action 
(0.1 nmol) 
[D-Cys(tBu)5]NPS Antagonizes NPS effects,  no effects 
per se  
(10 nmol) 
present work 
Rat cue-induced 
cocaine seeking 
Increasing of drug-
seeking 
(2 nmol) 
[D-Cys(tBu)5]NPS Prevented per se drug seeking 
(30 nmol) 
59 
Rat palatable food 
intake  
Anorectic action 
(1 nmol) 
[D-Cys(tBu)5]NPS Antagonizes NPS effects,  no effects 
per se  
(60 nmol) 
63 
Rat palatable food 
intake 
Anorectic action 
(1 nmol) 
[D-Cys(tBu)5]NPS Antagonizes NPS effects,  no effects 
per se  
(60 nmol) 
65 
Mouse TW and HP tests Antinociceptive action  
(0.1 nmol) 
[D-Cys(tBu)5]NPS Antagonizes NPS effects,  no effects 
per se  
(10 nmol) 
71 
Rat RR 
(ketamine and 
thiopentale) 
Arousal promoting 
action 
(1 nmol) 
[D-Cys(tBu)5]NPS Antagonizes NPS effects,  prolonged 
per se anaesthesia duration 
(20 nmol) 
40 
     
Mouse LA Stimulant action 
(0.1 nmol) 
[D-Val5]NPS Antagonizes NPS effects,  no effects 
per se  
(10 nmol) 
present work 
Mouse colonic transit Inhibition of bead 
expulsion time 
(0.01 nmol) 
[D-Val5]NPS Antagonizes NPS effects,  no effects 
per se  
(1 nmol) 
73 
Mouse food intake Anorectic action 
(0.1 nmol) 
[D-Val5]NPS Antagonizes NPS effects,  no effects 
per se  
(10 nmol) 
64 
Mouse formalin test Antinociceptive action  
(0.01 nmol) 
[D-Val5]NPS Antagonizes NPS effects,  no effects 
per se  
(10 nmol) 
64 
     
Mouse LA Stimulant action 
(0.1 nmol) 
[tBu-D-Gly5]NPS Antagonizes NPS effects,  no effects 
per se  
(3 nmol) 
present work 
Mouse RR 
(diazepam) 
Arousal promoting 
action 
(0.1 nmol) 
[tBu-D-Gly5]NPS Antagonizes NPS effects,  no effects 
per se  
(1 nmol) 
present work 
Rat palatable food 
intake 
Anorectic action 
(1 nmol) 
[tBu-D-Gly5]NPS Antagonizes NPS effects,  no effects 
per se  
65 
   (60 nmol)  
Mouse LA Stimulant action 
(0.1 nmol) 
SHA 68 Antagonizes NPS effects,  no effects 
per se  
(50 mg/kg) 
33 
Mouse OF Anxiolytic-like activity 
(0.5 nmol) 
SHA 68 Anxiogenic-like activity 
(2 nmol) 
25 
Mouse conditioned 
fear behaviour 
Reduction of freezing 
(0.5 nmol) 
SHA 68 Increase in freezing 
(2 nmol) 
25 
Rat EPM  Anxiolytic-like activity 
(1 nmol) 
SHA 68 Antagonizes NPS effects,  no effects 
per se  
(50 mg/kg) 
47 
Rat DB Anxiolytic-like activity 
(1 nmol) 
SHA 68 Antagonizes NPS effects,  no effects 
per se  
(50 mg/kg) 
47 
Mouse OF Anxiolytic-like activity 
(0.1 nmol) 
SHA 68 Inactive 
(50 mg/kg) 
present work 
Mouse LA Stimulant action 
(0.1 nmol) 
SHA 68 Antagonizes NPS effects,  no effects 
per se  
(50 mg/kg) 
present work 
Mouse RR Arousal promoting 
action 
(0.1 nmol) 
SHA 68 Antagonizes NPS effects,  no effects 
per se  
(50 mg/kg) 
present work 
Rat cue-induced 
cocaine seeking 
Increasing of drug-
seeking 
(2 nmol) 
SHA 68 Prevented per se drug seeking 
(30 mg/kg) 
59 
Inhibitory avoidance 
paradigm 
Increasing aversive 
memory 
(1 nmol) 
SHA 68 Antagonizes NPS effects,  no effects 
per se 
(50 mg/kg) 
69 
NPS was given i.c.v. with the exception of 25 where it was given intra amygdala; peptide NPSR antagonists  were given i.c.v. with the exception of 59 where they were 
given intra lateral hypothalamus; SHA 68 was given i.c.v., with the exception of 25 where it was given intra amygdala 
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NPSR(-/-) mice represent an useful genetic tool for the investigation of the neurobiology of 
the NPS/NPSR system. The first study using these mice was performed in 2006 by Allen et al. 83, 
next the behaviour of NPSR(-/-) mice and their sensitivity to NPS were evaluated in different 
laboratories 36-38,50.  We contributed to this field performing a deep investigation of the behavioural 
profile of NPSR(-/-) mice backcrossed on CD-1 strain. Our study revealed no locomotor differences 
between NPSR(+/+) and NPSR(-/-) mice, with the exception of rearing behaviour that was reduced 
in knockout animals. Furthermore, the behaviour of NPSR(+/+) and NPSR(-/-) mice in the EPM, 
OF and SIH tests was found to be superimposable. Similarly no differences were detected in the 
novel object recognition, forced swimming, RR and formalin assays. However, the stimulant 
actions of 1 nmol NPS in RR and in LA tests and the NPS anxiolytic-like effects in the EPM and 
OF assays were detected in NPSR(+/+) but not in NPSR(-/-) mice. Collectively our data suggest 
that endogenous NPS/NPSR system does not play a role in the control of locomotion, anxiety, 
depression and memory, at least under the present experimental conditions. Moreover these results 
demonstrate that the NPS stimulant and anxiolytic effects are selectively due to the NPSR 
activation. Thus the outcomes of this study corroborate the findings derived from the studies with 
the NPSR antagonists. Our CD-1 congenic NPSR(-/-) mice will be a powerful tool available to the 
scientific community to investigate the different biological function of the NPS system. 
Furthermore these mice will represent a tool of paramount importance to investigate the in vivo 
selectivity of action of novel NPSR ligands.  
 
In conclusion, the research activity performed during my PhD program led to the 
development of two different tools useful for the study of the NPS and its receptor: NPSR 
antagonists and NPSR(-/-) mice. In particular we identified the first generation of NPSR peptide 
antagonists. The use of these research tools in parallel with knockout studies generated converging 
evidence on the biological effects induced by the selective activation of NPSR. For performing 
more detailed and systematic studies in this field other tools and knowledge need now to be 
identified and developed, such as more potent peptide and non peptide NPSR antagonists; selective 
non peptide NPSR agonists able to elicits their effects after peripheral administration; ppNPS(-/-) 
mice. The availability of these tools will allow in the future a more detailed and deep investigation 
of NPS/NPSR neurobiology and pharmacology.  
From the limited information available nowadays it is possible to foreseen that NPSR 
agonists (and in some instances partial agonists) may be useful in the treatment of sleep, food 
intake, memory disorders, and anxiety states, while NPSR antagonists might possibly represent 
novel therapeutics for the control of drug addiction, in particular for inhibiting relapse.
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